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Resumen en Espanol

I. Introducciôn
I. in t r o d u c c iô n
La malaria es una enfermedad parasitaria producida por un protozoo apicomplejo 
del género Plasmodium  que infecta a  un amplio rango de hospedadores, entre los que se 
encuentran mamiferos, aves y reptiles (Klemba and Goldberg, 2002) y que se transmite 
mediante la picadura de mosquito hembra del género Anopheles sp. infectada. La malaria 
es la enfermedad humana parasitaria mas importante, que afecta a  un g ran numéro de 
poblaciones de las areas tropicales y subtropicales del mundo, asi como a un gran 
numéro de viajeros que visitan estas regiones. Aunque la malaria se produce en mâs de 
cien paises, es en Africa donde ocurren un mayor numéro de casos, siendo causa de 
mâs del 90%  de las muertes que tienen lugar en dicho continente (Williams et al., 1999). 
La malaria humana puede estar producida por cuatro especies del género Plasmodium, 
siendo P. falciparum  la que causa la forma mâs grave de la enfermedad y el responsable 
de la muerte de mâs de un millôn de personas al aho (Klemba and Goldberg, 2002).
El ciclo de vida del parâsito de la malaria es complejo y requiere de dos etapas: 
una etapa de reproduccién sexual, donde la multiplicacién se produce en el tubo digestive 
del mosquito y una etapa de reproduccién asexual, donde la multiplicacién se produce en 
el hospedador humano. En los estadios que se producen en el hombre se pueden 
distinguir dos fases importantes: la exoeritrocitica (fase hepâtica) y la eritrocitica 
(Frederich et al., 2002).
En humanos, la infeccién comienza con la picadura de una hembra de mosquito 
Anopheles que transmite las formas parasitarias que alberga en sus glândulas salivales al 
hospedador. Los esporozoïtos tras circular durante un corto période de tiempo en el 
torrente circulatorio, invaden las células del higado, donde se desarrollan a esquizontes 
exoeritrociticos en un période que varia entre 5 a 10 dias. Un esquizonte hepâtico 
(exoeritrocitico) puede contener de 10000 a 30000 merozoitos, que se liberan e invaden 
los globules rojos (Frederich et al., 2002). Una vez que los merozoitos han invadido los 
eritrocitos, comienzan a reproducirse asexualmente, hasta la formaciôn de esquizontes, 
pasando previamente por la formacion de anillos y trofozoitos (esquizogonia eritrocitica) 
(Frederich et al., 2002). Los eritrocitos que contienen los esquizontes maduros se rompen 
y liberan los merozoitos los cuales pueden invadir otros globules rojos (Frederich et al., 
2002), comenzando de nuevo el ciclo.
En 1996 se inicio un proyecto internacional para secuenciar el genoma de P. 
falciparum con la esperanza de que se abrieran nuevos caminos para la investigaciôn 
antimalârica. La secuencia del genoma de P. falciparum se obtuvo en el aho 2002  
(Gardner et al., 2002). Los 22.8  Mb del genoma de P. falciparum estân organizados en 14 
cromosomas lineales (Gardner et al., 2002), un genoma circular similar al de los 
cloroplastos y un genoma mitocondrial lineal (Bozdech et al., 2003). Los 14 cromosomas
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de P. falciparum  3D7 varian entre un tamano aproximado de 0 .643 a  3.29 Mb (Gardner et 
al., 2002). La predicciôn de los genes codificantes de proteinas en el genoma ha 
permitido contabilizar aproximadamente 5300 genes de los que el 60%  son proteinas 
hipotéticas de funciôn desconocida hasta la fecha (Gardner et al., 2002). Se debe resaltar 
el hecho de que se trata del genoma mâs rico en A+T secuenciado hasta la fecha, que 
llega a ser del 80.6%  en las regiones codificantes (Gardner et al., 2002).
Por otra parte, ha sido caracterizado el proteoma de los estadios de esporozoito, 
merozoito, trofozoito y gametocito de P. falciparum  (Florens et al., 2002). Mâs 
recientemente también se han caracterizado dos proteomas mâs, el de los estadios de 
anillo y esquizonte (Le Roch et al., 2004). De las 2415 proteinas identificadas en el primer 
estudio (mâs tarde ampliadas a 2904), solamente el 6%  se expresa durante los cuatro 
estadios del ciclo, mientras que algo mâs de la mitad son ünicas de una etapa. 
Prâcticamente la mitad de las proteinas del esporozoito son especificas de etapa, 
mientras que en los estadios sanguineos este numéro variaba del 20 al 30%  (Kooij et al., 
2006).
Estrategias de lucha contra la malaria
Todos los programas de control de malaria que se han llevado a cabo hasta la 
fecha han mostrado limitaciôn en cuanto a  la efectividad en erradicar la enfermedad. De 
hecho, la situacion de malaria en el mundo ha empeorado considerablemente. Existen 
varies factores que explican esta escasa efectividad, entre ellos, la apariciôn de 
resistencias a los fârmacos que se utilizan para combatirla, que aunque son relativamente 
recientes, son el factor mâs importante porque aum enta los reservorios de parâsitos 
résistantes en las âreas endémicas. En general, los esfuerzos para controlar la malaria 
incluyen el desarrollo potencial de vacunas eficaces, la erradicaciôn del vector, el 
desarrollo de nuevos fârmacos (Oaks et al., 1991; Olliaro et al., 1996) ademâs de las 
medidas higiénicas y sanitarias preventivas al uso. Sin embargo, las dificultades actuates 
para controlar al vector y desarrollar una vacuna eficaz, asi como el râpido desarrollo de 
resistencias ante los fârmacos existantes, subraya la necesidad de desarrollar nuevos 
agentes antimalâricos.
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Fârmacos Antimalâricos
La terapia mediante el empleo de fârmacos sigue siendo el pilar fundamental del 
tratamiento y prevenciôn de esta patologia (Daily, 2006). En general, se han clasificado 
cuatro clases de actividades farmacolôgicas con potencial antimalârico (Frederich et al., 
2002): esquizonticidas hepéticos, esquizonticidas sanguineos, gametocitocidas y 
esporontocidas.
La complejidad de la biologia y la gran flexibilidad genética del parasite son 
también responsables del limitado numéro de fârmacos antimalâricos disponibles. Los 
fârmacos usados mâs frecuentemente son derivados de las quinolonas, derivados del 
antifolato, derivados de la artemisina y antibioticos. Debido a la apariciôn de resistencias 
se recomienda una terapia combinada con al menos dos fârmacos que actüen en dianas 
diferentes.
Una de las drogas derivadas de las quinolonas, la 4-aminoquinolina sintética o 
cloroquina (CQ), se introdujo durante la segunda guerra mundial (Loeb et al., 1946) y 
debido a su baja toxicidad y a su efectividad, ha sido el principal tratamiento en la lucha 
contra la malaria durante ahos (Tilley et al., 2001).
Resistencia a farmacos antimalâricos
La resistencia trente a fârmacos antimalâricos se ha definido como la capacidad 
de una cepa de parâsito a sobrevivir y/o multiplicarse a pesar de la administracion y 
absorciôn de un fârmaco suministrado en dosis iguales o mayores que aquellas 
usualmente recomendadas, pero con tolerancia del paciente (Bloland, 2001).
Las resistencias se han desarrollado fundamentalmente en P. falciparum, que es 
la especie con mayor prevalencia en Africa tropical, Amazonia y Suroeste de Asia y, en 
general, ésta originada por mutaciones en una gran variedad de genes (Le Bras et al.,
2006).
La resistencia a la CQ se observé por primera vez en Tailandia en 1957 y en la 
frontera entre Colombia y Venezuela en 1959. Desde 1988 la resistencia se ha extendido 
fundamentalmente por toda Africa subsahariana y hoy en dia, la CQ ha perdido su 
eficacia en casi todas las âreas del mundo (Hyde, 2007). Ademâs, la expansion e 
incremento de la resistencia a otros fârmacos existantes contribuye enormemente a las 
dificultades para el control de la enfermedad (Hyde, 2007).
Gracias al desarrollo de nuevos métodos de anâlisis molecular y a la manipulacion 
genética de Plasmodium  se ha ido progresado en la comprensiôn de los mecanismos 
moleculares que utiliza P. falciparum  para revertir y adaptarse a estructuras qufmicas 
farmacolôgicas que se utilizan en la terapia antimalârica (Hyde, 2007).
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Dianas potenciales para nuevos antimalâricos
La secuenciaciôn del genoma de P. falciparum, la emergencia de resistencias a 
drogas y los avances en técnicas moleculares han redirigide los esfuerzos para el 
descubrimiento de fârmacos. Hasta la fecha existen diverses estudios dedicados a 
identificar dianas metabôlicas que puedan ser utilizadas con fines terapéuticos (Jana and 
PaliwaI, 2007; Linares and Rodriguez, 2007). De esta manera, se han identificado 
moléculas implicadas en la biosmtesis de membranas (Vial, 1996; Ancelin et al., 2003; 
Roggero et al., 2004), transportadores (Joet et al., 2003; Kirk et al., 2005), proteasas 
(Bailly et al., 1992; Rosenthal et al., 1996; Coombs et al., 2001; Singh and Rosenthal, 
2001 ; Lee et al., 2003; Pandey et al., 2005), la detoxificaciôn del grupo hemo 
(Padmanaban and Rangarajan, 2000; Kannan et al., 2005), reguladores de las 
modificaciones post-transcripcionales (Jomaa et al., 1999; Sullivan et al., 2006; Fennell et 
al., 2007), componentes centrales del sistema redox (Krauth-Siegel and Coombs, 1999; 
W ang et al., 1999; Luersen et al., 2000), del sistema mitocondrial (Krungkrai et al., 1997; 
Srivastava et al., 1997; Mi-lchi et al., 2005), del métabolisme de los âcidos nucleicos 
(Nduati et al., 2005; Ting et al., 2005) y del apicoplasto (McFadden and Roos, 1999; 
McLeod et al., 2001 ; He et al., 2004).
Proteasas
Desde hace dos décadas, las proteasas de los organismes del género 
Plasmodium  se han considerado potenciales dianas para la quimioterapia antimalârica 
debido a la importancia que sus actividades tienen en el ciclo de vida del parâsito y a  la 
posibilidad de disehar inhibidores especificos de las mismas (Wu et al., 2003). Muchas 
de las proteasas de Plasmodium  sp. que han sido caracterizadas parecen tener papeles 
cruciales en el ciclo de vida intraeritrocitico; por elle son potenciales dianas 
quimioterapéuticas (Rosenthal, 2001). Asi, el importante papel de las proteasas del 
Plasmodium  en la ruptura del eritrocito, la invasion y la degradacion de la hemoglobina, 
han sido el objeto de numerosos estudios (McKerrow et al., 1993; Rosenthal, 1998; 
Eggleson et al., 1999; Blackman, 2000; Klemba and Goldberg, 2002; Rosenthal, 2002; 
Rosenthal, 2004; Ersmark et al., 2006).
Ademâs, la secuenciaciôn compléta del genoma de P. falciparum proporciona las 
bases necesarias para identificar nuevas proteasas susceptibles de ser utilizadas como 
dianas para la quimioterapia antimalârica (Wu et al., 2003). El anâlisis genômico 
comparative, realizado mediante bûsquedas de secuencias por similitud, ha permitido 
revelar la presencia en este parâsito de 92 secuencias putativas de genes que codifican 
para enzimas proteoliticos pertenecientes a 26 familias de las cinco clases cataliticas
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descritas: aspârtico, cistein, metalo, serin y treonin proteasas., De estas 92 secuencias, 
se ha demostrado que, al menos 88, codifican productos génicos tanto a nivel de mRNA  
como de protema, segun revelan los datos obtenidos con estudios de microarrays y 
proteomica (W u et a i,  2003).
Modificaciôn post-transcripcional de proteinas
La liberaciôn de una cadena polipeptidica compléta desde un ribosoma, no suele 
ser el ultimo paso en la formaciôn de una nueva molécula de proteina. Con frecuencia 
ocurren diverses modificaciones covalentes, que tienen lugar durante o después de la 
sintesis de la cadena polipeptidica, de hecho, la mayoria de las proteinas experimentan 
modificaciones co- y/o post-traduccionales Las modificaciones post-traduccionales 
cumplen con un elevado numéro de propôsitos dentro de diverses procesos celulares 
como son la regulaciôn enzimâtica, transducciôn de sehales, localizaciôn de proteinas, 
interacciones entre estas e incluse su estabilidad (Reinders and Sickmann, 2007).
Las proteinas pueden ser modificadas de forma post-traduccional mediante un 
proceso proteolitico de las cadenas polipeptidicas recién sintetizadas, por el 
acoplamiento de moléculas de distintas clases formando enlaces covalentes, mediante la 
formaciôn de uniones intra- e intermoleculares, o, por una combinaciôn de varies de 
estes eventos (Eichler and Adams, 2005).
Estrés oxidativo
Las especies reactivas del oxigeno (RO S) estân présentes como contaminantes 
en la atmôsfera, son generadas como subproductos en procesos metabôlicos normales; y 
se forman ante exposiciones a radiaciôn X-, À-, o U.V. (Stadtman and Levine, 2003). En 
la célula, las ROS son generadas constantemente a baja concentraciôn en condiciones 
fisiolôgicas y participan en la regulaciôn redox de la misma (Dalle-Donne et al., 2006). El 
daho oxidativo celular se desarrolla cuando el equilibrio entre los sistemas de formaciôn y 
eliminaciôn de ROS se inclina en favor del primero (Dalle-Donne et al., 2006).
Las proteinas son las dianas principales de las ROS, ya que son los componentes 
mayoritarios de la mayoria de los sistemas biolôgicos (Davies et al., 1999). 
Modificaciones irréversibles como la carbonilaciôn y uniones protema-protema, son 
generalmente las responsables de que se pierda de forma permanente la funciôn de las 
proteinas dahadas, las cuales son posteriormente degradadas o se acumulan 
progresivamente en inclusiones intracitoplasmâticas, como se observa en algunos 
procesos neurodegenerativos (Ghezzi and Bonetto, 2003).
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Carbonilaciôn de proteinas y detecciôn del grupo carbonilo
La carbonilaciôn de proteinas mediada por ROS es un marcador de la oxidaciôn 
proteica y su detecciôn sirve como sistema indicador del daho oxidativo que pueden sufrir 
las proteinas en determinadas condiciones de estrés oxidativo, envejecimiento y 
desôrdenes fisiolôgicos (Butterfield and Kanski, 2001).
Un método altamente sensible para la detecciôn de proteinas carboniladas implica 
la derivatizaciôn del grupo carbonilo con 2,4-Dinitrofenilhidracina (DNPH), que conduce a 
la formaciôn de 2,4-Dinitrofenil (DNP) hidrazona astable que puede ser posteriormente 
detectada por diferentes métodos (Dalle-Donne et al., 2003). Asi, la determinaciôn de 
proteinas carboniladas es posible gracias a la disponibilidad comercial de anticuerpos 
especificos anti-DNP que permiten su identificaciôn mediante inmunodetecciôn (Dalle- 
Donne et al., 2003). Es por ello que el contenido de grupos carbonilo en proteinas 
individuates puede ser también determinado mediante espectrofotometria de masas de 
las proteinas objeto de estudio separadas previamente mediante electroforesis 
bidimensional (2-DE) y que han sido identificados tras la transferencia a membrana e 
inmunodetecciôn con anticuerpos anti-DNP (Dalle-Donne et al., 2003).
P. falciparum y estrés oxidativo
Todos los organismos aerobios estàn expuestos a las ROS generadas por su 
propio metabolismo. Los protozoos parâsitos no sôlo tienen que eliminar sus metabolites 
tôxicos endôgenos, sino que también deben soportar el ambiente oxidativo del sistema 
inmune del hospedador (Muller et al., 2003).
Se ha demostrado que el parâsito que produce la malaria es particularmente 
vulnerable al estrés oxidativo que se genera durante los estadios eritrociticos de su ciclo 
biolôgico (Hunt and Stocker, 1990; Simoes et al., 1992; Muller et al., 2003; Becker et al., 
2004). Este no es sorprendente, dado que estos parâsitos viven en ambientes pro- 
oxidantes que contienen hierro y oxigeno, componentes fundamentales para la formaciôn 
de ROS via la reacciôn de Fenton (Muller, 2004). La causa principal del estrés oxidativo 
en el parâsito es la degradaciôn de la hemoglobina del hospedador ya que esta proteina 
por si misma représenta la mayor fuente de energia metabôlica y sintética en 
Plasmodium  (Becker et al., 2004). En el eritrocito, el hierro del grupo hemo estâ, casi por 
completo, en estado ferroso (+2); durante su degradaciôn en las vacuolas digestivas del 
parâsito, el hierro se oxida pasando a estado férrico (+3). Los electrones liberados en la 
reacciôn de oxidaciôn se combinan con el oxigeno molecular, produciendo aniones 
superôxido (O 2 ). Esta combinaciôn conduce inevitablemente a la generaciôn de perôxido 
de hidrôgeno y posteriormente radicales hidroxilo, ambos altamente réactives e
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intermediarios tôxicos de! oxigeno (Francis et al., 1997; Liochev and Fridovich, 1999). 
Ademâs, el grupo hemo tôxico (ferri/ferroprotoporfirina IX; FP IX), es liberado en la 
digestiôn de la hemoglobina y por tanto debe ser detoxificado. La toxicidad del FP IX 
liberado es debida a que posee propiedades similares a los detergentes interfiriendo en la 
integridad de la membrana del parâsito y ademâs, porque tiene la capacidad de inducir 
reacciones redox, causando la generaciôn de ROS por su uniôn con el hierro (Muller, 
2004). La mayoria de FP XI liberado (hasta un 90% ) se biomineraliza o biocristaliza 
(Egan et al., 2002; Hempelmann, 2007) hasta formar hemozoina inerte, aunque se ha 
demostrado que una cantidad considerable de este (incluso hasta el 50% ) escapa a la 
biomineralizaciôn y debe ser degradado o secuestrado por otros medios (Loria et al., 
1999; Zhang et al., 1999) para prévenir danos en la membrana y la muerte del parâsito 
(Atamna and Ginsburg, 1993; Tilley, 2001; Becker et al., 2004). Entre otras vias de 
detoxificaciôn se incluyen la degradaciôn del FP IX (Zhang et al., 1999), la reacciôn con 
glutatiôn (Ginsburg et al., 1998) y la uniôn a proteinas aceptoras de FP IX (Hanwaldt et 
al., 2002; Campanale et al., 2003). Estas vias podrian contribuir también a  la 
detoxificaciôn del grupo hemo, ya que escapando sôlo pequeha cantidad del FP IX de los 
procesos de detoxificaciôn (Loria et al., 1999), éste puede causar daho oxidativo a  las 
proteinas y a la membrana del hospedador y del parâsito (Campanale et al., 2003; Famin 
and Ginsburg, 2003).
Farmacos antimalaricos que interfieren en el metabolismo redox: 
mecanismo de acciôn
Los antimalâricos quinolinicos como la CQ, representan una clase importante de 
fârmacos antimalâricos que actüan de forma especifica sobre vias de la degradaciôn de 
la hemoglobina. La amplia distribuciôn mundial de cepas P. falciparum  résistantes a CQ  
han supuesto un problema y un desafio para el control de la malaria durante las ultimas 
décadas, hasta el punto que la CQ se ha vuelto ineficaz en muchas regiones endémicas 
de esta enfermedad, ya que airededor de! 80%  de la poblaciôn parasitaria es resistente a 
este fârmaco (Ehrhardt et al., 2007) y, por lo tanto, ésta ha sido sustituida por otros 
fârmacos o por terapias combinadas. A pesar de haberse utilizado durante mâs de 50  
ahos, el mecanismo de acciôn de la CQ  y los mecanismos de resistencia a  la misma, son 
sôlo parcialmente conocidos (Koncarevic et al., 2007). Entre las diferentes teorias 
existentes, la mâs ampliamente aceptada es la hipôtesis de interacciôn entre CQ y FP IX, 
que plantea que la CQ y otras 4-aminoquinolonas ejercen su acciôn antimalârica 
previniendo la detoxificaciôn de hemo libre que se genera durante la degradaciôn de la 
hemoglobina del hospedador en la vacuola digestiva del parâsito (Koncarevic et al..
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2007). La CQ  se acumula en la vacuola digestiva (Egan, 2001 ; Spiller et al., 2002) donde 
interacciona con el dimero p.-oxo, formado por hemo oxidado (una de las formas quimicas 
posibles de dimeros de FP IX que se encuentran en la vacuola digestiva, [Fe(lll)FP IX ]20) 
(Chou et al., 1980; Moreau et al., 1982; Egan et al., 1997; Dorn et al., 1998; Leed et al., 
2002). Estudios realizados con RMN han sugerido que la interacciôn de la CQ con FP IX 
implica apilamiento t t  -  t t  (Moreau et al., 1982). La interacciôn de la CQ  con el p-oxo FP  
IX previene la formaciôn del dimero de hemozoina, que presumiblemente es un 
intermediario en la formaciôn de hemozoina cristalizada y, de ese modo se impide la 
detoxificaciôn del FP IX (Becker et al., 2004). Como se mencionaba anteriormente, la 
acumulaciôn de FP IX libre daha membranas y enzimas debido a las propiedades 
detergentes del FP IX, asi como su capacidad para participar en reacciones redox 
(Pandey et al., 2001 ; Tilley, 2001 ; Sullivan, 2002).
El estrés oxidativo que se genera en el mecanismo de acciôn de la CQ se ha 
considerado siempre como una diana directa o indirecte de la acciôn de esta droga 
(Becker et al., 2004). Se ha sugerido que la acumulaciôn de FP IX libre y del complejo 
CQ -FP IX podria ser létal para el parâsito, aumentando la toxicidad de las ROS  
producidas durante la degradaciôn de la hemoglobina (de Almeida Ribeiro et al., 1995; 
Loria et al., 1999). La implicaciôn de los eventos oxidativos en la cascada de efectos 
ocasionados por la CQ estâ apoyada por estudios de modulaciôn de la acciôn de éste 
fârmaco por distintos niveles de GSH (Becker et al., 2004). Se cree que el hemo no 
polimerizado existe en la vacuola digestiva y es posteriormente degradado por glutatiôn 
(Ginsburg et al., 1998). Se ha demostrado que la CQ inhibe de forma competitiva la 
degradaciôn de hemo por glutatiôn. En cierto modo, el incremento de los niveles celulares 
de glutatiôn conlleva un aumento de la resistencia a la CQ, mientras que la disminuciôn 
de los mismos résulta en un aumento de sensibilidad del parâsito al fârmaco (Ginsburg et 
al., 1998).
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II. OBJETIVOS
En este trabajo de tesis doctoral se han llevado a cabo estudios conducentes a 
profundizar en la biologia de P. falciparum  a nivel transcripcional, traduccional y post- 
traduccional, con el fin de encontrar potenciales dianas para el desarrollo de farmacos 
terapéuticos efectivos, asi como clarificar el mecanismo de acciôn de la cloroquina como 
antimalârico de gran eficiencia en el pasado para conocer con detalle las modificaciones 
post-traduccionales que aparecen en el parâsito con fenotipo resistente.
Para alcanzar estos propôsitos, los objetivos especificos a nivel experimental han sido las 
siguientes:
1- Estudios de expresiôn de mRNA del gen P fN n a l, en relaciôn con el efecto inhibidor de 
carboxypeptidasas (PCI) en el ciclo biolôgico del parâsito.
2- Anâlisis de polimorfismos del gen P fN nal en las cepas Dd2 y 3D7 de P. falciparum.
3- Anâlisis de la enzima bifuncional G 6PD -6PG L de P. falciparum, como modelo para el 
estudio del procesamiento de proteinas en este protozoo.
4- Caracterizaciôn del proteoma redox de P. falciparum  a lo largo del ciclo intraeritrocitico 
del parâsito y sus modificaciones en respuesta a  la cloroquina.
11

III. Conciusiones
III. CONCLUSIONES
Los resultados obtenidos en el presente trabajo de investigaciôn representan 
nuevas perspectivas para un mejor conocimiento de la biologia del parâsito y la 
quimioterapia antimalârica. De dichos resultados se elevan las siguientes conciusiones:
1- En Plasmodium falciparum, los elevados niveles de expresiôn del gen PfNnal y su 
sobreexpresiôn a nivel transcripcional por el PCI en estadios maduros del parâsito, 
sugieren la implicaciôn de esta proteina en actividades esenciales para el correcte 
desarrollo del mismo.
2- La proteina bifuncional ünica G 6PD -6PG L de Plasmodium  varia de tamano 
dependiendo del estadio intraeritrocitico del parâsito. De hecho, se puede sugerir la 
existencia de un patrôn controlado de procesamiento de la PfG 6PD-6PG L durante la 
maduraciôn del mismo. La detecciôn de dos bandas de diferente tamano utilizando 
anticuerpos anti-G6PD y anti-6PGL implica que esta proteina bifuncional podria madurar 
rindiendo dos polipéptidos diferentes con distintas actividades enzimâticas.
3- El perfil proteômico de la oxidaciôn es dependiente de los distintos estadios 
intraeritrociticos de P. falciparum, tanto en parâsitos tratados como en los no tratados 
con cloroquina.
4- El oxiproteoma de P. falciparum  révéla daho oxidativo en algunos componentes clave 
de las siguientes funciones celulares del parâsito: plegamiento, recambio y 
procesamiento proteolitico de proteinas, metabolismo energético, transducciôn de 
sehales y patogénesis.
5- La detecciôn de aductos 4-hidroxi-2-nonenal especificos indica que la lipoperoxidaciôn 
de proteinas se inhibe por la cloroquina, particularmente en estadios tempranos del 
desarrollo del parâsito.
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IV. APORTACIONES FUNDAMENTALES
El presente trabajo de tesis contribuye con cuatro bénéficies fundamentales:
(I) Los estudios de expresion de ARM mensajero de una metalocarboxipeptidasa 
codificada por el gen PfN nal en P. falciparum muestran su elevado nivel de expresion en 
los estadios maduros del parasite asi come una sobreexpresion transcripcional de la 
misma inducida por el inhibidor de carboxipeptidasas PCI. Estes hallazgos sugieren la 
implicacion de esta proteina en actividades esenciales para la supervivencia del parasite, 
por lo tanto, y de acuerdo con su potencial inhibiciôn, esta proteasa résulta ser un 
candidate en la selecciôn de nuevas dianas para la quimioterapia antimalârica.
(II) Los estudios post-traduccionales de la G 6PD -6PG L muestran evidencias que sugieren 
la existencia de un potencial procesamiento de la proteina en dos unidades funcionales 
separadas.
(III) La obtenciôn de cultives de P. falciparum con mas del 80%  de parasitemia ha 
permitido llevar a cabo con rigurosidad, los estudios de proteômica a lo largo del cicio 
intraeritrocitico del parasite. Hay muy pocos laboratories que hayan desarrollado esta
(IV) La informacion que se ha obtenido a partir de los estudios de proteômica redox 
puede ser de gran ayuda en la comprension de les mécanismes implicados en el 
desarrollo y progreso de la malaria. Ademâs, el analisis de proteômica redox de la 
resistencia de P. falciparum  a  la cloroquina proporciona nuevas potenciales dianas 
terapéuticas para el tratamiento de esta enfermedad, en la que proteinas particulares 
juegan un papel clave, tanto en el desarrollo del ciclo intraeritrocitico del parasite como 
para explicar la resistencia trente a este fàrmaco.
%
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1. SUMMARY
The complex biology and life cycle of Plasmodium falciparum has hindered 
attempts to control malaria infections and prevent transmission. In addition, there is 
increasing resistance of the malaria parasites to currently available drugs. Therefore, 
there is a need for the development of new chemotherapeutic agents against malaria and 
understanding the basis of the chemoresistance. Recent strategies for antiparasitic drug 
discovery include seeking for specific inhibitors of critical biological activities within the 
complex parasite cycle. In this context, protease genes have already demonstrated that 
play key roles in the biology of malaria parasites and offer potential new chemotherapeutic 
targets.
The first part of the present thesis focus on the analysis of m RNA expression of 
the PfNnal gene, a coding gene for a new metallocarboxypeptidase class member, in 
relation with the inhibition effect of potato carboxypeptidase inhibitor, PCI, on the parasite 
life cycle that allowed establishing a link between the inhibitor and the Nna-1 gene in P. 
falciparum. The Nna-1 like gene-m RNA expression pattern along the intraerythrocytic 
phase demonstrated that is maximally expressed in the mature developmental stages, 
phase at which PCI arrested parasite growth. Moreover, the transitional exposure of the 
parasite to PCI up-regulated PfN nal gene expression. These observations suggest the 
involvement of this putative peptidase gene in essential activities for the parasite survival.
The genome from P. faiciparum, the causative agent of human malaria, is 
characterized by an extreme high A+T content associated with abundant low complexity 
inserts within their proteins. The enzyme glucose-6 -phosphate dehydrogenase-6 - 
phosphogluconolactonase (G 6 PD-6 PGL) found in all Piasmodium  species has unique 
structural and bifunctional characteristics. Here, at the second part of thesis, we report the 
expression analysis of P. faiciparum  G 6 PD- 6 PGL along the intraerythrocytic cycle by 
immunological analysis with antibodies raised against its N- and C- terminal domains. The 
pattern modification of band sizes at the different stages of parasite development 
suggests intracellular protein processing involving the cleavage of the native bifunctional 
form to produce two main fragments, in vitro RNA-mediated PfG 6 PD-6 PGL gene 
silencing, studied along short-term parasite development also revealed the apparent 
intracellular protein modification dependent on the parasite stage. Fragment sizes were 
consistent with separating both catalytic functions of the enzyme. The proteolytic 
machinery underlying this specific PfG6 PD-6 PGL processing is still unknown in P. 
falciparum  but suggests the existence of distinctive mechanisms in the parasite to deal 
with unique protein structures of essential function resulting from its genome evolution.
In the post-genomic era, when all proteins can be linked to the genes encoding 
them, comparative studies of the proteins expressed at any given life cycle stage or tissue
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is a critical requirement for a full understanding of biological phenomena. The methods 
developed by Trager and Jensen in 1976 for the continuous culture of the erythrocytic 
stages of P. falciparum make this organism available to a large variety of scientists. As a 
result, much has been learned about P. faiciparum during the past 30 years. Recent 
developments in the diverse aspects such as chemotherapy, drug resistance, vaccine 
development, pathogenesis, molecular biology and biochemistry emphasize the 
usefulness of the culture method in research. In fulfilling comparative proteomic studies in 
P. falciparum, highly parasitized cultures were needed. Here, at the third part of the 
research work, we report a modified method of the Trager and Jensen’ culturing method in 
a way that synchronized cultures of P. faiciparum  with more than 80%  parasitized cells 
are obtained.
Chloroquine resistance in P. faiciparum has been worldwide spread in the last
decade hindering malaria control in endemic areas. Current hypotheses on the
chloroquine action mechanism involve ultimate interference with the parasite oxidative
defence systems. In the fourth part of the thesis, carbonyl derivatization by 2 ,4
dinitrophenylhydrazine and subsequent immunoproteomics have allowed to identify and 
compare oxidatively modified proteins across the different intraerythrocytic stages of 
control and IC50 chloroquine-treated cultures of the drug-resistant P. falciparum strain 
Dd2. Functional groups of plasmodial proteins that were widely represented among those 
oxidatively damaged are central to parasite physiology, including protein folding, protein 
fate, energy metabolism, signal transduction and pathogenesis. W hether a nearly 
constant number of oxidized proteins across the P. faiciparum life cycle were observed, 
chloroquine increased both, the amount of protein oxidation signal and the number of 
different oxidized proteins as the intraerythrocytic cycle proceeds to mature stages. 
Nevertheless, detection of specific 4-hydroxy-2-nonenal adducts indicated that protein 
lipoperoxidation was inhibited by chloroquine. Identification of those oxidatively modified 
proteins provides new insights into the molecular mechanisms triggering the parasite 
response to chloroquine, as well as its normal protein-oxidation modifications which could 
be involved in development and pathophysiology and whose targeting might provide ways 
of fighting against chloroquine-resistance and novel antimalarial targets.
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2. INTRODUCTION
2.1. Malaria
Malaria is caused by apicomplexan protozoa from the genus Piasmodium  which 
are capable of parasitizing a wide range of hosts including mammals, birds, and reptiles 
(Klemba and Goldberg, 2002). The human infection is transmitted by the bite of an 
infective female Anopheles sp. mosquito and it is the major parasitic disease affecting the 
populations of tropical and subtropical areas of the world, as well as an increasing number 
of travellers to these destinations. Although malaria occurs in over 100 countries, the 
African continent carries the major burden of disease (Fig. 1), with over 90%  of all deaths 
reported from this region (Williams et ai., 1999). Four species of Piasmodium  cause 
malaria in humans, but Piasmodium faiciparum  is the causative agent of the most severe  
form of human malaria being annually responsible for the death of more than 1 million 
people every year mostly children under the age of five (Klemba and Goldberg, 2002).
0 Û0 c
a 0
c -
per pereon per year
m  0 40.-0 53 
m g  0 15-0 39 
m g  038-0 14
# #  0 0 0 1 9 -0  0 3 7
0 OCOOO(X)19-3 D O l8  
1 I No m alara
Fig. 1. Clinical incidence of malaria around the world (World Malaria Report 2005, QMS).
2.1.1. The Life Cycle of the Malaria Parasite
The life cycle of the malaria parasite is complex (Fig. 2) and involves two stages: a 
sexual reproductive stage with multiplication (sporogony) which occurs in the midgut of 
the mosquito, and an asexual reproduction phase with multiplication (schizogony), which 
takes place in the human host. In the human part of the cycle , two important phases: the
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exoerythrocytic (hepatic) phase and the erythrocytic phase can be distinguished 
(Frederich et al., 2002).
As depicted in Figure 2, the sporozoites are transmitted to humans by a bite of an 
infected female mosquito of the genus Anopheles. They circulate for a short time in the 
blood stream, and then invade liver cells, where they develop into exoerythrocytic 
schizonts during the next 5 to 15 days. Plasmodium vivax and ovaie have a dormant 
stage, the hypnozoite (Krotoski at ai., 1982), that may remain in the liver for weeks or 
many years before the development of exoerythrocytic schizogony. This results in 
relapses of infection. P. faiciparum  and P. maiariae have no persistent phase, but P. 
malarias could persist in the blood for many years if inadequately treated (Frederich et al., 
2002). A hepatic (exoerythrocytic) schizont contains 10 000 to 30 000 merozoites, which 
are released and invade the red blood cells (Frederich at a i ,  2002). Invasion of 
erythrocytes by malarial parasites involves a complex series of events that depend on 
receptor interactions between the surface of both the erythrocyte and merozoite (Chitnis 
and Blackman, 2000). The entire invasion process takes about 30 seconds. Once the 
merozoites invade erythrocytes, they begin to undergo their asexual reproduction which 
leads to the formation of erythrocytic schizonts, through ring and trophozoite (erythrocytic 
schizogony) (Frederich at a i ,  2002).
The erythrocyte membrane containing the mature schizont is disrupted and the 
merozoites are released, invading other red blood cells. In the course of these events, 
some merozoites which have invaded erythrocytes could differentiate into 
microgamétocytes (male) and macrogamétocytes (female). Gametocytes are transmitted 
to a fem ale Anopheles  mosquito during a  blood meal to complete there their life cycle. 
Mature gametocytes taken into the midgut of the Anopheles mosquito are released from 
the human erythrocyte to form gametes. The microgamete moves quickly to fertilize a  
macrogamete and forms a zygote. Within18 to 24 hours, the zygote elongates into a  
slowly motile ookinete.
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Fig. 2. Life cycle of Plasmodium species. The malaria parasite life cycle involves two hosts. During a blood 
meal, a malaria-infected female Anopheles mosquito inoculates sporozoites into the human host O . 
Sporozoites infect liver cells O and mature into schizonts O , which rupture and release merozoites O .  (In P. 
wVax and P. ovale a dormant stage, hypnozoites, can persist in the liver and cause relapses by invading the 
bloodstream weeks, or even years later.) After this initial replication in the liver (exo-erythroc]^ic schizogony 
Q ) ,  the parasites undergo asexual multiplication in the erythrocytes (erythrocytic schizogony E 3 ) .  Merozoites 
infect red blood cells 0  The ring stage develops into trophozoites which mature into schizonts, that disrupt 
the erythrocyte to release merozoites 0 to maintain a continuous erythrocytic cycle E Some parasites 
differentiate into sexual erythrocytic stages (gametocytes) 0  Blood stage parasites are responsible for the 
clinical manifestations of the disease. The gametocytes, male (microgamétocytes) and female 
(macrogamétocytes), are ingested by an Anopheles mosquito during a blood meal 0. The parasites’ 
multiplication in the mosquito is known as the sporogonie cycle B .  While in the mosquito's digestive tract, the 
microgametes penetrate the macrogametes generating zygotes 0. The zygotes in turn become motile and 
elongated (ookinetes) 0 w h ich  invade the midgut wall of the mosquito where they develop into oocysts 0 .  
The oocysts grow, rupture, and release sporozoites 0 ,  which make their way to the mosquito's salivary 
glands. Inoculation of the sporozoites into a new human host perpetuates the malaria life cycle O .  Scheme 
adopted from www.dpd.cdc.gov/dpdx.
The ookinete cross the peritrophic membrane and the epithelial cell of the midgut, 
and then transforms into an oocyst beneath the basement membrane of the midgut 
epithelium. Between 7 and 15 days postinfection, depending on the Piasmodium  species 
and ambient temperature, a single oocyst forms more than 10000 sporozoites. The motile 
sporozoites migrate into the salivary glands and accumulate in the acinar cells of the 
salivary glands. W hen an infected mosquito bites a susceptible vertebrate host, the
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Plasmodium  life-cycle begins again (Frederich et al., 2002). The length of P. falciparum  
life cycle is mentioned in Table 1.
Table 1. Length of the different stages of life cycle of P. falciparum (Frederich et ai, 2002).
ORDER STAGE NAME TIME
1 Ookinetes formation 24 to 48 
hours
2 Oocyts maturation 9 days
Time for invasion of salivary glands (1 + 2) 10 days
3 Time of circulation of sporozoites in the blood stream Max. 1 hour
4 Hepatic schizogony 6 days
5 Hypnozoites Non existent
6 Erythrocytic schizogony 48 hours
7 Gametocytogony 10 days
Complete cycle (1 to 7) 27 days
2.1.2. The P. falciparum genome
The malaria parasite is a complex multi-stage organism, which has co-evolved in 
mosquitoes and vertebrates for millions of years. Designing drugs or vaccines that 
substantially and persistently interrupt the life cycle of this complex parasite will require a 
comprehensive understanding of its biology (Florens et a i,  2002). To this respect, the P. 
falciparum genome sequence is considered fundamental and represents new starting 
points in the long search for solutions to the malaria problem (Gardner et a i ,  2002).
An international effort was launched in 1996 to sequence the P. falciparum  
genome with the expectation that the genome sequence would open new avenues for 
research. The genome sequence of P. falciparum, cion 3D7, was fulfilled in 2002  
(Gardner et a i ,  2002).
The 22.8  Mb genome of P. faiciparum  is comprised of 14 linear chromosomes 
(Gardner et a i,  2002), a circular plastid-like genome, and a linear mitochondrial genome 
(Bozdech et a i, 2003). 14 chromosomes of the P. falciparum 3D7 rang in size from 
approximately 0 .643 to 3.29 Mb (Gardner et a i,  2002). The structures of protein-encoding 
genes were predicted using several gene-finding programs and manually curated. 
Approximately 5 ,300 protein-encoding genes were identified (Gardner et a i ,  2002). The
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number of protein-coding genes is comparable to those in the free-living yeasts, 
Schizosaccharomyces pom be  and Saccharomyces cerevisiae, although its genome is 
considerably larger than the genomes of these latter organisms (Carlton et al., 2002; 
Gardner et al., 2002; Mewes et al., 1997; Wood et al., 2002).
It should be emphasized that the P. faiciparum  genome is the most A + T  rich 
genome sequenced to date. In fact, the overall A +T composition is 80.6%  in coding 
regions (Gardner et a i,  2002). This bias pervades throughout all chromosomes; intergenic 
regions frequently show A+T percentages greater than 90% , while protein coding regions, 
generally, have a lower bias because of their codon use under the universal genetic code 
(Aravind et a i,  2003). However, high and unusual amount of adenine and thymine can be 
seen in the huge amount of AAT and AAA codons, translating as asparagine and lysine in 
many proteins of Piasmodium. On the other hand, a high amount (around 70% ) of 
guanine and cytosine (G+C) can be seen in other species of Plasmodium, such as P. 
vivax or P. cynomolgi (McCutchan et ai., 1984).
Introns have been predicted in 54%  of the P. falciparum  genes. Excluding introns, 
the mean length of P. falciparum  genes is 2.3 Kb, substantially larger than in other 
unicellular eukaryotic organisms in which the average gene lengths range from 1.3 to 1.6 
kb. Thus, P. falciparum  genes showed a markedly greater proportion of genes (15.5% ) 
longer than 4  kb compared to Schizosaccharomyces pombe  and Saccharomyces 
cerevisiae, 3 .0%  and 3.6% , respectively (Gardner et a i,  2002). The explanation for the 
increased gene length in P. faiciparum  is not clear. Many of these large genes encode 
uncharacterised proteins that may be cytosolic proteins, as they do not possess 
recognizable signal peptides (Gardner et a i,  2002). In fact, comparison of the initial 
annotation of the P. falciparum  nuclear genome with other genomes showed that 60%  of 
the predicted genes cannot be functionally assigned (Kooij et a i,  2006). The products of 
at least 1.3%  of the P. faiciparum  genes are known to be involved in cell-to-cell adhesion 
or invasion of host cells, and a further 3 .9%  are postulated to have a role in evasion of the 
host immune response; many of these 2 5 0 -3 0 0  proteins possess host-like extracellular 
adhesion domains (Kooij et a i, 2006). Curiously, only 8%  of the P. faiciparum genes could 
have assigned functions in metabolism, in contrast to 17% of the genes of the yeast S. 
cerevisiae (Goffeau et a i,  1996; Kooij et a i,  2006). This suggests either that enzymes are 
more difficult to identify by sequence homology in P. faiciparum  owing to its great 
evolutionary distance from other well-studied organisms or that the P. faiciparum  genome 
contains fewer enzymes as a consequence of its parasitic lifestyle (Kooij et a i,  2006).
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2.1.3. The P. falciparum proteome
Several detailed high-throughput mass-spectrometry studies of the P. falciparum 
proteome have been published. Reassuringly, the protein content of the different blood 
stages agrees well with the presence of transcripts of the genes encoding these proteins 
(Bozdech et ai., 2003; Le Roch et ai., 2003). In addition, the proteome of four stages of 
sporozoites, merozoites, trophozoites and gametocytes has also been profiled (Florens et 
al., 2002), identifying up to 2415 proteins sorting them into 10 functional categories. It 
should be emphasized that 51%  of them are classified as hypothetical proteins and 
therefore with unknown function. In addition, over half of the secreted proteins and integral 
membrane proteins (743 predicted) were annotated as hypothetical. This large class of 
proteins that has no homology to known proteins represents potential Plasmodium- 
specific proteins that may provide targets for new drug and vaccine development (Florens 
et ai., 2002). It has also been reported that the sporozoite proteome is markedly different 
from the other stages and about half of the sporozoite proteins are unique to this stage. In 
contrast, trophozoites, merozoites and gametocytes have fewer unique proteins, sharing a 
greater proportion of the total. Of the proteins found in multiple stages, the most common 
were mainly housekeeping proteins such as ribosomal proteins, transcription factors, 
histones and cytoskeletal proteins (Florens et al., 2002). The analysis undertaken by 
Lasonder and coworkers was similar except that they studied strain NF54 of P. falciparum 
(Lasonder et al., 2002) instead of the reference genomic and proteomic P. falciparum 
strain 3D7. However, this group adopted a complementary approach to sample 
classification, dividing the sexual stages into the gametocytes (formed in the human 
erythrocyte) and gametes (formed in the mosquito gut after the blood meal), while treating 
the asexual blood stages as just a single group. In this way, they identified 1289 proteins, 
714 of which were present in asexual blood stages, 931 in gametocytes and 645 in 
gametes. Among the last two categories 575 appeared to be unique to the sexual stages 
and included a subset of proteins containing domains indicative of a role in cell-cell 
interactions.
Proteome studies have also shown that in many cases, the proteins from P. 
falciparum  are consistently bigger than their homologous counterparts from other species, 
but the role of these parasite-specific inserts in the sequences of P. faiciparum proteins is 
uncertain (Pizzi and Frontali, 2001).
Additional proteomes from the ring, schizont and gamete stages were also 
included later which increased number of identified proteins to 2904 (Le Roch et al.,
2004).
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In addition to the reported proteomes of the whole life-cycle stages, proteome 
studies have focused on specific organelles and structures in malaria parasite. In fact, 
proteome analysis of subcellular components of Plasmodium  is at the early days for the 
difficulties encountered in their purification (Di Girolamo et al., 2005). Components of 
rhoptries, apical secretory organelles of merozoites, most probably involved in 
parasitophorous vacuole biogenesis, have been identified through proteomic combined 
with bioinformatic approaches (Sam-Yellowe e ta l., 2004). Among proteins predicted to be 
located in this compartment are proteases possibly involved in the processing of 
merozoite proteins targeted to the rhoptries, enzymes of lipid metabolism that might be 
implicated in the establishment of the vacuolar membrane, as well as, proteins known to 
localize to the vacuolar membrane to support the involvement of rhoptry components in 
the genesis of parasitophorous vacuole (Di Girolamo et al., 2005).
Other complementary studies have also been reported. One of them is devoted to 
Maurer’s cleft proteomics (Vincensini et al., 2005) where provided new insights on the 
important biological functions of this parasite-derived compartment. Maurer’s clefts, 
flattened elongated vesicles close to the erythrocyte plasma membrane (Langreth et al., 
1978), are part of a parasite membrane network extending or budding from the 
parasitophorous vacuole membrane (Deitsch and Wellems, 1996). This study confirms 
that Maurer’s cleft have characteristics of a secretory compartment addressing parasite 
proteins to the red cell surface. Moreover, it suggests that in addition to protein trafficking, 
these structures are also involved in signal transduction.
Another study based on high throughput proteomics have also identified antigens 
on the surface of infected erythrocyte (Florens et al., 2004). Proteins on the surface of 
parasite-infected erythrocytes have always been one of the major focuses of malaria 
research due to their role in pathogenesis and their potential as targets for immunity and 
drug interference.
Moreover, quantitative proteomics of P. falciparum  by isotope metabolic labeling 
presented an innovative method for identification and accurate comparative quantification 
of labelled peptides from expressed proteins synthesized by in vitro cultures subjected to 
different stimuli along the cell cycle (Nirmalan et al., 2004). This research has identified 
divergent patterns of protein and reported transcript levels suggesting modulation at 
translational level and provided evidence for significant levels of post-translational 
modification in the parasite. In addition, these studies demonstrate differential effects for a 
number of proteins unrelated to likely targets of tetracycline and pyrimethamine (Nirmalan 
et al., 2004).
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Proteomic studies are at present very informative particularly for revealing several 
candidate proteins as antimalarial drug targets and blood-stage malaria vaccine (Kooij et 
a!., 2006).
2.2. Strategies to fight against malaria
The Roll Back Malaria (RBM) Programme, launched in 1988, represents a new 
approach to the war against malaria (http://www.who.int/malaria/). The RBM relies 
primarily on six main strategies: curative measures based on research and evidence, 
early diagnosis, prompt and appropriate treatment, multiple prevention methods, dynamic 
global movement against the problem, and broad-based coordinated actions backed by 
focused research.
Past and present malaria control programmes, as well as the most recent Malaria 
Control Programme Plan, have achieved limited successes in eradicating the scourge. In 
fact, the malaria situation has steadily deteriorated. Several factors account for limited 
successes in eradicating malaria such as lack of political will and commitment, poor 
awareness of the magnitude of the malaria burden, poor health practices by individuals 
and communities, and the increased resistance to drugs and insecticides.
In general, malaria control efforts include attempts to develop an effective vaccine, 
eradicate mosquito vectors, and develop new drugs (Oaks et al., 1991; Olliaro et al., 
1996). Development of an effective malaria vaccine that could be deployed widely in 
endemic areas has proved to be more difficult than was anticipated, when the first clinical 
trials of malaria vaccines were conducted 30 years ago. In fact, a safe, effective and 
affordable vaccine, that provides sustained protection to the residents of malaria endemic 
areas, is still many years away (Greenwood, 2005). Efforts to control Anopheles 
mosquitoes have also had limited success, although the use of insecticide-impregnated 
bed nets does appear to reduce malaria-related death rates (Alonso et al., 1991). In 
addition, methods to replace natural vector populations with mosquitoes unable to support 
parasite development are under study and may contribute to malaria control in the long 
term (Collins and Besansky, 1994). However, the current limitations of vaccine and vector 
control, as well as the increasing resistance of malaria parasites to existing drugs, 
highlight the continued need for new antimalarial agents.
2.2.1. Antimalarial drugs
Antimalarial drugs have been used for centuries. Early natural products, including 
the bark of the cinchona tree in South America and extracts of the wormwood plant in 
China, were among the first effective antimicrobial agents to be used. Cinchona bark was
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used in Europe beginning in the 17th century, and upon its isolation from bark in 1820, 
quinine becam e widely used. In the last 50 years, extensive efforts, including the 
screening of hundreds of thousands of compounds, have led to the development of a  
number of effective synthetic antimalarial drugs (Rosenthal, 1998).
Drug therapy remains the mainstay of treatment and prevention of malaria. 
Piasmodium  has a  complex life cycle involving an arthropod vector and distinct stages 
within the human host. Each parasite stage plays a unique role in transmission, disease, 
and latency. These different stages may vary in their response to the various antimalarial 
compounds. Antimalarial compounds should be evaluated in the context of life cycle stage 
effect, molecular target, and half-life. Drug effect on each life cycle stage varies because 
of stage-specific biology (Daily, 2006).
Traditionally, four classes of potential antimalarial activities can be categorized 
according to their stage of action (Frederich et al., 2002):
a) Tissue schizonticides: These drugs act on the primary tissue forms of 
the plasmodia which after growth within the liver, initiate the erythrocytic 
stage. By blocking this stage, further development of the infection can 
be theoretically prevented.
b) Blood schizonticides: These drugs act on the blood forms of the parasite 
and thereby terminate clinical attacks of malaria. These are the most 
important drugs in antimalarial chemotherapy.
c) Gametocytocides: These drugs destroy the sexual forms of the parasite 
in the blood and thereby prevent transmission of the infection to the 
mosquito.
d) Sporontocides: These drugs prevent the development of oocysts in the 
mosquito and thus ablate the transmission.
Therapy usually poses challenging problems, because of the complexity of 
parasite which has led to the limited number of available antimalarial drugs. The most 
commonly used antimalarial drugs are detailed below.
2.2.1.1. Quinolines
Quinoline-containing antimalarial drugs, such as chloroquine, quinine, and 
mefloquine, are vital compounds in our chemotherapeutic armory which have long been 
used to combat malaria (Tilley et al., 2001). Quinine has been used for 300 years-ever 
since bark extracts from the Cinchona tree were first shown to have antimalarial activity.
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Early synthetic work in Germany produced the 8-aminoquinolines, primaquine and 
pamaquine. Primaquine is still used to eradicate the liver-stage hypnozoites of P. vivax 
and P. ovaie (Tilley et al., 2001). During World W ar II, the synthetic 4-aminoquinoline, 
chloroquine (CO) was introduced (Loeb et ai., 1946). Because of its low toxicity and, for 
many years, its effectiveness, CQ has been a mainstay in the fight against malaria ever 
since.
In general, the quinoline antimalarials function by targeting the parasite-specific 
pathway of haemoglobin breakdown (Becker et al., 2004). CQ is a weakly basic 
amphipath that has been shown to accumulate in the food vacuole (Egan, 2001; Spiller et 
ai., 2002). In this location it is thought to interact with oxidised haem (FP-Felll), the free 
toxic haem released by proteolysis of haemoglobin, and interfere with its detoxification 
process to make inert crystalline substance called haemozoin (Egan et al., 2002; Becker 
et al., 2004).
Resistance to CQ reported in many parts of the world by the end of the 1950s 
(White, 2006) and therefore lack of their therapeutical efficacy has contributed to a great 
deal of the difficulties in controlling malaria (Tilley e ta l., 2001; Ehrhardt eta l., 2007).
2.2.1.2. Antifolates
The most important antifolate drug is pyrimethamine which targets the 
dihydrofolate reductase (DHFR) activity of the bifunctional DHFR-thym idylate synthetase 
protein. DHFR is present in both host and parasite being essential to maintain a constant 
supply of fully reduced forms of folate cofactors for essential one-carbon transfer 
reactions, including the provision of nucleotides for DMA synthesis and the metabolism of 
certain amino acids (Hyde, 2007). Pyrimethamine is normally used in combination with 
other drugs as initially uses alone after its introduction in the 1940 /  1950s arose 
resistance rapidly (Hyde, 2007). Unfortunately, falciparum parasites are able to quickly 
accumulate multiple genetic mutations producing enzymes resistant to such drugs 
(Shanks, 2006). Other antimalarials of this family are proguanil, and sulfonamides such as 
sulfadoxine and sulfalene (Hyde, 2007). Although pyrimethamine and proguanil were 
initially used alone after their introduction in the 1940 / 1 950s, resistance to them also 
arose rapidly. To fight drug resistance, combinations such as pyrimethamine-sulfadoxine 
were then produced. However, resistance to this combination is increasing and therefore 
its therapeutical action is highly limited to the areas were not resistance reported 
(Warhurst, 2002).
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2.2.1.3. Artemisinins
The artemisinins are sesquiterpene lactones that derive ultimately from the 
Chinese herb qinghao {Artemisia annua), used for centuries to treat malaria and other 
parasitic diseases (Hyde, 2007).
Artemisinins are highly active, decreasing the parasite biomass 10 000-fold in a  
single asexual cycle (White, 1997; Woodrow et al., 2005). This makes artemisinins the 
most active and rapid-acting antimalarial drugs known today (Schlitzer, 2007).
A key structural feature of all artemisinins is the 1,2,4-trioxane substructure or, 
more precisely, the endoperoxide, which is mandatory for antimalarial activity. Despite the 
growing importance of artemisinins, their exact mechanism of action is still unresolved and 
remains a matter of intense debate (Schlitzer, 2007). It has been proposed that iron(ll)- 
mediated cleavage of the endoperoxide leads to the formation of different carbon- 
centered radicals (Schlitzer, 2007). For a long time it was thought that the formation of 
carbon radicals from artemisinin takes place in the digestive vacuole and that FP IX 
(ferri/ferroprotoporphyrin IX) is the activating species. The reactive carbon radicals are 
thought to subsequently react more or less indiscriminately with different protein targets 
as well as with FP IX itself, thus preventing haeme detoxification and inhibiting important 
enzyme activities. However, this concept has been questioned owing to some 
contradictory findings: artemisinins act against all developmental parasite stages, 
including those which do not produce haemozoin (Schlitzer, 2007). Recently, has been 
suggested that endoperoxide cleavage should take place in the cytoplasm catalyzed by a  
cytoplasmic iron(ll) source. The resulting reactive species then very specifically inhibits an 
ATP-dependent C a2+ pump (PfATP6) located on the endoplasmic reticulum, but remains 
unknown how the inhibition of PfATP6 leads to the rapid killing of the parasite (Schlitzer, 
2007; Hunt eta l., 2007).
Special properties of artemisinins make them the most important class of 
antimalarial agent, and a mainstay against multidrug resistant P. faiciparum. In early 2006, 
due to global concerns about the need to safeguard the efficacy of this antimalarial, the 
W H O  urged the malaria community to stop the production and use of artemisinin 
monotherapies and switch to artemisinin-based combination therapies. But, the major 
problem is that their use in many countries has been severely restricted by cost, and also 
artemisinins in combination are several-fold more expensive than the now almost useless 
CQ, or sulfadoxinepyrimethamine, whose efficacy is also declining (Woodrow et al.,
2005).
To document the existence of drug resistance it should be mentioned that although 
P. faiciparum isolates may vary in their in vitro sensitivity to artemisinin, no mutations or
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copy number changes were apparent in any of the genes that have been potentially 
implicated in the resistance of P. faiciparum  (Afonso et al., 2006). However, the studies, 
which support PfATP6 as the major target of artemisinins, showed that parasites 
harbouring a single point mutation in PFATP6 are resistant to artemisinin (Uhlemann et 
al., 2005). Recently, a critical mutation associated with resistance to artemisinin in C Q - 
resistant P. chabaudi has been found in a deubiquinating enzyme involved in the ATP- 
dependent protein degradation pathway. Such mutation might lead to an increase in 
degradation of proteins by the proteasome, eliminating artemisinin-induced dam aged  
proteins (Hunt et al., 2007).
2.2.1.4. Antibiotics
At first sight, it is surprising that several antibacterial agents display considerable 
activity against the eukaryotic malaria parasites, as antibiotics are known to specifically 
target prokaryotic structures. This apparent contradiction can be explained by the 
presence of two organelles, the mitochondrion and the apicoplast. Both organelles have 
their own DNA and bacteria like machinery for replication, transcription, and translation 
(Schlitzer, 2007). Apart from tetracyclines, which are thought to act mainly against the 
mitochondrion (Kiatfuengfoo eta l., 1989) all other antibiotics seem to act on the apicoplast 
(Vaidya, 2004). Tetracycline and derivatives such as doxycycline are very potent 
antimalarials and are used for both treatment and prophylaxis (Bloland, 2001). It has been 
shown that doxycycline blocks the expression of apicoplast genes (Dahl et al., 2006). 
Characteristically, most antibiotics do not exert any visible effect in the first intracellular 
cycle, but during the second cycle the parasites are killed after the invasion of the new  
host cell. This phenomenon is known “delayed kill effect.” As a result of the delayed kill 
effect, fever and parasite clearance times are significantly longer when antibiotics are  
administered as single agents in comparison with classical antimalarials (approximately 4 
versus 2 days). Because this delay may be fatal in non-immune patients, antibiotics are  
used only in combination with a faster-acting drug for the therapy of acute malaria 
(Schlitzer, 2007). For example, in areas where response to quinine has deteriorated, 
tetracyclines are often used in combination with quinine to improve cure rates (Bloland,
2001). However, antibiotics, especially doxycycline, can be used prophylactically as single 
agents, although they are not registered for this indication in most countries (Schlitzer, 
2007).
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2.2.1.5. Antimalarial drug combination therapy
Combination therapy with antimalarial drugs is the simultaneous use of two or 
more blood schizontocidal drugs with independent modes of action and different 
biochemical targets in the parasite to improve therapeutic efficacy and also delay the 
development of resistance to the individual components of the combination (W H O , 2001). 
The basis of combination chemotherapy in malaria is typically formed when a rapidly 
acting drug (quinine or artemisinin) is combined with a  slower acting drug (tetracycline, 
mefloquine etc) given over enough time (at least four parasite generations which is about 
eight days) to kill any residual parasites (White, 2004).
W hen two effective drugs are used, the probability of selecting a  mutant parasite 
with resistance to both drugs seems unlikely. Of currently available combinations which 
have been proven effective in field trials, quinine-tetracycline and chlorproguanil-dapsone 
have been reported (Shanks, 2006). As with any medication, each combination has its 
own advantages and disadvantages based on cost, tolerability and ease of administration 
(Shanks, 2006). It should also be emphasized that any benefits of combination therapy in 
preventing development or intensification of resistance may be lost due to unofficial and 
incorrect use of the component drugs outside of official health services (Bloland, 2001).
2.2.1.6. Protease inhibitors
Proteolytic enzymes play important roles in the life cycles of all medically important 
protozoan parasites, including the organisms that cause malaria (Rosenthal, 1999). 
Protease inhibitors have significantly been valuable reagents for studying the biological 
roles of proteases of malaria parasites and have demonstrated potent antimalarial effects 
(Rosenthal, 1999; Rosenthal, 2004). The range of protease inhibitors evaluated as 
potential antimalarial agents is small but growing in number (Go, 2003). Increasing 
evidence suggests that inhibitors of plasmodial proteases such as aspartic proteases 
(plasmepsin I and plasmepsin II) and cysteine protease (falcipain-2) have potent 
antimalarial activity and may be appropriate antimalarials (Rosenthal, 2001).
A collection of peptidomimetic compounds, designed as aspartic proteinase 
inhibitors, significantly blocked haemoglobin degradation and kill parasites in culture 
(Francis et ai., 1994; Moon et al., 1997). Pepstatin A, a general inhibitor of aspartic 
proteases was also reported to inhibit haemoglobin degradation in P. falciparum (Gluzman 
et ai., 1994).
Incubation of P. falciparum  culture in the presence of cysteine protease inhibitors, 
leupeptin and E64 results in accumulation of undegraded haemoglobin in the food vacuole 
(Rosenthal, 1995 ; Gam boa de Dominguez and Rosenthal, 1996). Production of hemozoin
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was also blocked by E64 (Asawamahasakda et al., 1994). Cysteine protease inhibitors 
also block rupture of the host cell membrane and release of merozoites which leads to 
clustered merozoite structures. Therefore, thiol proteinase inhibitors such as E64, 
leupeptin, and chymostatin appear to be a valuable template for the development of new  
inhibitors specific to individual plasmodial proteases (Bailly eta l., 1992).
Several aspartic and cysteine proteases have been evaluated as candidate drug 
targets (Singh and Rosenthal, 2001; Pandey et al., 2005). Inhibition of hemoglobinases in 
Plasmodium  remains as one of the most outstanding therapeutic strategies. In fact, use of 
inhibitors for both above mentioned classes of proteases in combination showed 
synergistic killing of the parasite (Semenov et ai., 1998).
The metal chelators such as EDTA, dipicolinic acid, and 1,10-phenanthroline 
inhibit falcilysin, a metallopeptidase involved in haemoglobin catabolism. Moreover, 
G M 6001, a well-known inhibitor of both the mammalian matrix and disintegrin 
metalloprotease family showed participation of malaria parasite metalloproteases during 
host cell invasion (Grobelny et ai., 1992; Ito et ai., 2004). Reduction of invasion by above 
mentioned metalloprotease inhibitor, 1,10-phenanthroline, has also been reported 
(Kitjaroentham et ai., 2006), pointing out the importance of metal-requiring proteases in P. 
faiciparum  merozoite entry into host red blood cells.
Amino acid dipeptide analogs, such as bestatin and its derivatives, which are 
potent inhibitors of the aminopeptidases also blocked the growth of P. falciparum in 
culture (Stack e ta l., 2007).
The parasite proteasome has also been inhibited by MLN-273, a small molecule 
dipeptidyl boronic acid proteasome inhibitor, which caused an overall reduction in protein 
degradation in P. faiciparum and blocked erythrocytic development at an early ring stage 
(Lindenthal e ta l., 2005).
In addition, recent advances in the characterization of other haemoglobinases and 
in proteases that are required for rupture or invasion suggest that inhibitors of many of 
these enzymes may also demonstrate antiparasitic activity and therefore can be 
considered as antimalarial candidates (Rosenthal, 2001).
2.2.2. Antimalarial drug resistance
Antimalarial drug resistance has been defined as the ability of a parasite strain to 
survive and/or multiply despite the administration and absorption of a drug given in doses 
equal to or higher than those usually recommended but within tolerance of the subject 
(Bloland, 2001).
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Drug resistant malaria is mostly due to P. faiciparum, the highly prevalent species 
in tropical Africa, Amazon, and Southeast Asia and, in general, originates from 
chromosomal mutations. (Le Bras et ai., 2006).
In the continuing absence of clinically proven vaccines, preventing or treating 
malaria parasite infections in the human host depends upon chemoprophylaxis and 
chemotherapy. Since the advent of the first synthetic antimalarials in the 1930s, only a 
small number of compounds has proved suitable for licensing as drugs for human use, 
and several of these are now greatly compromised by the spread of drug-resistant 
parasite strains, including the cheapest formulations that are important to underdeveioped 
countries, namely CQ and pyrimethamine-sulfadoxine (Hyde, 2007).
Resistance of malaria parasites arises from several factors, including overuse of 
antimalarial drugs for prophylaxis, inadequate or incomplete therapeutic treatments of 
active infections, a high levei of parasite adaptabiiity at the genetic and metabolic levels, 
product instability in tropical climate, and a  massive proliferation rate that permits seiected 
populations to emerge reiativeiy rapidly (Hyde, 2007).
0 0  resistance was first observed in Thaiiand in 1957 and on the Coiom bian- 
Venezuelan border in 1959. By 1988 resistance had spread to essentiaily ail of sub- 
Saharan Africa and today CQ has lost its efficacy in almost all areas of the world (Hyde, 
2007). Molecular studies have shown muitiple CQ  resistance founder mutations and a 
iarge scaie CQ resistance selective sweep from Southeast Asia to Africa as weil as other 
sweeps across the Amazon in South America and in Papua New Guinea (Wootton et ai., 
2002).
Despite multiple independent origins of C Q  resistance woridwide, CQ resistance 
parasites share some common phenotypes such as increased IC50 (Ringwald et ai.,
2000), reduced CQ accumulation in the acidic digestive vacuole (Sanchez et ai., 2003; 
Bennett et ai., 2004), reduced pH in digestive vacuole (Bennett et ai., 2004) and 
universally shared point mutations in a putative transporter gene termed P. falciparum 
chloroquine resistance transporter (pfcrt), which is the major determinant of CQ resistance 
(Jiang eta l., 2006).
Widespread and increasing resistance to other avaiiable drugs contributes 
enormousiy to the difficulties in controliing malaria (Hyde, 2007). Figure 3 represents the 
geographical distribution of resistance to the most common antimalarials in the endemic 
areas of P. falciparum malaria.
The principal antifolate drugs are pyrimethamine, proguanil, and the sulfonamides 
(such as sulfadoxine). P. faiciparum  can quickly create multiple genetic mutations which 
iead to resistance to these drugs (Shanks, 2006). in fact, resistance arose rapidly by
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monotherapy of pyrimethamine and proguanil after their introduction in the 1 9 4 0 /1 9 5 0 s . 
Then, combination of pyrimethamine-sulfadoxine were produced (Hyde, 2007). However, 
in South East Asia from the mid-1960s onwards, pyrimethamine-sulfadoxine combination 
failed as primary therapy in a very short period of time once it was in general use 
(Wongsrichanalai e ta l., 2002). These same resistance genes have rapidly spread across 
Asia and into Africa such that treatment with a single administration of sulfadoxine­
pyrimethamine often fails to cure (Peterson et al., 1988; Terlouw et al., 2003; 
Abacassamo e ta l., 2004). However, despite a rapid spread of pyrimethamine-sulfadoxine 
resistance and its diminishing efficacy, this reasonably priced combination has been 
extensively used to combat chloroquine-resistant parasites in Africa since the early 1990s  
(Hyde, 2007).
Mefloquine, a quinoline methanol derivative which introduced in the 1984 to fight 
against parasites that had become resistant to CQ and the antifolates, developed 
significant resistance within 6 years (Price eta l., 2004).
Sodium artesunate so far is the most effective artemisinin and can rapidly reduce 
parasite numbers -  lOM old in a single erythrocytic cycle (Hyde, 2007). However, the 
danger of using this type of drug in monotherapy was emphasized by a study where 
decreased sensitivity was observed in recrudescent parasites after 7 days of treatment 
with artesunate alone (Menard e ta l., 2005). Therefore, artemisinin combination therapies 
have recently been adopted as first-line therapy for P. falciparum  infections in most 
malaria-endemic countries (Alker et ai., 2007) and W H O  has recommended the use of this 
combination in the treatment of uncomplicated P. faiciparum infections (Faye e ta l., 2007). 
Although new generation artemisinin-based combination therapies are highly effective and 
life-saving in all but most advanced cases (World Malaria Report 2005, QM S), there is 
doubt to the effectiveness of certain of these combinations where the partner drug is 
already resistant (Duffy and Mutabingwa, 2006). Moreover, the main obstacles to the 
success of combination treatment in preventing the emergence of resistance will be 
incomplete coverage, or inadequate treatment. In fact, irrespective of the epidemiological 
setting, ensuring that patients with high parasitaemias receive a full course of adequate  
doses of artemisinin combination treatment would be an effective method of slowing the 
emergence of antimalarial drug resistance (White, 2004). Artemisinin combination 
therapies offer hope, but it is not clear that which drug combinations are most effective, or 
most sustainable, in different populations. That knowledge requires many more studies 
and continued surveillance for resistance after use of such combinations (Duffy and 
Mutabingwa, 2006). To this respect, it should be stressed that resistance to subcurative 
doses of artemisinin in the CQ-resistant clones of the rodent malaria parasite P. chabaudi
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have been experimentally obtained (Afonso et a!., 2006; Hunt at a!., 2007) and therefore, 
it is expected that resistance to artemisinins in human clinical practice would also be 
developed in a future.
' %>v.
■ I — : Ansas whwe maiaria IransmisaiDn Docuni ihigh.laiw) 
A  ChkjfCKUJlrw e^rststancïe
0  Siitfada*.ne {iyrl<ri6tfiam!R«s reaiaiance
MeflcquHic re-stslsnce 
Maiarn-frae areas
j« y
Fig. 3. Drug resistance to P. falciparum around the world (World Malaria Report 2005, QMS).
2.3. Potential targets for new antimalarials
While in the past century has been generated significant progress in anti-malarial 
drug development, many of the drugs are currently losing their efficacy due to the rise of 
drug resistant Plasmodium  strains. This increasingly serious problem has led to an urgent 
need to develop new and effective antimalarial molecules. This goal can be achieved in 
two ways; either by focusing on validated targets in order to generate new drug 
candidates; or by identifying new potential targets for malaria chemotherapy (Jana and 
Paliwal, 2007). Sequencing of the P. falciparum  genome, advances in molecular 
techniques, characterization of gene expression directly at the proteomic level, and the 
rapidly-expanding field of metabolomics have refocused antimalarial drug discovery 
efforts. However, despite substantial advances in our understanding of parasite biology 
and biochemistry, it appears that these organisms often use novel modes of metabolism, 
signaling, protein trafficking pathways, cell division and extracellular communication 
mechanisms. The proteins involved in these processes often possess significant 
sequence variation between them and show distinct biochemical or catalytic properties
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(Jana and Paliwal, 2007). Structural studies on desirable proteins are also necessary to 
do a rational drug design using structural information. In addition, understanding of the 
mechanisms of action and resistance to traditional antimalarial drugs is important in order 
to design newer and more effective drugs.
Several parasite biochemical pathways such as membrane biosynthesis (Vial, 
1996; Ancelin eta l., 2003; Roggero et a i ,  2004), transporters (Joet et a i,  2003; Kirk et a i,
2005), proteases (Bailly et a i,  1992; Rosenthal et a i,  1996; Coombs et a i,  2001; Singh 
and Rosenthal, 2001; Lee et a i,  2003; Pandey et a i,  2005), haem detoxification pathway 
(Padmanaban and Rangarajan, 2000; Kannan et a i ,  2005), post-translational modification 
pathways (Jomaa et a i ,  1999; Sullivan et a i ,  2006; Fennell et a i ,  2007), the redox system 
(Krauth-Siegel and Coombs, 1999; W ang et a i,  1999; Luersen et a i,  2000), the 
mitochondrial system (Krungkrai et a i ,  1997; Srivastava et a i ,  1997; Mi-lchi et a i,  2005), 
nucleic acid metabolism (Nduati et a i ,  2005; Ting et a i ,  2005), and the apicoplast 
(McFadden and Roos, 1999; McLeod et a i ,  2001; He et a i,  2004), have been exploited 
for drug target identification (Jana and Paliwal, 2007; Linares and Rodriguez, 2007).
2.3.1. Proteases
Proteases from a variety of protozoan parasites have been characterized at the 
molecular and cellular levels, and the many roles that proteases play in these organisms 
are coming into focus. Central roles have been proposed for proteases in diverse 
processes such as host cell invasion, catabolism of host proteins and host cell rupture 
(Klemba and Goldberg, 2002).
Malarial proteases have long been considered potential targets for chemotherapy 
due to the above mentioned roles in the parasite life cycle, and the feasibility of designing 
specific inhibitors (McKerrow et a i ,  1993; Rosenthal, 1998; Blackman, 2000; Rosenthal,
2002). Important advances over about the last decade have led to the biochemical and 
molecular characterization of a number of plasmodial proteases. Moreover, the 
completion of the P. falciparum  genome provides a basis to identify new proteases and 
therefore subsequent targets for antimalaria chemotherapy (W u et a i,  2003). The  
comparative genomic analysis, using an extensive sequence similarity search, has 
predicted in the P. falciparum genome up to 92 putative proteases belong to 26 families of 
five catalytic classes of aspartic, cysteine, métallo, serine, and threonine in this parasite. 
Of the 92, at least 88 have been demonstrated to code for gene products at the 
transcriptional levels, based upon the microarray and proteomics data (Wu et a i,  2003).
The biological processes where specific proteases have essential function in 
different intraerythrocytic stages P. falciparum  has further been detailed below.
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2.3.1.1. Host cell invasion
The P. falciparum invasion into the host erythrocytes requires the activity of 
parasite proteases (Blackman, 2004). Mature merozoites, the end product of the asexual 
replication cycle, burst out of the depleted host erythorcyte and rapidly enter new  
erythrocytes. The invasion process can be broken down into several steps: attachment of 
the merozoite to specific red blood cell receptors, reorientation to bring the apical end of 
the parasite in contact with the erythrocyte surface, release of the contents of specialized 
secretory organelles, and simultaneous formation of a  parasite-red cell junction through 
wich the merozoites enteres (Klemba and Goldberg, 2002).
The invasion by P. falciparum  merozoites has generally been shown to be inhibited 
by serine protease inhibitors such as chymostatin. Such observation suggested that some 
proteases play critical role in this process (DIuzewski eta l., 1986).
Subtilase-1 and Subtilase-2, two homologous serine proteases are expressed in 
schizonts and merozoites and demonstrated to be involved in merozoite invasion 
(Blackman et a i,  1998; Barale et a i,  1999; Hackett et a i,  1999). The gp76 GPl-anchored 
serine protease, which cleaves host erythrocyte surface proteins in P. falciparum (Braun- 
Breton et a i,  1988), is believed to facilitate parasitophorous vacuole formation and 
function in invasion (Roggwiller et a i,  1996). Two other Plasmodium  serine proteases, 
serine repeat antigen 5 (SERAS) and acid basic repeat antigen (ABRA), have been 
described to be involved in erythrocyte invasion (Blackman, 2004). SERAS is an abundant 
component of the parasitophorous vacuole that was present in a soluble form at merozoite 
release. Antibodies against it could interfere with merozoite release and erythrocyte 
invasion (Blackman, 2000). ABRA is a protein that accumulates during schizont 
maturation in the parasitophorous vacuole in a soluble form, but is also bound to the 
merozoite surface (Blackman, 2004). An slight reduction in invasion has been observed in 
transgenic parasites lacking surface form of ABRA (Mills et a i,  2002).
Besides serine proteases, cysteine protease may also play a role in invasion. It 
has been reported that falcipain-1, a cysteine protease, was active during the invasive 
merozoite stage (Greenbaum et al., 2002).
Finally, the malaria parasite may possibly employ metalloproteases during host cell 
invasion. In fact, mRNA expression analysis (Bozdech et a i,  2003), and also invasion 
inhibition of merozoites by 1,10-phenanthroline have revealed involvement of the 
metalloproteases in this process (Kitjaroentham et a i,  2006).
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2.3.1.2. Haemoglobin degradation
The parasite ingests and degrades most of the host cell haemoglobin during the 
different intraerythrocytic stages of ring, trophozoite, and schizont (Goldberg, 1993). 
However, the metabolic activity varies between them and is most pronounced during the 
trophozoite stage (Francis at a!., 1997). Studies using protease inhibitors have proven 
haemoglobin degradation to be essential for parasite survival (Bailly et al., 1992; Francis 
eta l., 1994; Rosenthal, 1995; Olson eta l., 1999).
Several enzymes have been shown to be involved in haemoglobin proteolysis. In 
P. falciparum these are aspartic proteases of plasmepsin I, II, IV, and the closely related 
histoaspartic protease (HAP) (Banerjee et al., 2002), cysteine proteases of falcipain-1 
(Salas et al., 1995; Sijwali et al., 2004), falcipain-2 (Shenai et al., 2000), falcipain-2 
(Sijwali and Rosenthal, 2004), and falcipain-3 (Sijwali et al., 2001), a metalloprotease 
(falcilysin) (Eggleson et al., 1999), and dipeptidyl aminopeptidase 1 (DPAP1) (Klemba et 
al., 2004). The degradation process appears to follow an ordered pathway (Gluzman et 
al., 1994; Eggleson et al., 1999). However, it has been difficult to determine the exact 
sequence of events, especially whether a plasmepsin or a falcipain catalyzes the initial 
cleavage (Gluzman e ta l., 1994; Sijwali e ta l., 2001; Coombs e ta l., 2001; Ersmark e ta l., 
2006). The general pathway is outlined in Figure 4.
Plasmepsins 
(I, II, IV and HAP)
Falcilysin
Falcipains
(-1 ,-2 ,-2 , and -3) DPAP1
Haemoglobin ------------------------ ^  Small Peptides  ► Smaller Peptides
i Amlnopeptldases parasite cytoplasm
Haem
, Amino Acids
Biocrystalization
Haemozoine
Fig. 4. The general pathway for haemoglobin metabolism in P. falciparum (Ersmark et al., 2006). 
Degradation into small peptides can be accomplished by both plasmepsins and falcipains (Francis at al., 
1997). Falcilysin is only able to cleave small polypeptides, producing even shorter oligopeptides (Eggleson at 
al., 1999). DPAP1 cleaved off dipeptides from haemoglobin-derived oligopeptides in the food vacuole (Klemba 
at al., 2004). Last hydrolysis to free amino acids is considered to take place in the parasite cytoplasm by 
aminopeptidases (Gavigan etal., 2001).
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2.3.1.3. Host cell rupture
Once an intracellular parasite has completed its development in the host cell, it 
must release to infect new cells and accompany the completion of the erythrocytic cycle 
(Klemba and Goldberg, 2002). Studies with different protease inhibitors showed the 
involvement of proteases in this step (Debrabant and Delplace, 1989; Hadley et al., 1983; 
Lyon et al., 1986; Salmon et al., 2001 ; Wickham et al., 2003).
Proteases capable of disrupting the erythrocyte membrane skeleton have been 
considered as responsible factors (Klemba and Goldberg, 2002). There are evidences 
that in addition to haemoglobin degradation, plasmepsins II and IV may also be involved 
in cleavage of the red cell membrane skeleton as they could degrade the host cytoskeletal 
protein, spectrin, in schizonts (Le Bonniec et al., 1999; Banerjee et al., 2002; W yatt and 
Berry, 2002).
Another erythrocyte skeletal protein, ankyrin, was cleaved by a cysteine protease 
activity in P. falciparum  extracts (Raphael et al., 2000). Older studies showed the 
accumulation of mature schizonts in cultures treated with leupeptin, a cysteine protease 
inhibitor (Hadley eta l., 1983; Lyon eta l., 1986; Debrabant and Delplace, 1989). Two other 
studies have further explored this event. Thus, E-64, another cysteine protease inhibitor, 
blocked the lysis of the parasitophorous vacuole membrane (Salmon et al., 2001). This 
result suggested the implication of cysteine protease activity in the hydrolysis of 
parasitophorous vacuole membrane-associated proteins to mediate merozoite release. A 
second report showed that two cysteine protease inhibitors, leupeptin and antipain, 
blocked lysis of the erythrocyte membrane (Wickham e ta l., 2003). Accordingly, it appears 
that the release of merozoites is a two-step process, requiring hydrolysis of proteins 
associated with the parasitophorous vacuole and erythrocyte membranes, and therefore 
cysteine protease activity appears to be required for both steps (Rosenthal, 2004).
2.3.2. Post-translational modification of proteins
With complete genome sequences appearing, attention is becoming increasingly 
directed towards the gene products of a given organism, in a specific situation. Proteomic 
studies have revealed that the repertoire of expressed proteins can expand beyond what 
is predicted by direct translation of the complement of open reading frames contained 
within a genome. For example, the proteome can acquire additional levels of complexity 
with differential expression of individual polypeptides or members of protein families as a  
function of developmental stage or in response to environmental cues. However, one of 
the most important and fundamental aspects of proteomic complexity comes from the 
various processing events that many proteins experience following their synthesis, i.e.,
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post-translational modification (Eichler and Adams, 2005). While posttranslational 
modifications enhance the already high complexity of a cellular proteome, they have key 
functions with many different purposes in various cellular processes such as enzyme 
regulation, signal transduction, mediation of protein localization, interactions and stability 
(Reinders and Sickmann, 2007). Genomic data can only partly predict such modifications 
although specific software and databases are rapidly evolving (Blom et al., 2004; Chen et 
al., 2006; Lee et al., 2006; Xue et al., 2006). Therefore, proteomics is the method for the 
analysis of modified proteins and peptides. However, the analysis of posttranslational 
modifications is probably the most versatile and difficult, but also most frequently studied 
area of interest in proteomics research (Reinders and Sickmann, 2007).
Proteins can be modified post-translationally by proteolytic processing of the newly 
synthesized polypeptide chain, by covalent attachment of one or more of several classes 
of molecules, by the formation of intra- or intermolecular linkages, or by any combination 
of these events (Walsh eta l., 2005).
Proteolytic processing of newly synthesized polypeptide chains allows the cell to 
control the folding and function of a protein. By removing specific targeting sequences or 
other stretches of amino acid residues, the cell is able to control where, when, and how a 
protein will act. As such, post-translational modifications can significantly modulate the 
physicochemical and biological properties of a protein through effects on protein function, 
subcellular localization, oligomerization, folding, or turnover (Eichler and Adams, 2005).
By chemically linking of different modifying groups either permanently or 
temporarily and by allowing for changes in the molecular composition of the modifying 
moieties, covalent modifications can provide proteins with properties that are very different 
from those that are predicted by the encoding genes. Examples of such covalent 
modifications include glycosylation, lipid attachment, phosphorylation, méthylation and 
protein oxidation (Eichler and Adams, 2005; Reinders and Sickmann, 2007).
In common with studies on many other organisms, mass spectrometry of P. 
falciparum extracts separated on 2-D  gels, highlights the presence of many proteins that 
are represented by more than one spot in the gel. These isoforms of a particular protein 
assumed to be post-translationally modified variants of that protein (Nirmalan eta l., 2004; 
Sims and Hyde, 2006). Biochemical studies have indicated that glycosylation (Gowda and 
Davidson, 1999) and phosphorylation (Jones and Edmundson, 1990; Suetterlin et al., 
1991) occur quite widely on parasite proteins, while acétylation has been observed on the 
parasite histones (Freitas-Junior et al., 2005) and actin (Schmitz et al., 2005).
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A comprehensive analysis of different post-translational modifications in parallel is 
usually not possible on a global scale. Therefore, the analysis should either be focussed 
on a single or very few distinct proteins or be directed towards a certain type of 
modification (Reinders and Sickmann, 2007).
2.3.2.1. Proteolytic processing
Protein processing is considered as a  regulatory mechanism in function of many 
proteins such as receptors, kinases, transcription factors, and structural components. 
Such modification can remove regulatory proteins when they are not needed, alter an 
existing function or transform others from the inactive forms into the biologically active 
state. The latter mechanism often involves a subsequent change of cellular localization 
(Ehrmann and Clausen, 2004).
Proteolytic processing is a common posttranslational modification of a number of 
proteins involved in attachment and invasion of apicomplexan parasites such as 
Plasmodium  spp. (Carruthers and Blackman, 2005). Processing of these proteins occurs 
either during transport through the secretory pathway or after secretion onto the parasites’ 
surface. In many cases, proteolytic processing of these proteins has been shown to be 
crucial for invasion of host cells by these parasites (Carruthers and Blackman, 2005; 
Wanyiri eta l., 2007).
In P. falciparum, a comparison of orthologous proteins reveals that Plasmodium  
proteins can be up to 50%  longer than the yeast proteins (Aravind et al., 2003). This 
increased size is in striking contrast to the marked reduction in protein size that is seen in 
another parasitic eukaryote, Encephalitozoon (Katinka et al., 2001). Analysis of this size 
difference brings up a remarkable feature of Plasmodium  proteins; they are vastly more 
enriched in stretches that are predicted to form nonglobular structures than most other 
eukaryotes. These stretches show a characteristic composition in terms of being biased 
toward one or a few amino acids and are often characterized by homopolymeric runs of 
residues (most frequently asparagines) (Aravind et al., 2003). These stretches possess 
low entropy or complexity (Wootton, 1994). In contrast, those regions of a protein that 
form globular structures show a greater diversity of amino acids in any given stretch of 
primary structure and are accordingly high entropy or high complexity regions (Wootton, 
1994). Enrichment of low complexity regions in asparagines distinguishes the Plasmodium  
from most other eukaryotes (except Dictyostelium discoideum), whose low complexity 
regions are typically enriched in glutamate and glutamine (Aravind et al., 2003). In most 
eukaryotes studied to date, low complexity regions are seen mainly in transcription factors 
and nuclear proteins, and some large cytoskeletal proteins. In contrast, Plasmodium
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contains low complexity regions in several proteins that have never been observed to 
contain such segments in other eukaryotes. Furthermore, in Plasmodium  the low 
complexity regions invade even ancient compact globular domains, and may vary in 
length, from small inserts of less than 10 amino acids to inserts of more than 100 amino 
acids (Aravind eta l., 2003).
Among proteins possessing such insertions, P. falciparum  glucose-6-phosphate 
dehydrogenase-6-phosphogluconolactonase (G 6PD-6PG L), a bifunctional enzyme  
exclusive to Plasmodiumspec\es, can be mentioned (Clarke eta l., 2001). This protein has 
a subunit molecular mass of 107 kDa (Kurdi-Haidar and Luzzatto, 1990). Its C-terminal 
half (residues 3 11 -9 11 ) is clearly homologous to other described G 6PDs (with glucose 6- 
phosphate dehydrogenase activity), though sequence similarity is interrupted by a 62  
amino acid stretch with no similarity found to date (Clarke et al., 2003). It has been 
nonetheless experimentally shown that this 62 amino acid insertion is necessary for the 
activity of the bifunctional enzyme (Clarke et al., 2003). In contrast, the 310 amino acid 
protein sequence of the N-terminal region clearly differs from most eukaryotic and 
prokaryotic G6PDs, and shows 6-phosphogluconolactonase activity. The first two steps of 
the pentose phosphate pathway (PPP) is catalyzed by this bifunctional enzyme (Clarke et 
al., 2001). In both the host and parasite, the PPP is essential for neutralizing reactive 
oxygen species during red blood cell infection with the malaria parasite. Therefore, PPP  
activity is greatly increased in infected erythrocytes compared to noninfected ones, and 
the parasite PPP is responsible for 82%  of this activity (Atamna eta l., 1994 ; Clarke e ta l.,
2001).
In cultures of P. falciparum, the effects of PfG 6PD-6PG L gene silencing on the 
mRNA expression of parasite antioxidant defense genes have been shown (Crooke et al.,
2006). This gene silencing caused arrest of the trophozoite stage and increased 
gametocyte formation. Moreover, an immediate transcriptional response was shown by 
thioredoxin reductase suggesting the physiological importance of this bifunctional enzyme  
in the specific response of the parasite to intracellullar oxidative stress (Crooke et al.,
2006).
Therefore, P. falciparum  G 6PD -6PG L could be considered as a candidate 
therapeutic target not only because of its structural characteristics which make it different 
from its human equivalent, but also because of the importance of this enzyme in the 
intraerythrocytic stage (Clarke et al., 2003).
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2.S.2.2. Oxidative stress
2 .3 .2 .2 .1. Reactive oxygen species
Reactive oxygen species (ROS): (a) are present as pollutants in the atmosphere; 
(b) are generated as by-products of normal metabolic processes; and (c) are formed 
during exposure to X-, X-, or U.V.-irradiation (Stadtman and Levine, 2003). In the cell, 
ROS are constantly generated at low concentrations under physiological conditions, 
playing a part in the cellular redox regulation (Dalle-Donne et a!., 2006). ROS can also 
occur as the outcome of acute cell stresses or as a secondary effect of pharmacological 
treatment (Dalle-Donne et a!., 2006). Cellular oxidative damage develops when the 
balance between ROS-generating systems and ROS-scavenging ones tilts in favour of the 
former (Dalle-Donne eta l., 2006).
The primary cellular target of oxidative stress can vary depending on the cell type, 
the absolute level and duration of oxidant production, the species of ROS generated, its 
site of generation (intra- vs. extra-cellular), and the proximity of the oxidant to a specific 
cellular substrate. Therefore, the extent of damage to particular targets depends on 
different factors. Proteins are major targets for ROS as they are the major component of 
most biological systems (Davies et al., 1999). Higher concentrations of the target protein 
considers as one of the crucial factors which cause more oxidation damage (Dalle-Donne 
et al., 2006). There is increasing evidence that accumulation of oxidized dysfunctional 
molecules in the cell over a lifetime contributes to the reduction of its half-life (Berlett and 
Stadtman, 1997; Beckman and Ames, 1998).
Some ROS-induced protein modifications can result in unfolding or alteration of 
protein structure, and some are essentially harmless events (Cabiscol and Ros, 2006). 
Irreversible modifications such as protein carbonylation, and protein-protein cross-linking 
are generally responsible for permanent loss of function of the dam aged proteins which 
are subsequently degraded or may progressively accumulate in intra-cytoplasmic 
inclusions as observed in some neurodegenerative diseases (Ghezzi and Bonetto, 2003). 
In fact, such permanent modifications are implicated in the etiology or progression of a  
number of disorders and diseases (Stadtman and Levine, 2000).
2.3.2.2.2. Oxidation of the protein backbone by free radicals
Free amino acids and amino acid residues in proteins are highly susceptible to 
oxidation by one or more reactive species (RO S) which include radical species such as 
superoxide (O 2* ), hydroxyl (’OH), peroxyl (R O 2*), alkoxyl (RO*), hydroperoxyl (HO 2’ ), and 
non radical species such as hydrogen peroxide (H 2O 2). (Berlett and Stadtman, 1997; Dean 
et al., 1997). The mechanisms of these ROS-mediated oxidations reactions were
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elucidated by different groups (Garrison et al., 1962; Schuessler and Schilling, 1984; 
Garrison, 1987) who exposed solutions of amino acids, peptides, and proteins to ionizing 
radiation under conditions where *0H  or a mixture of *0H  and 0 2 ” are formed. Results of 
these studies demonstrated that the 'OH-dependent abstraction of a  hydrogen atom from 
the a-carbon of amino acids and the protein polypeptide backbone and also from the 
aliphatic side chains of hydrophobic amino acid residues of proteins are initial sites of 
attack (Stadtman and Levine, 2003). As illustrated in Fig. 5, abstraction of the hydrogen 
atom leads to formation of a carbon-centred radical (reaction c), which in the presence of 
oxygen is rapidly converted to the peroxyl radical (reaction d). This peroxyl radical is 
readily converted to the alkyl peroxide by reaction with the protonated form of the 
superoxide radical (reaction e) or by abstraction of a hydrogen atom from another 
molecule (reaction f). Further reactions with H 02* can lead to formation of the alkoxyl 
radical (reaction h) and its conversion to the hydroxy derivative (reaction j). Although the 
reaction sequence illustrated in Fig. 5 was established by using ionizing radiation for the 
generation of ’OH and H 0 2 ’ , it is likely that cleavage of H 2 0 2  by iron or copper (reaction 
b. Fig. 5) is a major source of ’OH under physiological conditions. Furthermore, as shown 
in Fig. 5, Fe(ll) is also able to replace H 0 2 ’ in the reactions leading to formation of the 
alkyl peroxide, alkoxyl radical, and the hydroxy derivative (reactions g, i, and k ). 
Significantly, all reactions depicted in Fig. 5, following the hydrogen abstraction by 'O H, 
are dependent upon the addition of 0 2  to the carbon-centered radical (reaction d). In the 
absence of 0 2 , two carboncentered radicals can react with one another to produce 
carbon-carbon cross-linked derivatives (reaction I, Fig. 5) (Stadtman and Levine, 2003).
In addition to the reactions illustrated in Fig. 5, the oxidation of proteins by ROS 
can lead also to the cleavage of peptide bonds (Stadtman and Levine, 2003). The alkoxyl 
radicals and alkylperoxide derivatives of proteins can undergo cleavage by either a- 
amidation or diamide pathways (Garrison, 1987). In the oc-amidation pathway, the 0 -  
terminal amino acid of the fragment derived from the N-terminal region of the protein will 
exist as the amide derivative and the N-terminal amino acid of the fragment derived from 
the C-terminal portion of the protein will exist as an a-keto-acyl derivative. In contrast, the 
C-terminal amino acid of the fragment derived from the N-terminal portion of the protein 
via the diamide pathway will exist as the diamide derivative and the N-terminal amino acid 
residue of the peptide fragment derived from the C-terminal region of the protein will exist 
as the isocyanate derivative (Stadtman and Levine, 2003).
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mOH HO,
CO Hc-c
OH‘
Fig. 5. Free radical-mediated oxidation of the protein polypeptide backbone (Stadtman and Levine, 
2003).
2.3.2.2.3. Site-specific m etal-catalyzed oxidation
In addition to the free radical-mediated oxidation of the protein polypeptide 
backbone (Fig. 5), the side-chains of amino acid residues of some proteins are readily 
oxidized by metal ion-catalyzed oxidation systems (Pucci eta l., 1983; Levine, 1983; Rivett 
et al., 1985; Amici et al., 1989; Stadtman et al., 1990). Direct oxidation of the side-chains 
of lysine, arginine, proline, and threonine residues has been shown to yield carbonyl 
derivatives (Stadtman and Levine, 2003). In studies with E. coli glutamine synthetase, it 
was found that amino acid residues situated at metal binding sites on the enzyme are 
uniquely sensitive to metal-catalyzed oxidation by a site-specific mechanism (Farber and 
Levine, 1986; Stadtman and Levine, 2003). For example, lysine residues can be the target 
for Fe(ll)-catalyzed oxidations where the chelate complex formed by the binding of Fe(ll) 
to the E-amino group reacts with hydrogen peroxide to generate a hydroxyl radical that 
will preferentially attack the lysine moiety leading to its conversion to a 2-amino-adipic- 
semialdehyde residue (Stadtman and Levine, 2003). Similar reactions of the Fe(ll) with 
other amino acid targets lead to the generation of carbonyl derivatives (arginine, proline, 
and threonine residues) (Stadtman and Levine, 2003).
2.3.2.2.4. Protein carbonylation and carbonyl group detection
ROS-m ediated protein carbonylation is an important marker of protein oxidation 
and its measurement is thought to be a good and the most widely used indicator for the
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extent of oxidative damage of proteins associated with various conditions of oxidative 
stress, aging and physiological disorders (Butterfield and Kanski, 2001). Carbonyl groups 
may be introduced in the protein at different sites and by different mechanisms (Ghezzi 
and Bonetto, 2003). As it is explained, direct reaction of proteins with RO S can lead to 
formation of protein derivatives (Fig. 5) or peptide fragments possessing highly reactive 
carbonyl groups (ketones, aldehydes) (Stadtman and Levine, 2003). As illustrated in Fig. 
6, proteins containing reactive carbonyl groups can also be generated by secondary 
reactions of primary amino groups of lysine residues of proteins with reducing sugars or 
their oxidation products (glycation/glycoxidation reactions) and also by Michael- addition 
reactions of lysine, cysteine, or histidine residues with a, (3-unsaturated aldehydes formed 
during the peroxidation of poly-unsaturated fatty acids (Stadtman and Levine, 2003). A 
general scheme of origins of carbonylated proteins can be seen in Fig. 7.
A CHO 
(HÇOH),
R
R O S -^  P-Lyft-NHj
CHO 
C=0
R
CH=NH4_y*
R
B
R-Ç-C=CH-<C.
OH H
P-Ow-SH
CHaNH-tys-P
c«o
(HCOH)«.,
R
Amadori
Product
Im-Hl8-P 
H N  , 
R -C -C -C H ^  
ONH H
Cy»-P
OHH
^y»-P 
OHH "
Fig. 6. Generation of carbonyl derivatives of proteins. A By glycation/glycoxidation of lysine amino groups. 
B By reactions of a-p-unsaturated aldehydes with lysine, cysteine, or histidine residues of proteins (Stadtman 
and Levine, 2003).
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and
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Oxidative cleavage of the protein backbone
Fig. 7. Origins of carbonylated proteins. Protein carbonyl derivatives can be produced by different oxidative 
pathways. ROS can react directly with the Lys, Arg, Pro, and Thr side chains of proteins mainly through metal- 
catalysed oxidation (pathway 1). Direct oxidation of proteins by ROS can also yield highly reactive carbonyl 
derivatives resulting from the cleavage of peptide (pathway 2). Carbonyl groups may be introduced into 
proteins by adduction of reactive aldehydes derived from the metal-catalysed oxidation of polyunsaturated 
fatty acids (pathway 3). These lipoxidation products include a,p-unsaturated aldehydes which can undergo 
Michael-addition reactions and react with the sulfhydryl group of Cys, the E-amino group of Lys or the 
imidazole group of His residues, di-aldehydes and y-ketoaldehydes which react with Lys residues. Finally, 
carbonyl groups can also be generated by secondary reaction of the primary amino group of Lys residues with 
reactive carbonyl derivatives (ketoamines, ketoaldehydes, deoxyosones), produced by the reaction of 
reducing sugars or their oxidized products with lysine residues of proteins (pathway 4) (Dalle-Donne et al., 
2006).
Carbonyl (CO) groups (aldehydes and ketones), produced on protein side chains 
(especially of Pro, Arg, Lys, and Thr) when they are oxidized, are chemically stable that is 
useful for both their detection and storage (Dalle-Donne et a!., 2003). Protein carbonyl 
content is actually the most general indicator and by far the most commonly used marker 
of protein oxidation (Berlett and Stadtman, 1997; Chevion et al., 2000; Shacter, 2000; 
Beal, 2002; Poon et al., 2004; Reverter-Branchat e ta l., 2004; Poon e ta l., 2005; Chen et 
al., 2006; Sultana et al., 2006; Calabrese et al., 2007; Vaishnav et al., 2007; Yeh et al., 
2008). Highly sensitive assays for detection of protein carbonyls involve derivatisation of 
the carbonyl group with 2,4-dinitrophenylhydrazine (DNPH), which leads to the formation 
of a stable 2,4-dinitrophenyl (DNP) hydrazone product. Then, the stable DNP adduct can 
be detected by various means (Dalle-Donne et al., 2003). The DNP group itself absorbs 
ultraviolet light so that the total carbonyl content of a protein or mixture of proteins can be 
quantified by a spectrophotometric assay (Levine et al., 1990), which can be coupled to 
protein fractionation by high-performance liquid chromatography (HPLC) to give greater
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sensitivity and specificity than measuring total carbonyls in a protein mixture (Levine eta l., 
1994).
In the last years, the identification of carbonylated proteins has been facilitated by 
the availability of commercial specific antibodies to anti-DNP that allow their detection by 
immunoblotting analysis (Dalle-Donne et al., 2003). Immunoblotting assays based on the 
use of anti-DNP antibodies have been developed in an attempt to identify oxidatively 
damaged proteins in human tissues and body fluids (Keller et al., 1993; Shacter et al., 
1994; Robinson e ta l., 1999).
Moreover, carbonyl content in individual proteins can also be assessed by two- 
dimensional electrophoresis (2-DE) followed by Western blot immunoassay, which have 
significantly more sensitivity and specificity than all other total carbonyl assays, but they 
are only semiquantitative. (Dalle-Donne e ta l., 2003). 2-D  PAGE and subsequent Western 
blot immunoassay (2-D immunoblotting), followed by mass spectrometry, are actually 
widely used methods of redox proteomics for identification of oxidized proteins under 
oxidative stress (Choi et al., 2002; Butterfield, 2004; Reverter-Branchat eta l., 2004; Poon 
et al., 2004; Poon et al., 2005; Tezel et al., 2005; Sultana et al., 2006; Vaishnav et al., 
2007).
2.3.2.2 .5 . Oxidative stress in Plasmodium
All aerobic organisms are exposed to ROS generated by their own metabolic 
activity. Parasitic protozoa not only have to eliminate their endogenous toxic metabolites 
but they must also cope with the oxidative burst of the host immune system (Muller et al.,
2003).
Although oxidative stress has been suggested to play a key role in the 
pathogenesis of malaria (Becker et al., 2004), it has been shown that malaria parasites 
are particularly vulnerable to oxidative stress during their erythrocytic life stages (Hunt and 
Stocker, 1990; Simoes et al., 1992; Muller et al., 2003; Becker et al., 2004). This is not 
surprising as the parasites live in a pro-oxidant environment that contains oxygen and 
iron, the key prerequisite for the formation of ROS via the Fenton reaction (Fig. 8) (Muller,
2004). Interestingly, its susceptibility to oxidative stress (Muller, 2004) has advocated this 
metabolism as a promising target for antimalarial chemotherapy (Becker et al., 2004). 
Apart from the large amounts of reactive oxygen species (RO S) generated by the active 
metabolism of the growing and multiplying malaria parasite, a main source of oxidative 
stress is the degradation of host haemoglobin (Becker et al., 2004). Haemoglobin 
represents the major source of amino acids for for parasite development, but its 
degradation in an acidic food vacuole results in the production of toxic free haem
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(ferri/ferroprotoporphyrin IX; FP IX) and ROS (Muller, 2004). In the erythrocyte, haem iron 
is almost entirely in the ferrous (+2) state. Upon degradation in the parasite digestive 
vacuole, the iron is oxidized to the ferric (+3) state. Electrons liberated by oxidation 
combine with molecular oxygen to produce superoxide anions (Og ). This combination 
inevitably leads to the generation of hydrogen peroxide and subsequently hydroxyl 
radicals, both highly reactive and toxic oxygen intermediates (Fig. 8) (Francis e ta l., 1997; 
Liochev and Fridovich, 1999). Furthermore, free FP IX is toxic because it has detergent­
like properties interfering with membrane integrity and has the ability to undergo redox 
reactions causing the generation of ROS because of the bound iron (Muller, 2004). In P. 
falciparum, most of the released FP IX is biomineralized (Egan e ta l., 2002; Hempelmann, 
2007) to form inert haemozoin (Fig. 8). Alternative detoxification pathways, including FP 
IX degradation (Zhang e ta l., 1999), reaction with glutathione (Ginsburg et al., 1998), and 
the binding to FP IX-binding proteins (Harwaldt e ta l., 2002; Campanale e ta l., 2003), may 
also contribute to FP IX detoxification since escaping small amount of the FP IX from the 
detoxification processes (Loria et al., 1999) could cause redox dam age to host and 
parasite proteins and membranes (Campanale eta l., 2003; Famin and Ginsburg, 2003).
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Fig. 8. Sources of ROS In P. falciparum. The major source for ROS In P. falciparum during Its 
intraerythrocytic life is the digestion of host cell haemoglobin in the parasite’s FV. FP IX is released from the 
digested haemoglobin and the majority of that is biocrystallized to haemozoin (Egan et al., 2002). Alternative 
detoxification pathways ( Ginsburg et al., 1998; Zhang et al., 1999; Harwaldt etal., 2002; Campanale etal., 
2003) may also contribute to FP IX detoxification. However, some free FP IX (Loria etal., 1999) releases from 
the FV into the parasite cytosol where it causes membrane damage and can undergo redox reactions which 
lead to the generation of superoxide anions in this parasite compartment. Superoxide anions, resulting from 
the oxidation of haem-iron in haemoglobin, are either detoxified by SOD, to yield H2O2 , or can react in a 
spontaneous reaction with H2O2 leading to the formation of hydroxyl radicals. In addition, hydroxyl radicals are 
generated in the presence of free iron via the Fenton reaction. These radicals are highly reactive and cause 
cell damage. H2O2 generated by the SOD reaction has to be detoxified by reduction to H2O. In P. falciparum, 
this is exclusively achieved by thioredoxin peroxidases because the parasites lack catalase and glutathione 
peroxidases. FP IX, ferri/ferroprotoporphyrin IX; FV, food vacuole; HbO-Fe^"^, oxy-haemoglobin containing 
ferriprotoporphyrin IX; MetHb-Fe^'', methaemoglobin containing ferroprotoporhpyrin IX; SOD, superoxide 
dismutase. (Muller, 2004).
2.3.2.2 .6 . Antimalarial drugs interfering with redox metabolism
In spite of being used more than 50 years, the mode of CO action and the 
mechanisms of resistance are only partly understood (Koncarevic et al., 2007). Among 
different theories, the most widely spread hypothesis is the C Q -FP IX interaction 
hypothesis, which states that GO and other 4-aminoquinolines exert their antimalarial 
action by preventing the detoxification of free haem which is generated during the 
degradation of host haemoglobin in the parasites’ digestive vacuole (Koncarevic et al.,
2007), where CO accumulates (Egan, 2001; Spiller et al., 2002). In this location it is 
thought to interact with the p-oxo dimer form of oxidized haem (one of the various possible 
chemical forms of dimeric FP IX, [Fe(lll)FP  IX ]20) (Chou et al., 1980; Moreau et al., 
1982; Egan e ta l.,  1997; Dorn e ta l., 1998; Leed e ta l.,  2002). Studies using NMR have
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been taken to suggest that the interaction of CQ with FP IX involves tt-  tt  stacking 
(Moreau et al., 1982). The interaction of CQ  with the FP IX p-oxo dimmer prevents the 
formation of the haemozoin dimer which is presumably an intermediate in the formation of 
the haemozoin crystal and CQ  binding thereby prevents FP IX detoxification (Becker et 
al., 2004). It has been suggested that the consequent build-up of free FP IX and CQ -FP IX 
complexes is lethal for the parasite, as free FP IX has been proposed to damage 
membranes and enzymes due to its detergent-like properties as well as its ability to 
participate in damaging redox reactions (de Almeida Ribeiro, 1995; Loria et al., 1999; 
Pandey et al., 2001; Tilley, 2001; Sullivan, 2002). Therefore, oxidative stress in the 
mechanism of action of CQ has always been thought as one of the indirect or direct 
targets of CQ action (Becker e ta l., 2004).
The involvement of oxidative events in the downstream effects of CQ is also 
supported by studies of the modulation of CQ action by G SH levels (Becker eta l., 2004). 
Moreover, nonbiomineralized haem seems to be degraded by glutathione (Ginsburg eta l., 
1998) and given that CQ competitively inhibits the degradation of haem by glutathione, the 
increasing cellular levels of glutathione leads to increased resistance to CQ, whereas 
decreasing them results in enhanced sensitivity to the drug (Ginsburg e ta l., 1998).
Thus, the enhancement of intracellular ROS is considered the final consequence 
of the C Q  action, but it remains unknown how this toxic environment modifies the 
essential functions of the parasite.
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3. OBJECTIVES
The complex biology and life cycle of P. falciparum  has hindered attempts to 
control infections. In addition, there is increasing resistance of the malaria parasites to 
currently available drugs. In general, the efforts to control malaria have been focused on 
the chemotherapy, mosquito control and in the development of vaccines. Nowadays, the 
lack of an effective vaccine and the increasing parasite resistance to available drugs 
suggest the necessity to identify new targets that allow the development of new drugs and 
vaccines. Completion of Plasmodium  genome sequences has provided a  vast amount of 
molecular information. This, together with the transciptome and proteome analysis along 
the parasitic developmental stages pursue a deep understanding of the peculiar parasite 
biology in the context of exploring new therapeutic and immunization strategies.
The first part of this project explored a new protease, PfNnat gene, encoded in P. 
falciparum genome with interest as a potential target for inhibitors. Transcription analysis 
of this new metalocarboxypeptidase and the effect of potato carboxypeptidase inhibitor 
(PCI) on the erythrocytic cycle of the parasite have been studied.
The particular bifunctional P. falciparum G 6PD - 6PG L protein, which is exclusive to 
Plasmodium  species and catalyses the first two stages of the pentose phosphate 
pathway, was explored in the second part of this thesis. The interest of this gene relies on 
its potential protein processing along the different intraerythrocytic stages. Such enzyme 
could be a potential therapeutic target not only because of its unique structural 
characteristics that make it different from its host, but also because of the importance of 
this enzyme in the parasite’s intraerythrocyte cycle.
To achieve high yields of isolated proteins, which are necessary to work on protein 
level and to do a comparative study of protein profiling by proteomic analysis, highly 
parasitized cultures are needed. In the third part of the work, to fulfil requirements for 
proteome studies of intraerythrocytic stages of P. falciparum, we have therefore worked in 
large-scale and produced a high percentage parasitaemia.
In the fourth part of the present work, a proteomic approach has been applied to 
identify and compare oxidatively modified proteins in the different intraerythrocytic stages 
of non-treated and chloroquine-treated P. falciparum from a chloroquine-resistant strain. 
Such studies are informative with regard to the importance of such proteins in the life 
cycle of the malaria parasite and as potential new therapeutical targets to fight 
chloroquine and other quinolines resistant P. falciparum  strains.
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Overall, in this context the general objective of the work relies on studying the biology 
of P. falciparum  in transcriptional, translational and post-translational levels to find 
potential targets for the development of effective therapeutic drugs. Particular emphasis 
was given to clarify the mechanism of action of chloroquine, as efficient antimalarial in the 
past, in order to know in detail the post-translational modifications shown by the resistant 
phenotype parasite. For this purpose, the specific experimental objectives were the 
following:
1- Studying mRNA expression of PfN nal target gene in relation with the 
carboxypeptidase inhibitor (PCI) effect on the parasite life cycle.
2- Analyzing PfNnat gene polymorphysm in the strains Dd2 and 3D7 of P. 
falciparum.
3- Analyzing the P. falciparum  bifunctional enzyme of G 6PD -6PG L as a model to 
study protein processing.
4- Characterizing the P. falciparum  redox proteome across the intraerythrocytic cycle, 
and the modifications caused in response to chloroquine.
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1. Abstract
The complex biology and life cycle of Plasmodium falciparum  has hindered 
attempts to control infections and prevent transmission. In addition, there is increasing 
resistance of the malaria parasites to currently available drugs. Therefore, there is an 
urgent need for the development of new chemotherapeutic agents that can control the 
parasite. Recent strategies for antiparasitic drug discovery include seeking for specific 
inhibitors of critical biological activities within the complex parasite cycle. In this context, 
protease genes have already demonstrated that play key roles in the biology of malaria 
parasites and offer potential new chemotherapeutic targets.
The present study, focus on transcription analysis of the P fN nal gene in relation 
with the potato carboxypeptidase inhibitor (PCI) effect on the P. falciparum  erythrocytic 
cycle. Identification and characterization of the PfNnal gene has been previously 
reported. Experimental confirmation that PCI inhibited parasite growth has been in vitro 
and in vivo assessed in a different project with participation of our research group. The 
reported specificity of the inhibition suggested the presence of a putative functional 
protease, which is essential for the parasite life cycle, in the P. falciparum  genome. In fact, 
analysis of mRNA expression allowed establishing a link between the inhibitor and the 
PfN nal gene in P. falciparum. The P fN nal mRNA expression pattern along the 
intraerythrocytic phase demonstrated that is maximally expressed in the mature 
developmental stages, phase at which PCI arrested parasite growth. Moreover, the 
transitional exposure of the parasite to PCI up-regulated the expression of PfNnal gene. 
These observations suggest the involvement of this putative peptidase gene in essential 
activities for the parasite survival.
Keywords:
Carboxypeptidase inhibitor /  PfNnat /  Plasmodium falciparum i  Proteases /  Transcription
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2. Introduction
Malaria caused by Plasmodium  parasites kills approximately 1-3 million people 
and causes disease in 300-500  million people annually throughout the world (Tripathi et 
al., 2005). The current limitations of malaria vaccine development, and the emergence  
and spread of insecticide-resistant vectors and drug-resistant parasites are major causes 
behind the re-emergence and severity of a worldwide malaria problem (Sharma, 2007).
In the last 50 years, extensive efforts, including the screening of hundreds of 
thousands of compounds, have led to the development of a number of effective synthetic 
antimalarial drugs. The most important of these, CQ, has been the mainstay of 
antimalarial chemotherapy for the last 50 years. However, resistance to CQ has been 
steadily increasing since the drug’s initial use in South America and Southeast Asia in the 
late 1950s (Rosenthal, 1998). CQ resistance is now widespread in most P. falciparum- 
endemic areas of the world (Olliaro at a i,  1996). Thus, the use of CQ for treatment of 
falciparum malaria is usually no longer appropriate as about 80%  of the parasite 
population is resistant to this drug (Ehrhardt at a i,  2007). Moreover, resistance to C Q  of 
P. vivax, the second most lethal human malaria parasite, is increasing in South Asia 
(Murphy ata l., 1993).
In fact, the antimalarial drug resistance progressively acquired by many parasite 
strains all over the world do not allow the disease control and favour its transmission to 
other previously controlled areas (Bloland, 2001). Consequently, there is a need for new  
drugs and the identification of new chemotherapeutic targets. To this respect, publication 
of the complete genome sequence from P. falciparum (Gardner at a i,  1998; Bowman at 
a i,  1999; Gardner at a i,  2002) opens new possibilities for the development of new  
therapeutic drugs and vaccines.
All parasitic protozoa contain multiple proteases that some of which are attracting 
attention as drug targets (Coombs at a i ,  2001). Aspartic proteases are already the targets 
of some clinically useful drugs, like chemotherapy of H IV infection (Wlodawer and 
Vondrasek, 1998; Tomasselli and Heinrikson, 2000), and a  variety of factors make these 
enzymes potential targets for novel antimalarial therapies (McKerrow at a i,  1993).
Extensive evidence demonstrates that proteases play substantial roles during the 
malaria parasite life cycle (Rosenthal, 2001; Rosenthal, 2002). They appeared to be 
involved in multiple processes essential for metabolism and development of the parasite, 
including haemoglobin hydrolysis, the processing of parasite proteins, merozoite release, 
and invasion of red blood cells (Schrevel at a i ,  1990).
The erythrocytic life cycle, which is responsible for all clinical manifestations of 
malaria, begins when free merozoites invade erythrocytes (Rosenthal, 1998). The  
intraerythrocytic parasites develop from small ring-stage organisms to larger, more
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metabolically active trophozoites and then to multinucleated schizonts. The cycle is 
completed when mature schizonts rupture erythrocytes, releasing numerous invasive 
merozoites. Erythrocyte entry and host cell rupture require the activity of parasite 
proteases, and these enzymes are therefore attractive targets for rational approaches to 
new drug development (Blackman, 2000). Malarial proteases play a  role in at least two 
distinct aspects of host cell invasion; modification of parasite proteins involved in host cell 
recognition and entry; and restructuring of the host cell itself during and following invasion, 
and in order to allow parasite release from the host cell (Blackman, 2000). Moreover, 
proteases appear to be required for the degradation of haemoglobin (Fig. 1) that is 
necessary for the growth of erythrocytic malaria parasites (Rosenthal, 1998). These  
results strongly suggest that plasmodial proteases could be appropriate targets for the 
development of chemotherapeutic drugs (Rosenthal, 1998).
.^Erythrocyte invasion 
h  Merozoites
V J " .
Erythrocyte rupture
Schizont
Haemoglobin degradation 
Trophozoit
Fig. 1. Protease targets In erythrocytic malaria parasites. The P. falciparum erythrocytic life cycle is shown 
schematically.
The first indications that proteolytic activity is important during the malaria life cycle 
came from experiments investigating the effects of broad-spectrum protease inhibitors on 
invasion process and haemoglobin degradation (Blackman, 2000). Considering parasite 
proteases, that are required for its survival, as a potential new target for chemotherapy, 
protease inhibitors are in the spotlights as antimalarial drugs, however, protease inhibitors 
must be highly potent and specific for parasite proteases to be recognized as biological 
tools (Sharma, 2007). Although studies evaluating the antimalarial effects of protease 
inhibitors are limited to date, experience with other systems, such as HIV aspartic 
protease (Deeks et a!., 1997), suggests that inhibitors of essential proteases can be 
developed as antimalarial drugs (Rosenthal, 2002). Some of the main P. falciparum 
protease inhibitors identified up to date include cysteine protease inhibitor leupeptin
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(DIuzewski at a!., 1986; Rosenthal et a!., 1988; Vander Jagt et a/., 1989) and E-64  
(Rosenthal e ta !., 1988; Vander Jagt et a!., 1989; Bailly eta !., 1992; Asawamahasakda et 
a!., 1994; Rosenthal, 1995); aspartic protease inhibitor pepstatin (Bailly et a!., 1992; 
Rosenthal, 1995; Banerjee et a!., 2002); serine protease inhibitor GlcA-valine-leucine- 
glycine-lysine-NHC2Hs (Mayer et a!., 1991); aminopeptidase inhibitor bestatin (Vander 
Jagt e ta !., 1989; Nankya-Kitaka et a!., 1998) and proteasome inhibitor lactacystin (Gantt 
et al., 1998). Protease inhibitor combinations also seems appropriate to inhibit parasite 
growth as it has been shown with cysteine and aspartic proteases which appear to act 
cooperatively in haemoglobin degradation (Francis et al., 1994). Pepstatin used in 
combination with E64 or N-M e pipu-Leu-Hph-VSPh, gave promising results and are 
examples of such synergistic effects (Semenov et a i,  1998).
The potato carboxypeptidase inhibitor (PCI) (Aviles et al., 2006), was used by our 
group to inhibit the growth of P. falciparum. PCI is a 39-amino acid protein naturally 
occurring in potatoes that can inhibit several carboxypeptidases (Vendrell et a i ,  2000). Its 
inhibitory effect on tumor cell growth was reported before (Blanco-Aparicio et a i ,  1998). 
Inhibition of P. falciparum cultures by PCI proves that a kind of carboxypeptidase activity 
should function in the malaria life cycle. Searching for the target gene of PCI in the 
molecular databases showed the existence of a new metallocarboxypeptidase, P. 
falciparum  N nal-like (P fN n a l) gene of M l4 family (Rodriguez de la Vega et a i,  2007). 
This gene has been reported to be highly up-regulated in spinal cord of mice subjected to 
sciatic nerve injury (Harris et a i ,  2000) and has therefore been named N nal ( Nervous 
system Nuclear protein induced by Axonomy). A detailed genomic scanning found about 
100 N nal homologues in bacteria, Protista, and Animalia (Rodriguez de la Vega et a i,
2007). This study shows that N nal-like  proteins ranged from 400 to 2000 residues in 
length and comprise a common metallocarboxypeptidase domain of -3 0 0  residues and a  
N-terminal conserved domain that is -1 5 0  residues in length and contains two other 
conserved motifs such as FESG and PYTY. These peptidases conserve the Zn^^ ligands 
and the catalytic residues of metallocarboxypeptidases, but where the motifs take place 
differ from each other and make different subfamilies (Rodriguez de la Vega et a i ,  2007). 
As methalocarboxypeptldases, these enzymes catalyze the hydrolysis of C-terminal 
amino acids from peptides. The lack of the N-terminal signal peptide in the N nal-like  
proteins of eukaryotes (Rodriguez de la Vega et a i,  2007) means that they function in the 
cleavage of cytosolic proteins. It is believed that these proteins are involved in the 
proteolytic processing of a-tubulin, the only cytosolic protein known to undergo C-terminal 
processing, a-tubulin is initially produced with a C-terminal tyrosine, which is removed 
(Hallak et a i,  1977) by possible function of N nal-like  proteins as tubulinyl-Tyr 
carboxypeptidase (Rodriguez de la Vega et a i,  2007; Kalinina et a i ,  2007).
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PfN nal is a large gene (more than 1000 residues) with long N- and C-terminal 
extensions and extensive non-conserved insertions of up to 300 residues long (Rodriguez 
de la Vega et a!., 2007). P. falciparum growth inhibiton by PCI, alongside with the possible 
function of PfN nal as tubulinyl-Tyr carboxypeptidase, considering tubulin as a  
fundamental protein for cytoskeleton, suggest PfNnal as an important therapeutic target. 
Therefore, the gene expression analysis of this candidate protein for antimalarial 
chemotherapy has been done in this work.
3. Material and methods 
Parasite and cultures
P. falciparum  strains Dd2 (CQ  resistant) and 3D7 (CQ sensitive) were cultured in 
vitro in group human erythrocytes using previously described conditions (Trager and 
Jensen, 1976), with some modification. Briefly, parasites were cultured in RPMI 1640  
medium (Sigma), supplemented with 25 mM HEPES, 0 .5%  AlbuMAX I (Invitrogen), 1.77  
mM sodium bicarbonate, 100 pM hypoxanthine, and 12.5 pg/ml gentamicin sulphate, at a  
pH of 7.2. W here needed, the cultures were synchronized by sequential treatments with 
5%  (w/v) sorbitol (Lambros and Vanderberg, 1979). Experiments were performed with a  
5%  haematocrit and parasitaemia between 1 -2% .
Nucleic acid extraction
Genomic DNA was isolated from parasite extracts by treatment with lysis buffer 
(40 mM Tris-HCI, pH 8.0; containing 80 mM EDTA, 2%  SDS and 2 mg/ml Proteinase K) 
and incubated for several hours at 37°C. The DNA was extracted by phenol/chloroform 
and recovered by ethanol precipitation (Singh eta l., 1996).
Total RNA was isolated from 12 pi of infected red blood cell cultures with 2-3%  of 
parasitaemia using “RNA Blood-DNA Method” from Applied Biosystems on the ABI 
PRISM® 6100 Nucleic Acid PrepStation.
Reverse transcription/PCR
Isolated RNA was retrotranscribed to cDNA using the High-Capacity™ cDNA  
Archive Kit (Applied Biosystems) as described by the manufacturer. Both random primers 
and P fN nal specific primers (reverse primers of Table 1) were used for 
generating different cDNA first strands in two separate reverse transcription (RT) 
reactions. All RT reactions were done at 37"C for 2 h.
Two different Reverse Transcription PGR (RT-PCR) were used, standard and 
quantitative. The standard RT-PCR reaction was performed to amplify the PfNnal cDNA
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to determine the length of the sequence involved in gene in transcription. Also, these 
fragments were used to sequence the whole transcription unit from two strains Dd2 and 
3D7. For this cDNA amplification, the AmpliTaq Gold kit (Applied Biosystems) was used 
throughoutly. R T-PCR  was performed using the following cycle profile: 94'C, 1 min; 
58.1*0, 30 sec; 62*C, 3 min for 40 cycles with an i nitial 7-min dénaturation at 95*C and a 
final 7-min elongation at 62*C. The sequences of th e specific oligonucleotides used are  
given in Table 1. On the other hand, quantitative real time RT-PCR (qRT-PCR) was done 
to assess the relative abundance of PfNnal mRNA along the parasite cycle. The cDNA  
was amplified in the ABI PRISM® 7000 Sequence Detector (Applied Biosystems). The  
TaqMan® Universal PCR Master Mix, No AmpErase® UNG (Applied Biosystems) was 
used for ABI PRISM® 7000 amplification and detection. Molecular beacon probes and 
primers sequences are given in Table 2. According to our preliminary assays all primers 
and probe were used in a concentration of 300 nM. Real-time PCR involved 1 cycle each 
of 50*C for 2 min and 95*C for 10 min, foliowed by 45 cycles of 57*C for 1 min, 95*C for 
30 sec, and 45*C for 29 sec for fluorescence detect ion.
Primers and molecular beacons design
Primers for qRT-PCR, and the standard RT-PCR (Table 1) were designed (Primer 
Express 2 .0  software. Applied Biosystems) in a way that they could cover the whole 
PfNnal gene (GenBank Accession No. N C _004325) amplification with overlapping 
amplicons.
Molecular beacon and primers used for cDNA expression analysis (qRT-PCR) 
were designed according to previously published procedures (Bustamante et al., 2004) 
and are shown in Table 2. The quantification of mRNA from the Nna-1 like gene was done 
using the constitutive gene 18S rRNA as endogenous control.
Probes were labelled at the 5' end with 6-carboxyfluorescein (FAM). TAM RA was 
used as the 3' quencher. Probes were purchased from Isogen Life Science (Maarssen, 
The Netherlands), and primers were purchased from Genotek (Barcelona, Spain).
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Table 1. Primers of PfNnal gene for qRT-PCR and the standard RT-PCR.
Primer 
name (F: 
Forward, R: 
Reverse)
Primer sequence Fragment size (bp)
IF ATGGTGTTTACTGTTTTACTTATAATAATTTTAG 201
1R CAAATGG TTTGTCTCCTTGTCTTTTATTCTCTT
2F TGATAATATAAAAATGCAACAAGCC 165
2R ATTTTTGTTCCTATTTCTACGATATACTATAGA
3F ATCCATATGATAATGTGAACGCA 150
3R ATTTTTTCATCATTCATTTTGC TO
4F AATAAAGGAAGAAAATGACAAAGAAGT 102
4R ATAACTAGCACTGAAATAGAACCACTG
5F AAAGGTGTATGAATCAATATTTGAATG 99
5R AATTTATCACATGCGTCTAACGA
6F AAATAGAGAATATACAATGGGAAAGAAAT 151
6R TGCATACGTAAAATCATAACTAAATTCTA
7F TCATGTGGGTTTGATTGCC 150
7R CCATCCCATCAACCAATTTT
8F GTGGTAAATAATTTATTTGTTGATATGAAA 174
8R AACATTCTTTACACATATTATCATTTGAAT
9F TCGAGTTATGCAATACATGGATT 180
9R TCGGATTAGACCATTGCCTAT
10F GATTATATTTTTTTGTGATTTTCATAGTCA 180
10R CTCATTATCTGCTTTATATACAGTGTCG
11F GGTAAAAGAGGTATATGAGTTAGGAAGAA 154
11R CAGGACCTTTATACTTACCATTAGGAT
Table 2. Primers and molecular beacons designed for cDNA expression analysis of PfNnal.
Gene Forward primer 5 -3' Reverse primer 5 -3' Molecular beacon 5 -3'
PfNnat
PFA0170C
ATGTGTGAAGTTTTCCCAGAAATAT TTGCGCTCCCCTTATTCTC CGCGGATTACCTTGGTTTGCTCTTGTCGACACCQÇG
18S rRNA 
M l 9172
TGACTACGTCCCTGCCCTT ACAATTCATCATATCTTTCAATCGG GGGGGACACCGCGCGTCGCTGCCCC
The underlined sequence In the molecular beacon corresponds to the stem.
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mRNA expression analysis using the 2“^ ^^ method
The analysis of relative gene expression was performed using the 2'^^^ method 
described in detail in (Schmittgen and Zakrajsek, 2000). This involves comparing the 
target C j values of the treated samples with a non-treated sample. The target C t values of 
both treated and non treated samples must be normalized to the endogenous gene 18S  
rRNA. For the A A C j calculation to be valid, the amplification efficiencies of the target and 
internal control must be approximately equal. In order to validate our method, sample 
amplifications were performed on serial 10-fold dilutions using primers (Table 2) for the 
internal control (18S rRNA) and the target genes. The average C j was calculated for both 
internal control and target genes and the A C t ( C t ,T arg e t- C j, 18S rRNA) was determined. 
Plots of the log DNA dilution versus A C j were made. The absolute value of the slope (m) 
was below 0.1, so, the efficiencies of the target and internal control genes were 
considered as similar.
A A C t calculation for the relative quantification of targets were performed according to 
Equation A: AACT=(Ci,Target-CT, 18S rRNA)y- (CT.Target-C j, 18S rRNA)y, 
where x = variable under investigation (treated samples) and y=calibrator sample (non­
treated samples). Results for each treated sample were expressed in N-fold changes in 
target gene expression relative to the same gene target in the calibrator sample, both 
normalized to 18S rRNA:
Equation B: N-fold =2 ’^^^ (Livak and Schmittgen, 2001).
DNA sequencing
Final RT-PCR products were purified by QIAquick® PCR Purification Kit and were 
automated sequenced (Applied Biosystems 3730 DNA Analyzer) in both strands using 
separately the primers employed in PCR (Table 1). All the Data from sequencing was 
analysed using ABI PRISM® SeqScape® software version 2.0 (Applied Biosystems).
4. Results
Expression pattern of PfNnal across the P. falciparum intraerythrocytic cycle
Identification of PCI target gene, P fN n a l, has been reported previously (Rodriguez 
de la Vega et a!., 2007). This gene was identified in PlasmoDB (www.plasmodb.org) as 
PFA0170C, protein-coding gene of the PfNnal protein, an atypical putative zinc 
carboxypeptidase from P. falciparum  strain 3D7. Clustal alignment of PFA0170c with 
homologous atypical carboxypeptidases (NP_056054.1 Homo sapiens, 0 0 9 2 9 6  
Caenorhabditis elegans, X P _311036.1 Anopheles gam biae and EAA15579.1 Plasmodium
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yoelii) showed homology not only with the carboxypeptidase domain, but also with two 
other regions near to N-terminus (Fig. 2).
Moreover, Clustal alignment of PFA0170c with metalocarboxypeptidases of the 
other species of Plasmodium  can be seen in Figure 3.
In order to know whether the target gene (P fN nat) is expressed along the 
intraerythrocytic parasite stages that are inhibited in the presence of PCI, quantitative RT- 
PCR with the target gene-specific primers was assayed using total RNA extracted from 
synchronized parasites. Quantification of the gene was assessed using the molecular 
beacon probe and primers (defined in Table 2) designed from the C C P zone (a common 
motif in carboxypeptidases) of the PfNnat gene. As shown in Figure 4, the expression 
analysis in different asexual erythrocytic stages demonstrated that this gene was 
expressed at highest level in the mature forms of the parasite life cycle in both strains 
assayed. In the strain Dd2, the maximum PfN nal mRNA level was observed in schizonts 
which resulted 3-fold higher than in rings. In the 3D7, PfNnal mRNA level was 3.3-fold 
higher in trophozoites, with the highest amount of the mRNA, than rings. Comparison of 
the gene expression between both strains showed that PfNnal was expressed at higher 
level in 3D 7 than in Dd2. Particularly, there was around 2-fold increase in trophozoites of 
3D7 in comparison with maximum mRNA expression obtained in Dd2 (Figure 4).
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Fig. 2. ClustalX alignment of PfNnal gene of P. falciparum (PFA0170c) with atypical carboxypeptidases from 
otfier representative organisms {H. sapiens, C. elegans, A. gambiae, and P. yoelii). Boxes show homologies 
between motifs of “PYTY” and “FESG”, and carboxypeptidase domain.
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Fig. 3. ClustalX alignment of PfNnal gene of P. falciparum  (PFA0170c) with its homologues in P. berghei, P. 
yoelii, P. chabaudi, P. falciparum, P. knowiesi, and P. vivax. Boxes show homologies between motifs of “PYTY” and 
“FESG”, and carboxypeptidase domain.
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Fig. 4. Asexual stage-specific gene expression of PfNnal determined in RNA isolated from P. 
falciparum  cultures. Transcripts were detected in rings (10 h), trophozoites (27 h), and schizonts (39 h). 
Normalized expression levels against 18S rRNA expression are shown in both strains. A: Dd2 and B; 3D7.
To know whether the PCI effect on the parasite cycle could modify the mRNA  
expression pattern of the PfN nal gene, and thus indicating its regulation by inhibiting the 
protein product, transient inhibitory assays were performed. To optimise the incubation 
time at which PCI modify PfNnat gene expression, asynchronized P. falciparum (strain 
Dd2) microcultures were incubated with 40 pM of inhibitor over 8 h and aliquots were 
taken at 1, 2, 3, 4, 6 and 8 h. Then, the relative PfN nal gene expression was quantified 
using the corresponding isolated RNA. Target gene expression was mostly inhibited after 
3 h, and therefore, 3 h of incubation with PCI was selected as the treatment time-span.
P fN nal mRNA expression was studied in synchronized cultures incubated with 
PCI during 3 h across the intraerythrocytic cycle. The experiment started with parasites 
(1.5%  parasitaemia) in very young rings and lasted during 57 h. Six time intervals 
corresponding to main parasite stages were analysed during this complete 
intraerythrocytic cycle. Figure 5 shows the amount of PfN nal mRNA expression in 
cultures incubated with PCI during 3 h in comparison with the control non-treated culture 
at the same time point. PfN nal was highly expressed in PC I-treated cultures, and more 
particularly in the mature schizont forms at 45 h where the highest amounts of PfNna-1 
m RNA were detected, reaching up to 4.7-fold the amount in the absence of PCI.
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Fig. 5. Expression pattern of the PfNnal gene along a single intraerythrocytic cycle of P. falciparum.
Cultures were transiently Incubated with PCI during 3 h i/s control culture In the absence of PCI. The given 
time Indicates the time points of harvesting after 3 h PCI Incubation. Standard deviation of triplicate cultures Is 
shown. (A), Time-course PfNnal mRNA expression In PCI-treated cultures vs. non-treated control. (B) N-fold 
changes (In log scale) of PfNnal expression in PCI-treated cultures vs. non-treated control, normalized to the 
188 rRNA reference gene. R: Ring, ~ 0-20 h; T: Trophozoite, ~ 20-44 h; 8: Schizont, ~ 44-50 h.
Transcript and sequence analysis of the Nna-1 like gene
In order to analyse possible post-transcriptional modifications or cryptic splicing, 
m RNA from the Nna-1 like gene was studied by RT-PCR. Eleven Pairs of primers were 
designed (Table 1) to amplify the full-coding sequence of the gene by overlapping PCR  
fragments in six combinations of primers pairs (Fig. 6A). All amplified fragments by RT- 
PCR (using both random and gene specific primers for reverse-transcription reaction), 
with expected and unexpected sizes, were analysed by DNA sequencing and cloning.
Some smaller fragments appeared when RT-PCR was done using specific 
primers. Cloning and sequencing of these fragments proved just mismatched priming 
effect in A+T rich regions in the retrotranscription at 37°C and consequent smaller size 
amplification (results not shown). Nevertheless, random primers in the reverse
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transcription allowed the generation of the expected RT-PCR fragment sizes without 
producing any small unspecific fragment.
DNA sequencing of the expected size RT-PCR products (Fig. 6B & 6C) showed 
that these gene sequences did not show differences between cDNA and genomic DNA. 
Moreover, this was confirmed by the qR T-PC R  analysis of mRNA expression along the 
gene with the same set of overlapping primers. As shown in Table 3, Ct values obtained 
with RNA correlate with the values obtained with genomic DNA, indicating that all 
fragments are in a relative proportion of expression level. These data suggest that not lack 
of expression of any fragment in the PfN nal gene could reveal any cryptic of alternative 
splicing.
Table 3. Average Ct values for the PfNnal gene amplification. qPCR and qRT-PCR were done using the 
eleven primer pairs shown at left. SYBRGreen I was used to detect and quantify double-stranded DNA.
Pair of Primers C t  in DNA C t in cDNA
1F+1R 20,950 ±0,100 31,450 ±0,171
2F+2R 22,230 ±0,141 31,663 ± 0,247
3F+3R 21,440 ± 0,06 29,597 ± 0,080
4F+4R 21,355 ±0,019 27,197 ±0,199
5F+ 5R 21,895 ± 0,054 28,410 ±0,116
6F+6R 26,340 ±0,171 37,987 ± 0,698
7F+7R 19,715 ±0,133 26,147 ±0,253
8F+8R 25,070 ± 0,084 33,120 ±0,167
9F+9R 23,525 ± 0,038 28,450 ±0,010
10F+10R 20,800 ± 0,098 32,970 ±0,124
11F+11R 20,085 ± 0,038 28,677 ± 0,227
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Fig. 6. Expression detection of the PfNnal gene by RT-PCR using P. falciparum RNA from strain Dd2.
(A): six combinations of primers (Table 1) over the full-coding sequence of the PfNnal gene. (B): RT-PCR 
products. The first lane on the left: A/Hindlll molecular size marker. Nos. 1 to 5 show the amplicons using 
primer pairs: 1F+3R, 2F+4R, 4F+6R, 5F+8R and 8F+10R respectively. There was not any amplification using 
primer pair of 10F+11R (No. 6). No. 7 used RNA as a negative control. (C): RT-PCR product. The first line on 
the right: A/Hindlll molecular size marker. No. 1 is the amplicon using primer pair 10F+11R. Here, gene 
specific primer was used for the reverse-transcription reaction as there was not any amplification using 
random one (B, No. 6). RT, reverse transcription.
The sequence analysis of the overlapping fragments was performed in cDNA and 
DNA from strains 3D7 and Dd2. The complete genome sequence of P. falciparum 
(Gardner at a!., 1998; Bowman at a!., 1999; Gardner at a!., 2002) is available in strain 
3D7. The comparison of the genomic DNA sequences from strains 3D7 and Dd2, 
detected two main mutation events. First, in the overlapping segment of fragments 1 and 
2 (Fig. 6A), it was detected an inframe insertion of 36 bp at position 582-583 in the Nna-1 
like gene from strain Dd2 with regard to the reference sequence in GeneBank from strain 
3D7 (Fig. 7A). This mutation deduces the insertion of 12 new amino acids in the protein 
without the loss of the open reading frame. Second, in fragment 3 (Fig. 6A), it was 
revealed an inframe deletion of 63 bp in the Nna-1 like gene from strain Dd2, which with 
regard to the reference sequence in GeneBank from strain 3D7 is located at position
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1609-1671 (Fig. 7B). This mutation deduces the lack of the 21 amino acids in the protein 
without the loss of the open reading frame.
Multiple alignment of metallocarboxypeptidases of Plasmodium  genus (Fig. 3) 
showed that despite sharing large conserved parts between them, there are some 
sequences which are species specific in P. falciparum.
582 583
AATGATTATACG
^ ------  Insertion ——
GATGATTATACAAATAAATGTAATCAATATAATGAT AATGATTATACG
hlXàilVMlhVMttm1609 1671
AATATTGTAAATAA 3D7GGTAATAATATAAAC
Deletion
GGTAATAATATAAAC AATATTGTAAATAA Dd2
(C) T 307
Insertion hetween 
587 583 lj,i
1207-1347 
FESG zone
2059 -2325 3145 ........... -3784
PYTY zone CCP zone
Fig. 7. Mutation event in the PfNnal gene of P. falciparum, strain Dd2. (A) shows an insertion (duplication 
of the flanking sequence on the left) which exists in the Dd2 strain, 12 amino acids are repeated in PfNnal 
protein in P. falciparum, Dd2 strain. (B) shows a deletion which occurred in the Dd2 strain, 21 amino acids 
deleted in PfNnal protein in P. falciparum, Dd2 strain. (C) shows the situation of mutations over the 
PfNnal gene of 3D7 strain.
5. Discussion
The limitations of antimalarial chemotherapy underline the need for new drugs, 
ideally directed against new targets. Potential targets for chemotherapy include malarial 
proteases which play important roles during the malaria parasite life cycle (McKerrow et 
a!., 1993). Initial studies of partially purified protease activities and of the biological effects 
of protease inhibitors have now been complemented by molecular and biochemical 
analyses of important proteases of all four major catalytic classes (cysteine, aspartic, 
serine and métallo) due to the knowledge of the P. falciparum  genome (Gardner at a!., 
2002; W u at a!., 2003). However, in the P. falciparum  genome has been identified
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sequences that likely encode additional proteases, therefore, more protease activities can 
still be expected (Rosenthal, 2001 ; W u et a!., 2003).
The present study focus on the expression of a recently annotated 
carboxypeptidase gene (Rodriguez de la Vega et a!., 2007) in the malaria parasite P. 
falciparum. The evidence that PCI, as a carboxypeptidase inhibitor (Aviles et al., 2006), 
had inhibited parasite growth indicated the important role of this new carboxypeptidase as 
a functional protease in parasite life cycle. Searching for the target gene of PCI in the 
molecular databases showed the presence of P fN nal gene, a metallocarboxypeptidase, 
belonging to the M l4 family (Rodriguez de la Vega e ta l., 2007). These proteins hydrolyze 
single C-terminal amino acids from polypeptide chains (Grobelny at a i,  1992; Rodriguez 
de la Vega et a i,  2007). Neither its mechanism of action nor its protein or peptide target is 
actually known in P. falciparum  or in other organisms (Harris et a i,  2000). Therefore, 
considering PfN nal protein as the target for PCI, further molecular studies on that, as a 
target for chemotherapy in malaria, have been done by our group.
Both, mRNA expression pattern across intraerythrocytic stages and transcriptional 
up-regulation of the P fN nal gene by PCI demonstrated high expression levels of this 
gene in mature stages. Time course analysis of P fN nal m RNA expression showed that it 
is maximally expressed at 45 h post invasion, in schizonts, and being up-regulated in PCI 
treated cultures. Therefore, higher abundance of PfN nal mRNA in mature erythrocytic 
stages and in PCI-treated schizonts suggested the critical role of PfNnal in essential 
activities for the parasite survival.
The involvement of proteases is considered part of essential functions in P. 
falciparum  life cycle. Cysteine and aspartic protease inhibitors are now under study as 
potential antimalarials (Rosenthal, 1998; Rosenthal, 2004; Ersmark et a i,  2006) for 
interfering haemoglobin hydrolysis, erythrocyte rupture, and erythrocyte invasion. 
G M 6001, an inhibitor of both matrix and disintegrin metalloprotease family (Grobelny et 
a i,  1992; Ito et a i,  2004), was used to address the function of metalloproteases during 
host cell invasion. The IC50 of GM6001 for schizont-derived merozoite invasion was 112 
pM, which implicates the role of metalloprotease. A P. falciparum  metalloaminopeptidase 
belonging to M l family has been also identified (Florent et a i,  1998). In addition to 
haemoglobin degradation (Gavigan et a i,  2001), this metalloaminopeptidase has been 
proposed to have a role in growth and invasion as bestatin and nitrobestatin inhibitors are 
able to block P. /a/c/pamm development (Nankya-Kitaka et a i,  1998; Allary et a i,  2002).
The participation of P fN n a l, as tubulinyl-Tyr carboxypeptidase (tubCP), in the 
proteolytic processing of a-tubulin have been hypothesized (Kalinina et a i,  2007; 
Rodriguez de la Vega et a i,  2007). a-tubulin is initially produced with a C-terminal 
tyrosine, which is removed by the tubCP (Hallak et a i,  1977). Tubulin, a heterodimer of a-
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and p-tubulin, is the major component of microtubules which are subcellular components 
present in all eukaryotes and have function in a wide range of cellular processes including 
chromosome separation during mitosis, intracellular transport of organelles and cell 
motility. Moreover, they maintain the structural integrity and cytoplasmic architecture of 
the cells (Hyams and Lloyd, 1994). Posttranslational modifications such as C- terminal 
detyrosination of a-tubulin makes more stabilized microtubules with slower rates of protein 
turnover in comparison with the tyrosinated a-tubulins associated with dynamically 
unstable microtubules with short half-lives (W ebster eta l., 1987; Fennell e ta l., 2007).
It has been reported that tubCP activity increased in the nervous cells and also in 
proliferating cells when cells undergo differentiation (Wehland and W eber, 1987; Contin 
and Arce, 2000). In addition, in situ analysis of developing embryonic nervous tissue 
showed N nal was highly expressed in differentiating neurons suggesting its contribution 
in differentiating and regenerating neurons (Harris et al., 2000). Higher abundance of 
PfNnal m RNA in mature stages (i. e. schizonts of the Dd2 strain) and PCI-induced 
transcriptional up-regulation of this gene in shizonts of P. falciparum could confirm tubOP 
activity of PfN nal as schizonts are involved in cell division, differentiation, and biogenesis 
of motile merozoites. All these events need participation of tubulins (Bell, 1998), 
specifically detyrosinated a-tubulins which are associated with more stabilized 
microtubules (W ebster et al., 1987; Fennell et al., 2007), and therefore imply the active 
presence of PfN nal enzyme as tubCP in the schizont stage. The possible function could 
make PfN nal a candidate target for chemotherapy of malaria.
In general, genes of malaria parasites and other unicellular organisms have larger 
exons with fewer and smaller introns than metazoans (Singh et al., 2004). It is believed 
that such differences in gene structure cause simpler mechanisms for transcriptional 
control and mRNA processing (Singh et al., 2004). The P. falciparum genome is highly 
A+T rich, reaching 80%  in most genes (Gardner e ta l., 2002; Szafranski eta l., 2005). This 
particular biased composition had led to suggest an elevated thermodynamic capacity for 
quick genetic change allowing faster adaptations, even at the level of gene 
rearrangements and intro-exon boundaries. According to the large and unique species- 
specific insertions found in the alignments of the PfNnal gene we investigated whether 
cryptic splicing sequences could favour a post-transcriptional processing (Singh et al.,
2004) resulting in a  different mature protein than that expected for the Nna-1 like gene. 
Interestingly, transcript and sequence analysis of PfNnal gene showed that all parts of 
this large gene were involved in transcription, thus no splicing was detected. This proved 
that all sequence should code for mature polypeptide. Nevertheless during this study, we 
found two large inframe mutations between two strains, suggesting the easiness in P. 
falciparum  for change in protein structures, since the two mutation events account for a
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total of 33 amino acid differences. It should be noted that these two large changes were 
found in not conserved areas, and therefore allowing to maintain the main protein function 
of the Nna-1 like gene.
Large insertions have also been identified in several other plasmodial proteins, 
such as, protein kinase, heat shock protein-90, RNA polymerase, a-glutamyl cysteine 
synthetase, and both bifunctional enzymes of glucose-6-phosphate dehydrogenase-6- 
phosphogluconolactonase and ornithine decarboxylase/S-adenosylmethionine 
decarboxylase (Giesecke et a/., 1991; Kappes et a/., 199 5 ; Bonnefoy et al., 1997; 
Luersen e ta l., 1999 ; Muller et a i ,  2000; Clarke et a i,  2001; Birkholtz et a i,  2004). All of 
these insertions are characterised by a high abundance of charged amino acids, such as 
Asp, Asn, Glu, Gin, Ser and Lys (Muller et a i,  2005). Our results show that the inserted 
part in PfN nal gene contains such charged amino acids in abundance as well. The 
consequences of these inframe insertions/deletions could be similar to the ones caused 
by missense mutations. On the other hand, the effects of these kinds of mutations on the 
structure and functionality of a protein can be quite different. Occasionally, such mutations 
increase the efficiency of a protein, conferring some selective advantage for the organism 
itself. P. falciparum  genome were found polymorphic, containing amplificatons and 
deletions (Kidgell et a i,  2006) in the genes that introduce drug resistance (Foote et a i,  
1 98 9; Price et a i,  2004) and those that change the mechanisms for invasion of 
erythrocytes (Triglia et a i, 2005). This suggests that such mutations could be important 
determinants for the survival and spread of the parasite and possibly for the outcome of 
the disease (Ribacke et a i,  2007).
Although in our case we have not the above-mentioned evidences, the existence 
of the gene duplication and deletion in PfNnal gene of the CQ-resistant strain (Dd2) 
express new and interesting clues for further future studies of this gene and its any 
possible participation in pathogenesis. However, in general, the extent of these mutations, 
their function in plasmodial proteins, and their possible contribution to the virulence of the 
malaria parasite is still unknown (Aravind et a i,  2003; Muller et a i,  2005; Ribacke et a i,  
2007).
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1. Abstract
The genomes from the organisms of the Plasmodium  genus, the causative agents 
of human and animal malaria, are characterized by an extreme high A+T content and an 
associated abundant low complexity inserts within their proteins. The enzyme glucose-6- 
phosphate dehydrogenase-6-phosphogluoonolactonase (G 6PD-6PG L) found in 
Plasmodium  species has unique structural and bifunctional characteristics. Here, we 
report the expression analysis of P. falciparum G 6PD- 6PG L along the intra-erythrocytic 
cycle by immunological analysis with antibodies raised against its N- and C- terminal 
domains. The pattern modification of band sizes at the different stages of parasite 
development suggests intracellular protein processing involving the cleavage of the native 
bifunctional form to produce two main fragments. In vitro RNA-mediated PfG 6PD-6PG L  
gene silencing, studied along short-term parasite development also revealed the apparent 
intracellular protein modification dependent on the parasite stage. Fragment sizes were 
consistent with separating both catalytic functions of the enzyme. The proteolytic 
machinery underlying this specific PfG 6PD-6PG L processing is still unknown in P. 
falciparum but suggests the existence of distinctive mechanisms in the parasite to deal 
with unique protein structures of essential function resulting from its genome evolution.
Keywords:
Glucose-6-phosphate dehydrogenase /  dsRNA /  Gene silencing /  Malaria /  Protein 
processing
2. Introduction
Plasmodium falciparum is the causative agent of the most severe form of human 
malaria being responsible for the death of more than 1 million people a year (Snow et al.,
2005). The efforts to control the illness have been focused on the chemotherapy, 
mosquito control and in the development of vaccines. Nowadays, the lack of an effective 
vaccine and the increasing parasite resistance to available drugs suggest the necessity to 
identify new targets that allow the development of new drugs and vaccines. Completion of 
Plasmodium  genome sequences (Gardner et a!., 1998; Bowman et al., 1999; Gardner et 
al., 2002) has provided a vast amount of molecular information. This, together with the 
transcriptome (Bozdech et a!., 2003; Le Roch et a!., 2003) and proteomic analysis along 
the parasitic developmental stages (Lasonder et a!., 2002) pursue a deep understanding 
of the peculiar parasite biology in the context of exploring new therapeutic and
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immunization strategies. Since 1993, different technologies of P. falciparum genetic 
manipulation have been developed as gene disruption by homologous recombination (W u  
et a!., 1995; Crabb and Cowman, 1996; Crabb et a!., 1997; Lobo et al., 1999; Om ara- 
Opyene et a!., 2004; Sijwali and Rosenthal, 2004), antisense RNA (Gardiner et al., 2000; 
Noonpakdee e ta l., 2003) and more recently, RNA interference that has been successfully 
applied to understand the in vivo functions of P. falciparum genes (Kumar et al., 2002; 
McRobert and McConkey, 2002; Crooke eta l., 2006).
Genom e comparison from lower eukaryotes have shown that Plasmodium  proteins 
are notably longer in size than their respective orthologous genes. This is due to the 
extraordinary attribute of Plasmodium  proteins that are hugely enriched in stretches 
biased toward 1-3 residues (mainly Asn, Lys, and lie) due to the high A+T content (about 
80%  average). Due to this particular composition these stretches acquire low entropy or 
complexity (Wootton, 1994). These regions are embedded into highly conserved domains 
that form globular structures with larger variety of residue composition with high entropy 
and complexity (Wootton, 1994). Although many eukaryotes have also low complexity 
areas in nuclear proteins, transcription factors, and some cytoskeletal proteins, 
Plasmodium  species display low complexity stretches in unique genes, not observed 
before in genomes from other organisms. In addition, these unusual regions even 
penetrate in independent functional domains with unpredictably length between 10 and 
100 residues (Aravind eta l., 2003).
P. falciparum  G 6PD -6PG L is a bifunctional enzyme exclusive to Plasmodium  
species (Clarke et al., 2001) that probably arose from the fusion of two genes in a 
common ancestor (Scopes et al., 1997). The deduced protein has a subunit molecular 
mass of 107 kDa, in agreement with the tetramer molecular weight calculated by size 
exclusion chromatography (Kurdi-haidar and Luzzatto, 1990). Its C-terminal half (residues 
311-911) is clearly homologous to other described G6PDs (with glucose 6-phosphate 
dehydrogenase activity) though sequence similarity is interrupted by a 62 amino-acid 
stretch with no similarity found to date. It has been nevertheless experimentally shown 
that this 62 amino acid insertion is essential for the activity of the bifunctional enzyme  
(Clarke et al., 2003). In contrast, the 310 amino-acid protein sequence of the amino 
terminal region clearly differs from most eukaryotic and prokaryotic G6PDs, and shows 6- 
phosphogluconolactonase activity; thus G 6PD -6PG L catalyses the first two stages of the 
pentose phosphate pathway (Clarke et al., 2001). The occurrence of large insertion 
sequences that differ with respect to their homologous proteins in other species has been 
often observed in many gene products of P. falciparum and other Plasmodium  species, 
but their structural functions and origins are unknown ( Pizzi and Frontali, 2001; Clarke et 
al., 2003). W e have been interested to know whether the low complexity invasions of
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globular domains could have a role in regulating protein turnover along the parasitic cycle, 
and therefore, in the present paper, the unique bifunctional P. falciparum  G6PD- 6PG L  
protein was explored as a  model gene to study dynamics of its protein processing along 
the intraerythrocytic cycle and under gene silencing conditions.
3. Materials and methods 
Parasite cultures and electroporation
P. falciparum strain 3D7 was grown and double synchronised using standard 
procedures (Trager and Jensen, 1976; Lambros and Vanderberg, 1979). Parasites (ring 
stage 8-10%  parasitaemia) were transfected by electroporation with 40 pg of dsRNA as 
described (W u et al., 1995). The parasites transfected with dsRNA-G 6PD or dsRNA- 
RabSa were kept for 24 h in 75 cm2 flasks. The growth and development of each 
transfection was monitored by Giemsa staining blood films.
dsRNA design
A 21 basepair dsRNA (sense: UACAUCAUGCACCAACGAAdTdT; antisense: 
UUCG UUG G UG CAUG AUG UAdTdT) was designed for the target sequence 
(UACAUCAUGCACCAACGAA) of the G 6PD -6PG L gene, following Dharmacon 
siDESIG N Center criteria (httD://desian.dharmacon.com/). In addition, a  dsRNA  
corresponding to the PfRab5a gene (GenBank^*^ accession number AE001399) (target 
sequence: UAUGCAAGUAUUGUCCCAC; sense: UAUG CAAGUAUUGUCCCACdTdT; 
antisense: GUGGG ACAAUACUUGCAUAdTdT) was also designed to use as control. All 
dsRNAs were obtained from Dharmacon Research (Lafayette, CO, USA) in annealed and 
lyophilised form and were suspended in RNase-Dnase-free water before use.
Immunodetection
Antibodies were raised against two different recombinant P. falciparum  G 6PD - 
6PD L polypeptides expressed in the vector pGEX (Amersham Biosciences), which 
contains the glutathione-S-transferase sequence upstream from the polylinker to produce 
a fusion protein with the insert. Sequences from ntG6PD-6PGL  
(AAYYICKEIYDKQQ INKDG YVVIGLSG GRTPIDVYKNM CLIKDIK IDKSKL) and ctG6PD- 
6PG L (KILKSIPSIKLEDTIIG Q YEKAENFKEDENNDDESKKNHS) (see Fig. 1 for their 
location within the G6PD protein) were amplified and cloned into pGEX. Expression in E. 
coli was achieved following the manufacturer's instructions and the two glutathione-S- 
transferase/G6PD-6PDL fusion proteins were separately purified using a glutathione 
sepharose affinity column (Amersham Biosciences). Cleavage of the fusion protein by
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factor X and subsequent separation in SDS-PAG E provided pure protein for antibody 
production. Antibodies against ntG6PD-6PGL and ctG 6PD-6PG L where raised separately 
in rabbits but used as a mixture in the Western blot analyses to increase the signal.
anti- 6PGL-domain anti-G6PD-domain
anti-6PGL domain (a a y y ic k e iy d k q q in k d g y v v ig l s g g r t p id v y k n m c l ik d ik id k s k l ) 
anti-GGPD domain (k il k s ir s ik l e d t iig q y e k a e n f k e d e n n d d e s k k n h s )
Fig. 1. G6PD-6PGL protein and location of antibody reactivity. Scheme showing primary structure of the 
G6PD-6PGL gene with two main functional domains, the low complexity stretch (red) and the sequences of 
the peptides corresponding to the two antibodies raised (see text).
For Western blot analyses, infected red blood cells (IRBCs) from a 10 ml-culture 
were suspended in 2 volumes of 0.2%  saponin in PBS and incubated for 15 min at 37°C, 
to lyse the RBC membranes. The released parasites were pelleted at 10000 x g for 10 
min and washed three times in cold PBS. The parasite pellet was solubilized in 100 pi of 
TTP  (PBS containing 1% Triton X-100 and a protease inhibitor cocktail, Complete Mini, 
Roche Diagnostics) and incubated for 30 min at 4°C with frequent vortexing. Next, the 
soluble parasite fraction was frozen (at -70°C for 5 min) and thawed (at 37°C for 5 min) 
only once and centrifuged for 10 min at 10000 x g. Approximately 10 pg of total protein 
supernatant was boiled in 5x loading buffer and separated on 10% SDS-PAG E. After 
electrophoresis, proteins were transferred to PVDF membranes and probed with the 
above-mentioned antibodies at 1/200 dilutions. Antibody binding was detected by 
incubation with secondary 1/5000 HRP-conjugated sheep anti-rabbit Ig Abs, followed by 
chemoluminescence detection using SuperSignal W est Pico (Pierce, Biotechnology Inc, 
Rockford, IL). Bands were quantified using Quantity O ne® software (BioRad, Hercules, 
CA).
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4. Results
PfG6PD-6PGL protein expression patterns across the intraeryhrocytic cycle
Expression patterns at the protein level were examined through immunodetection 
of parasite G 6PD -6PG L using antibodies against N- and C- terminal separately and a 
mixture of both of them. Bands with different molecular weight were consistently observed 
in western blots. As shown in Figure 2, a 107 kDa band corresponding to the theoretical 
molecular mass of the deduced protein sequence was abundant mainly in mature stages 
and detected with both antibodies. Also two other abundant bands of 73 and 69 KDa were 
observed, predominantly in the mature parasite. Thus, the 73 kDa band, detected by the 
anti-6PGL domain antibody, has a size that includes the N-terminal domain with the 
expected 6PG L activity and the main low-complexity stretch between both domains. The 
69 kDa band, detected by the anti-G6PD domain antibody, match with the expected size 
of the G 6PD domain. In addition, in the mature stages two other smaller bands were also 
detected: a 44  kDa band detected with the anti-6PGL domain and a 39 kDa band detected 
with the anti-G6PD domain, which could result from processing of their corresponding 73  
kDa and 69 kDa band, respectively.
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Fig. 2. G6PD-6PGL protein patterns across the Intraerythrocytic cycle of P. falciparum. Expression 
patterns at protein level were examined through immunodetection of the parasite G6PD-6PGL. Parasites 
harvested at the three main stages, rings (R), trophozoites (T) and Schizonts (S) were transferred and 
immunodeveloped with three different conditions using anti-6PGL domain, anti-G6PD domain, and a mixture 
of both of them.
dsRNA silencing of the PfG6PD-6PGL and expression pattern
In an attempt at silencing the G 6PD -6PG L gene, erythrocytes infected with ring- 
stage P. falciparum 3D7 (pyrimethamine-sensitive clone) were electroporated with a 
dsRNA-G 6PD duplex, RNase-free water and dsRNA-RabSa (the last two as controls) as 
previously reported (Crooke et al., 2006).
The G 6PD-6PG L protein band pattern during the P. falciparum intra-erythrocyte 
cycle, as revealed by immunodetection with both antibodies is shown in Figure 3A. In all 
stages, two main bands of different molecular weight were observed, a  107 kDa band 
corresponding to the theoretical molecular mass of the deduced protein sequence and the 
73 kDa band with 2 other subforms in the mature parasites.
Compared to the control, gene silencing by dsiRNA reduced G 6PD -6PG L  
immunoreactivity as observed in cultures at 3 and a 24 h (Fig. 3B). Thus, as earlier as 3  h, 
a 54%  and 69%  reductions in the 73 kDa and 107 kDa bands, respectively, were 
observed (Fig. 3C). After 24 h, this effect started to diminish, and only 14% and 19%  
decreases in the two bands, respectively, were observed (Fig. 3C). These data confirm 
previous findings that silencing through dsRNAG6PD instantly took place after 3 h of 
electroporation at the ring stage, with normal levels gradually restored at the trophozoite 
stage, 24  h post-transfection (Crooke e ta l., 2006).
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Fig. 3. Effect of dsRNA on parasite protein levels. (A) Immunoblot analysis of wild-type synchronized 3D7 
rings and trophozoites. The G6PD-6PGL protein band pattern immunodetected during the intra-erythrocyte 
cycle of P. falciparum includes the 107, 73, 69 and 53 kDa bands labelled with arrows. (B) Immunoblot 
analysis of synchronized wild-type and dsRNA-GSPD parasites (10 pg of total protein per lane) at 3 and 24 h 
after electroporation. (C) Immunoblot quantification of synchronized wild-type and dsRNA-G6PD parasites. 
The 107 and 73 kDa bands signal detected were quantified by densitometry using a Fluor-S Multi Imager and 
Quantity One quantitation software (Bio-Rad). Value for PfG6PD-6PGL in dsRNA-GGPD parasites is 
expressed as a percentage of control levels in wild-type parasites transfected with water. The positions of 
molecular mass standards are indicated (kD).
5. Discussion
The data presented above indicate that this unique bifunctional Plasmodium  
G 6PD-6PG L protein varies in size depending on the parasite developmental stage. Thus, 
the 69 KDa band detected by the anti-G6PD domain antibody coincides with the expected 
size of the G6PD domain at the C-terminal, and the 73 kDa band identified by the anti- 
6PGL domain antibody could have a size that including the essential insertion (Clarke et 
al., 2003) corresponds to the N-terminal of the protein with the 6PG L activity. Thus, it 
seems that the bifunctional protein could mature to render two different polypeptides with 
separate enzyme activities but sharing the essential insertion.
101
Protein processing
To assess specific biological gene function in the parasite, several systems for the 
functional analysis of P. falciparum  genes have been developed, including gene silencing 
by antisense RNA (Gardiner et al., 2000; Crooke et al., 2006) or more recently, by RNA  
interference (Kumar et al., 2002; McRobert and McConkey, 2002; Crooke et al., 2006). 
Antisense RNA has been found in humans, mice, plants and protozoan parasites such as 
P. falciparum. The fact that endogenous antisense RNAs are widespread in P. falciparum, 
suggests that they could be a natural gene expression regulatory mechanism 
(Gunasekera et al., 2004; Militello et al., 2005). In our model, P. falciparum G 6PD-6PG L  
was silenced in vivo through a  dsRNA. Although mechanisms of RNAi silencing in many 
organisms are not well known, this technique has been used to study gene function in a 
great variety of organisms including other parasites (Ullu et al., 2004). Despite the fact 
that, so far, the genes encoding the required RNAi machinery have not been detected in 
any of the currently available Plasmodium  databases, RNAi silencing has been achieved 
in Plasmodium  (Kumar et al., 2002; McRobert and McConkey, 2002; Crooke e ta l., 2006). 
Thus, it could be that the data reported for Plasmodium, as well as our results using 
dsRNA-G 6PD, are the consequence of an antisense RNA rather than a direct RNAi effect. 
However, it is also true that, to date, 60%  of the genes predicted for P. falciparum  have no 
known homologues, and we have no clues as to their function (Gardner e ta l., 2002).
The protein expression patterns examined by gene silencing showed that after 3 h 
of transfection, when most of the parasites are at the ring stage, the complete 107 kDa 
band predominates in both transfected and not transfected parasites. However, after 24 h 
of electroporation when the parasites were mainly at the trophozoite stage, the main band 
was the 73 kDa band. Again, this data suggest protein size change across parasite life 
cycle by protein processing or by alternative splicing. To this respect, different sizes of 
mRNA G 6PD -6PG L have been observed in parasites in the ring and trophozoite stages 
(Cappadoro et al., 1998). Thus, there seems to be specific P. falciparum  mechanisms for 
processing this mRNA, controlled by the parasite’s development cycle, which could be 
unique or shared with other genes (Singh et al., 2004; Muller et al., 2005). The 69 kDa 
band could coincide with the C-terminal end of the protein corresponding to G 6PD activity 
in such a way that it would not show the N-terminal end that corresponds to the 6PGL  
activity. Based on the data shown, we can hypothesize a controlled pattern of PfG6PD- 
6PGL processing during parasite maturation as depicted in Figure 4.
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Fig. 4. Hypothetical processing of G6PD-6PGL. The protein product sizes observed by immunodetection 
analysis across the intraerytrocytic P. falciparum life cycle could be explained by two steps of controlled 
maturation of the protein to take apart, optimize and recycle, the two functional enzymatic activities in the 
parasite cell.
An independent role of the 6PG L function has been addressed, and although its 6- 
phosphogluconolactone substrate is highly unstable in vitro, some increase in the 
efficiency of the pathway may be evident (Clarke et al., 2001; Miclet et al., 2001). To this 
respect, the lactonase activity shown by the bifunctional enzyme is ten times lower than 
that of the monofunctional domain 6PGL (Clarke et al., 2001), demonstrating its low 
efficiency for 6-phosphogluconolactone hydrolysis. Moreover, from a structural standpoint, 
it has also been questioned whether the bifunctional protein is more efficient in producing 
NADPH than two separate enzymes (Clarke etal., 2001). NADPH is also the co-substrate 
of Plasmodium glutathione reductase and thioredoxin reductase enzymes that protects 
against oxidative stress caused mainly by digestion of host cell haemoglobin at the late 
ring-early trophozoite stage (Bozdech and Ginsburg, 2004). Thus, different NADPH  
efficiencies could be required at different developmental stages with particular 
specialization by the bifunctional protein (Clarke etal., 2001). Another explanation of this 
apparent processing, is the genome economy shown by the small Plasmodium genome  
containing a proportionally high number of genes compared to similar genome sizes 
(Enright and Ouzounis, 2001; Veitia, 2002). Several other unique bifunctional enzymes 
have been described in Plasmodium species (Bzik et al., 1987; Pashley et al., 1997;
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Muller et a!., 2000) reflecting the parasite’s rapid evolution in its constant fight to
overcome host defence mechanisms.
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1. Abstract
The methods developed by Trager and Jensen in 1976 for the continuous culture 
of the erythrocytic stages of Plasmodium falciparum  make this organism available to a 
large variety of scientists. As a result, much has been learned about P. falciparum  during 
the past 30 years. Recent developments in the diverse aspects such as chemotherapy, 
drug resistance, vaccine development, pathogenesis, molecular biology and biochemistry 
emphasize the usefulness of the culture method in research. In the post-genomic era, 
when all proteins can be linked to the genes encoding them, comparative studies of the 
proteins expressed at any given life cycle stage or tissue is a critical requirement for a full 
understanding of biological phenomena. In fulfilling proteomic studies, highly parasitized 
cultures were needed. Here we report a  modified method of the Trager and Jensen’s 
culturing method in a way that synchronized cultures of P. falciparum with more than 80%  
parasitized cells are obtained.
Keywords:
Culture /  Parasitaemia /  Plasmodium falciparum
2. Report
A large effort and time have been invested for in vitro growth of the erythrocytic 
stages of the Plasmodium  life cycle which is the stage most often associated with the 
pathogenesis of malaria and a major target for vaccine and drug development (Trager and 
Jensen, 1997; Schuster, 2002). A significant accomplishment in this area was defining in 
vitro conditions for continuous cultivation of P. falciparum. This was accomplished by 
Trager and Jensen (Trager and Jensen, 1976; Trager and Jensen, 1977) using HEPES- 
buffered RPMI 1640, a tissue culture medium developed for in vitro cultivation of 
leukocytes, supplemented with human serum, erythrocytes, and sodium bicarbonate.
The methods for cultivation of the erythrocytic stages of P. falciparum have been 
usefully applied in nearly every aspect of research on malaria: chemotherapy, drug 
resistance, immunology and vaccine development, pathogenesis, gametocytogenesis and 
mosquito transmission, genetics, the basis for resistance of certain mutant red cells, 
cellular and molecular biology and biochemistry of the parasites and of their relationship 
with their host erythrocytes (Trager and Jensen, 1997).
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To study the dynamic nature of the P. falciparum  parasite, efforts to characterize 
gene expression directly at the proteomic level have strikingly come under the spotlight. 
To achieve high yields of isolated proteins which are necessary to study on protein level, 
highly parasitized cultures are needed. In this work, we have focused on reaching a high 
percentage parasitism to fulfil protein and proteomics studies on different intraerythrocytic 
stages of P. falciparum.
The chloroquine-sensitive 3D7 and chloroquine-resistant Dd2 P. falciparum  
isolates were used for cultivation. Parasites were grown in vitro in groups A'' or O'" human 
erythrocytes following previously described conditions (Trager and Jensen, 1976), with 
some critical modifications specially in applied methods. Parasites were cultured in 
RPM11640 medium (Sigma), supplemented with 25 mM HEPES, 0 .5%  AlbuMAX I 
(Invitrogen), 1.77 mM sodium bicarbonate, 100 pM hypoxanthine, and 12.5 pg/ml 
gentamicin sulphate, at a pH of 7.2 in a gas mixture of 96%  nitrogen, 3%  carbon dioxide 
and 1% oxygen. The culture medium without sodium bicarbonate (incomplete medium) 
was prepared weekly and stored at 4°C. To avoid increasing pH, sodium bicarbonate was 
added freshly after heating the medium at 37°C and just before use.
The cultures were contained in 150 cm^ culture flasks (Iwaki). Cultures were 
prepared using low red blood cell suspensions (0.8 % for first invasions, then up to 1 %  
haematocrit for the last invasion) and up to four times daily replacement of culture 
medium after last invasion. The volume of the culture medium was usually 140 ml and the 
parasites were normally sub-cultured at intervals of 2 days.
Fresh GDP (citrate phosphate dextrose) whole blood obtained from the donor was 
stored at 4°C for at least one day. Afterward, the upper serum layer was removed and 
erythrocytes were washed to remove any left serum, GDP, and white blood cells. 
Thereafter, washing medium (RPM11640 medium, 25 mM HEPES, and 12.5 pg/ml 
gentamicin sulphate) and Lymphoprep (Axis-Shleld) was used to obtain isolated and 
purified red blood cells, that were stored at 4°G until use. While fresh whole GDP blood 
was stored up to 18 days after blood extraction at 4°G, the washed erythrocytes never 
were used after 5 store days.
To study stage-specific differential proteins oxidation pattern, cultures were sorbitol 
synchronized as described previously (Lambros and Vanderberg, 1979). A detailed 
laboratory protocol is given in Annex I, where all experimental procedures to culture the 
parasite are shown.
Synchronized cultures of P. falciparum  with more than 80%  parasitized cells were 
obtained by our method (Fig. 1). It should be emphasized that parasite were
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synchronized, where needed in appropriate time, up to two (mostly) to three (rarely) times 
in two weeks. Actually, the sequential treatment with sorbitol was preferably avoided 
during the whole process. W e  do believe that sequential treatment with sorbitol would 
weaken the red blood cells and subsequently decrease parasitaemia. Moreover, we found 
that there was an inverse correlation between parasite density and haematocrit. Such 
evidence has been reported before (Saute et al., 2002; Ljungstrom at al., 2004; Vernot 
and W asserm an, 1990). W e  also had more yields with sub-culturing every 48 hour and 
just some hours before invasion. This was done by dividing the contents of each flask into 
two to m ake one more flask. Then, the haematocrit and medium volume of the two flasks 
compensated with fresh erythrocytes and medium to keep the haematocrit between 0.8- 
1% in -1 4 0  ml total culture medium. This helps parasites to get fresh and intact red blood 
cells for invasion every other day. Taking into account all above-mentioned critical points 
to improve the in vitro growth conditions, we could increase the parasitaemia of P. 
falciparum  (Dd2 and 3D7 strains) cultures from 20%  to higher than 80%  (more than 4-fold 
yield increase).
In general, the procedure described here allows us to obtain very high level of 
invasion and therefore high parasitaemia, which is a necessity to study the proteins of P. 
falciparum  that can be exploited in the search for vaccines and new drugs.
'  l |
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Fig. 1. Intraerythrocytic stages of highly parasitized cultures of P. falciparum, stra in  Dd2. Different 
stages were obtained from sorbitol synchronized cultures. (A) & (B) The ring stage: a thick rim of cytoplasm 
with nucleus in a dark blue condensed form can be seen in the ring stage. (C) & (D) The trophozoite stage: the 
surface area of the parasite has enlarged in this stage. Moreover, pigment vacuole, which contains haemozoin 
crystals, can be seen as yellow-brown part. (E) & (F) The schizont stage: parasite has grown greatly and 
covered the most parts of the erythrocyte in this stage. Pigment vacuole has also become compacted into a 
single, dense, rounded mass. In the more developed ones, budding merozoites from the surface of the 
schizont can be seen. (F) Specifically shows isolated schizonts of a highly parasitized culture after 5 min 
centrifugation at 2500 rpm. In such condition, schizonts situate on the top of the infected erythrocytes as a 
dark brown layer. (G), Schizonts, released merozoites and new rings (H).
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1. Abstract
Resistance of Plasmodium falciparum  to chloroquine hinders malaria control in 
endemic areas. Current hypotheses on the action mechanism of chloroquine evoke its 
ultimate interference with the parasite's oxidative defence systems. Through carbonyl 
derivatization by 2,4-dinitrophenylhydrazine and immunoproteomics, we compared 
oxidatively-modified proteins across the parasite’s intraerythrocytic stages in untreated 
and transiently IC50 chloroquine-treated cultures of the chloroquine-resistant P. falciparum  
strain Dd2. Functional plasmodial protein groups found to be most oxidatively dam aged  
were among those central to the parasite’s physiological processes, including protein 
folding, protein fate, energy metabolism, signal transduction and pathogenesis. While an 
almost constant number of oxidized proteins were detected across the P. falciparum  life 
cycle, chloroquine treatment led to increases both in the extent of protein oxidation and 
number of proteins oxidized as the intraerythrocytic cycle progressed to mature stages. In 
contrast, by detecting specific 4-hydroxy-2-nonenal adducts, it was revealed that protein 
lipoperoxidation is inhibited by chloroquine. Our data provide new insight into the 
molecular mechanisms triggering the parasite response to chloroquine and the normal 
protein-oxidation modifications that could be involved in the development and 
pathophysiology of the parasite and strongly suggest that chloroquine causes specific 
oxidative stress sharing common features with eukaryotic cells. Targeting these 
processes might provide ways of combating chloroquine-resistance and developing new  
antimalarial drugs.
Keywords:
Chloroquine /  Plasmodium falciparum /  oxidized proteome
2. Introduction
Plasmodium falciparum is the causative agent of the most virulent form of human 
malaria with up to 2.7 million deaths per year attributed to this pathogen (Bremen, 2001). 
Entry of the malaria parasite into its host red blood cell initiates the intraerythrocytic 
asexual cycle, which is responsible for the clinical manifestations of malaria. It is at this 
stage, that 75%  of the parasite’s genes are transcribed (Bozdech et al., 2003). Although 
oxidative stress has been suggested to play a key role in the pathogenesis of malaria 
(Becker et al., 2004), the fact that the malaria parasite is also vulnerable to oxidative 
stress (Muller, 2004) has advocated this metabolism as a  promising target for antimalarial
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chemotherapy (Becker et al., 2004). Apart from the large amounts of ROS generated by 
the active metabolism of the growing and multiplying malaria parasite, a  main source of 
oxidative stress is the degradation of host haemoglobin (Becker et al., 2004). 
Haemoglobin digestion in the food vacuole is the main source of amino acids for parasite 
development, and the release of free haem (FP IX) upon degradation promotes ROS  
production (Muller, 2004). Free FP IX is toxic owing both to its detergent-like properties, 
whereby it disrupts membrane integrity through its incorporation in the lipid bilayer, and to 
its ferric-state (3+) bound iron, which catalyses and undergoes redox reactions resulting in 
ROS production (Muller, 2004). In P. falciparum, most haem aggregates into the insoluble 
crystalline FP IX dimer, known as malaria pigment or haemozoin (Egan et al., 2002). 
Alternative detoxification pathways such as FP IX degradation (Zhang et al., 1999), 
reaction with glutathione (Ginsburg et al., 1998), and binding to FP IX-binding proteins 
(Campanale et al., 2003; Harwaldt et al., 2002) also contribute to avoiding intracellular 
oxidative damage. However, small amounts of FP IX escaping from detoxification 
processes (Loria et a!., 1999) could cause redox damage to host and parasite proteins 
and membranes (Campanale et al., 2003; Famin and Ginsburg, 2003).
Although CQ has been the standard antimalarial drug for over 50 years, its 
mechanism of action is not completely understood (Koncarevic et al., 2007). A widely 
accepted hypothesis is that C Q  binding to free FP IX prevents its biocrystalisation to 
haemozoin, allowing the partial release of FP IX (Koncarevic et al., 2007), which ultimately 
leads to lethal oxidative stress in the parasite (Becker et al., 2004). Thus, increased 
intracellular ROS is considered the final consequence of the mechanism of CQ action, but 
it remains unknown how this toxic environment modifies the essential functions of the 
parasite. As a by-product of normal metabolism and also as a secondary effect of 
pharmacological treatment, constantly generated ROS are known to cause oxidative 
dam age to cell components such as proteins, DNA, and lipids. Such dam age leads to 
structural modifications and loss of biological function (Berlett and Stadtman, 1997). 
Superoxide anions cause the release of iron-sulphur clusters of several enzymes leading 
to their inactivation (Gardner and Fridovich, 1991). The hydroxyl radical generated by 
H2O 2 and transition metals, such as iron, is involved in protein backbone fragmentation or 
modification of amino acid side chains (Stadtman and Levine, 2003). Oxidatively-modified 
proteins accumulate as a function of age in human erythrocytes and other cells (Oliver et 
al., 1987; Stadtman, 1992) and there is increasing evidence that the build-up of these 
dysfunctional molecules over a lifetime contributes to reducing their half-life (Beckman 
and Ames, 1998; Berlett and Stadtman, 1997).
The spread over the past decade of CQ-resistant P. falciparum strains has been a 
challenging problem in malaria control, reaching the point that C Q  is virtually useless in
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many of the world’s regions, in which the high prevalence of clinical CQ-resistant isolates 
determines the need for substitute drugs or combined therapy (Ehrhardt et al., 2007). It 
should be, nevertheless, emphasised that CQ  resistance in the parasite is a  trait acquired 
by increasing the C Q -IC 50 of a given strain by serial passage with subcurative doses of 
the drug. As such, this resistance should be considered as the adaptation of the parasite 
to higher concentrations of the drug through natural selection, since C Q  levels above this 
newly tolerated IC50 value are still lethal for the parasite (Rosario, 1976). Accordingly, a P. 
falciparum  strain is considered CQ-resistant when its C Q -IC 50 value increases above the 
normal 6-17 nM (Quashie et al., 2006), as is the case for the strains Dd2 (IC 50=89 nM), 
and K 1  ( I C s o = 1 4 3  nM) (Akoachere et al., 2005).
Oxidative dam age to proteins can be assessed by determining the carbonyl groups 
generated in some amino acid side chains under stress conditions (Levine et al., 1994; 
Shacter et al., 1994). Protein oxidation results in the formation of carbonyl groups 
(aldehydes and ketones) in susceptible amino acids, and these can be derivatized using 
DNPH. The derivatized proteins can be separated by two-dimensional electrophoresis (2- 
DE) and then analysed for their carbonyl contents by immunoassay using anti-DNP  
antibodies (Levine et al., 1994; Shacter et al., 1994). Moreover, lipid hydroperoxides can 
also be generated in membranes by lipid peroxidation during oxidative stress (Uchida, 
2005). These oxidative modifications yield several breakdown products including HNE. 
This oxidative stress by-product can react with proteins through a  Michael-type addition as 
an additional source of protein carbonylation (Dalle-Donne et al., 2006), which can also be 
assessed using specific anti-HNE antibodies.
In the present study, a  proteomic approach was used to identify and compare 
oxidatively-modified proteins in the different intraerythrocytic stages of a CQ-resistant P. 
falciparum  strain in the presence or absence of CQ . The results are discussed in terms of 
the role of such proteins in the life cycle of the malaria parasite and as potential functional 
targets for combating CQ-resistance.
3. Materials and methods
Highly parasitized cultures and in vitro 00  assay
The CQ-resistant strain of P. falciparum  Dd2, was used in all experiments. 
Parasites were grown in vitro in group A^ human erythrocytes under conditions described 
previously (Trager and Jensen, 1976) with some modification. Briefly, parasites were 
cultured in 150 cm^ flasks in RPM I1640 medium (Sigma), supplemented with 25 mM 
HEPES, 0 .5%  AlbuMAX I (Invitrogen), 1.77 mM sodium bicarbonate, 100 pM 
hypoxanthine, and 12.5 pg ml'  ^ gentamicin sulphate, at pH 7 .2  in an atmosphere of 96%  
nitrogen, 3%  carbon dioxide and 1% oxygen. Synchronised cultures of P. falciparum
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showing more than 80%  parasitized cells were obtained using low haematocrit (0 .8 - 1 %) 
red blood cell suspensions and replacing the culture medium three to four times daily after 
the last invasion. The volume of the culture medium was usually 140 ml and parasites 
were normally sub-cultured at intervals of 2 days. To examine stage-specific differential 
protein oxidation patterns, cultures were sorbitol synchronised as described previously 
(Lambros and Vanderberg, 1979) to obtain the stages ring (10-16 h), trophozoite (28-34 h) 
and schizont (39-45 h).
To test the effects of C Q  on protein oxidation, the drug was included at IC50 (160  
nM) in synchronised parasite cultures only 6  h before harvesting.
Two-dimensional gel separation of parasite proteins
Harvested parasites were mixed with 0 .05%  saponin/PBS (w/v) for 5 min at room 
temperature to lyse the erythrocyte membrane. The lysate was collected by centrifugation 
at 25000  g for 10 min at 4°C and washed three times with ice-cold PBS, followed by one 
wash in 10 mM Tris-HCI, pH 7.4, to reduce contamination with erythrocyte-derived (3- 
haematin, which causes dark staining of the gels. Parasite pellets were resuspended in 3 
volumes (w/v) of lysis buffer (PBS, 0 .1%  Triton X-100, one Roche Complete-Mini™  
protease inhibitor cocktail tablet per 10 ml buffer). Parasite cells were lysed by subjecting 
them to 5 cycles of quick-freezing at -20*0 and subsequent thawing. Supernatants were 
clarified by centrifugation at 25000  g for 10 min at 4°C and protein concentrations 
determined. Protein carbonyl groups were derivatized with DNPH as previously described 
(Levine et a i ,  1994).
Proteins from cell extracts were precipitated with ammonium acetate in methanol 
following phenol extraction (Peck at a i,  2001) and resuspended in rehydration buffer [7M  
urea, 2M  thiourea, 2%  (w/v) CHAPS, lOm M dithiothreitol (DTT), 1% IPG buffer pH 3-11 
(G E Healthcare), and traces of bromophenol blue]. Next, about 800 pg total protein was 
loaded onto IPG strips (pH 3-11, 18 cm, G E Healthcare). The IPG strips were rehydrated 
overnight according to the manufacturer’s instructions. For the first-dimensional 
separation, isoelectrofocusing (lEF) was performed using the Ettan IPGphor II lEF system 
(GE Healthcare) at 20°C. The voltage was gradually ramped in a  step-and-hold manner to 
1000 V in three increasing steps: 1 h 200 V, 1 h 500 V and 1 h 1000 V. The voltage was 
increased to 4500  V  in a linear gradient over the next 9 h. The run was terminated after 
-7 5 0 0 0  Vh. The focused strips were equilibrated in 10 ml equilibration solution (100 mM  
Tris- HCI, pH 6 .8 , 6  M urea, 30%  glycerol, 2%  SDS) with 0 .5%  D TT reducing agent for 12 
min, followed by 10 ml of 4 .5%  iodoacetamide equilibration solution for 5 min. To run the 
second dimension, strips were soaked in running buffer, loaded on 10%  SD S-PAG E gels 
and covered with 0 .5%  agarose gel. The running conditions were 30 min at 2W /gel and
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subsequently 4 h at 20W /gel, using the Laemmli buffer system. The gels were stained 
with colloidal CBB (Coomassie Brilliant Blue) (Neuhoff et al., 1985) to visualize total 
proteins and used for protein identification. Twin gels were run in parallel under identical 
2D electrophoresis conditions.
Western blot analysis
One of the twin gels loaded with Ya total protein (200 pg) was transferred to a  
PVDF membrane (Amersham Biosciences). Immunodetection of protein-bound DNPH in 
crude extracts of P. falciparum  was conducted as previously described (Shacter et al., 
1994) with minor modifications as follows: the anti-2,4-DNP antibody (Sigma Ref. D9656) 
was incubated for 2 h at room temperature at a 1/4000 dilution, followed by HRP- 
conjugated anti-rabbit IgG (Amersham Biosciences Ref. NA9340V) at a 1/5000 dilution. 
Detection was performed using the SuperSignal chemiluminescent substrate (Pierce) and 
exposure to X-ray film. Each experiment (different condition or parasite stage) was 
repeated tree times.
Tryptic digestion and MALDI-MS
Based on W estern blot analysis, the gel spots of interest (stage-specific, 
predominant or those differently expressed) were manually excised from 2-D  gels using 
biopsy punches. Proteins selected for analysis were in-gel reduced, alkylated and  
digested with trypsin as described (Shevchenko et al., 1996). Briefly, spots were washed 
twice with water, shrunk 15 min with 100%  acetonitrile and dried in a  Savant SpeedVac  
for 30 min. The samples were then reduced with lOm M DTT in 25 mM ammonium  
bicarbonate for 30 min at 56°C and subsequently alkylated with 55 mM iodoacetamide in 
25m M ammonium bicarbonate for 20 min in the dark. Finally, samples were digested with 
12.5 ng/pl sequencing grade trypsin (Roche Molecular Biochemicals) in 25 mM  
ammonium bicarbonate (pH 8.5) overnight at 37°C. After digestion, the supernatant was 
collected and 1 pi was spotted onto a MALDI (matrix-assisted laser desorption/ionization) 
target plate and allowed to air-dry at room temperature. Next, 0 .4  pi of a 3mg/ml of a- 
cyano-4-hydroxy-transcinnamic acid matrix (Sigma) in 50%  acetonitrile were added to the 
dried peptide spots and allowed, again, to air-dry at room temperature.
MALDI-TO F (time-of-flight) MS (mass spectrometry) analyses were performed in a  
4700 Proteomics Analyzer M ALDI-TO F/TO F mass spectrometer (Applied Biosystems) 
operated in positive reflector mode, with an accelerating voltage of 20000 V. Mass spectra 
were then collected for Peptide Mass Fingerprinting (PMF). Additionally, proteins 
ambiguously identified by PM F were subjected to M S/M S (tandem mass spectrometry)
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sequencing. Thus, from the MS spectra, suitable precursors were selected for M S/M S  
analyses with collision-induced dissociation (atmospheric gas was used) in the 1 Kv ion 
reflector mode and precursor mass windows +/- 10 Da. The plate model and default 
calibration were optimised for M S/M S spectra processing. The parameters used to 
analyze the data were: Signal to Noise =  20, resolution >6000.
Protein identification was performed by subjecting trypsin digested peptide masses 
to three databases (NCBI, Swissprot and EMBL-EBI) separately using the M ASC O T 1.9 
fhttp://www.matrixscience.com) through the Global Protein Server v3.5 from Applied 
Biosystems. The parameters for the combined search were as follows: modification on 
cysteine residues by carboxyamidomethylation was set as obligate, methionine oxidation 
was considered as a variable modification; the maximum number of missed tryptic 
cleavages was one; peptide mass tolerance was set to 100 ppm (parts per million) and 
M S/M S tolerance to 0.3 Da; and monoisotopic masses were considered. All the identified 
proteins fulfilled the criteria of being significant (p<0.05) according to probability based on 
Mowse score.
Analysis of the immunoblot images
Immunoblot images, used to compare the carbonyl contents and quantify spots for 
the different intraerythrocytic stages of non-treated and CQ-treated parasites, were 
analysed using PDQuest software, version 7.3  (Bio-Rad).
Lipoperoxide-induced protein oxidation analysis
HNE adducts derived from lipid peroxidation were detected by W estern blot 
analysis. 5 pg of protein samples were separated by SDS-PAG E on 10% polyacrylamide 
gel, and transferred (50 mA, overnight at 4®C) to a PVDF membrane (Amersham  
Biosciences). After blocking with 10%  nonfat dry milk overnight at 4°C , the membrane was 
incubated overnight with anti-HNE antibody (Calbiochem, Cat. No. 393207) at a 1/1000  
dilution, followed by incubation for 1 h at room temperature with peroxidase-linked anti­
rabbit IgG antibody (Dakocytomation Ref. P0448) at a 1/1000 dilution. 
Chemiluminescence signals were developed using the SuperSignal chemiluminescent 
substrate (Pierce) and exposure to X-ray film.
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4. Results
Oxidized proteins in the non-treated and CQ-treated parasites
Protein carbonyl formation is one of the most widely used indicators of oxidative 
stress (Butterfield, 2004; Cabiscol et a!., 2000; Castegna et al., 2002; Poon et al., 2004; 
Reverter-Branchat et al., 2004). To determine stage specific protein oxidation and the 
direct effects of CQ, P. falciparum  Dd2 cultures were synchronized to reach the three 
main parasite stages of intraerythrocytic development, ring, trophozoite and schizont, in 
the presence and absence of CQ  IC50. Crude extracts from each stage were then 
derivatized with DNPH and proteins subjected to 2-D E (Fig. 1) followed by Western  
blotting with anti-DNP (Fig. 2).
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Fig. 1. Colloidal CBB staining of 2-D membranes obtained from Intraerythrocytic stages of P. 
falciparum Dd2 In control untreated and CQ-treated parasites. (A), (B), and (0) ring, trophozoite and 
schizont stages respectively. (D), (E), and (F) CQ-treated cultures of rings, trophozoites and schizonts 
respectively. Numbered spots in all plates (3, 4, 6, and 11) are representative of similar protein amounts with a 
corresponding oxidation signal depending on the stage and/or treatment. Numbered spots not labelled in all 
plates (1, 7, 14, 15, 18, and 26) are representative spots whose oxidation signal correlates with their presence 
in a given plate.
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Fig. 2. Redox proteome patterns across the intraerythrocytic stages of P. falciparum strain Dd2 in 
control untreated and CQ-treated parasites. (A), (B), and (C) Comparative carbonyl immunoblots for tfie 
stages ring, tropfiozoite and schizont respectively. (D), (E), and (F) Comparative carbonyl immunoblots for 
cultures of rings, trophozoites and schizonts, respectively, exposed to CQ for 6 h. Numbered spots show the 
oxidized proteins identified, which are listed in Tables 2-5. The exposure time of the membrane to the film was 
5 min for all blots.
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In total, 107 matching spots of oxidized signals in colloidal CBB-stained 2-D E  gels 
were subjected to identification by matrix-assisted laser desorption/ionisation time-of- 
flight/time-of-flight mass spectrometry (M ALDI-TO F/TO F MS) and database searching. 
Figure 2 shows reference carbonyl immunoblots corresponding to all the non-treated and 
CQ-treated stages in which a  total of 79 spots were identified and assigned to 41 proteins. 
These results are summarised in Tables 1-6.
By comparing spots containing carbonyl groups and their signal intensities, we 
were able to observe that the non-treated cultures showed a relative constant number of 
spots across the stages (range 121-141) while for the CQ-treated cultures, the number of 
carbonylated spots increased as the parasite cycle progressed (from 80 at the ring to 260  
at the schizont stage). This effect was also observed when we compared total spot 
intensities. Thus, while in the absence of CQ, spot intensities diminished from the ring and 
trophozoite stages to the schizont stage, in the presence of CQ  a reverse effect was noted 
whereby intensities were 6 -fold higher in the schizonts than rings (Table 1). In addition, a 
large proportion of the carbonylated spots for the control and CQ-treated parasites could 
be matched across the cycle. Thus, more than 50%  of the spots detected for a given 
stage or treatment were also seen in extracts corresponding to the other stage and/or 
treatment. An exception was observed for the CQ-treated parasite rings, such that the 
drug seemed to largely inhibit protein carbonylation rendering the lowest number of spots 
(80 vs 122 for controls) and total spot intensities (3x10^ vs. 10x10^ for controls).
The patterns shown in Figure 2 (D, E & F) also indicate that CQ led to increased 
protein oxidation in mature stages. Effectively, the number of carbonylated spots for the 
CQ-treated schizonts (Figure 2F) almost doubled the spots recorded for control schizonts 
(Fig 2C), with a relatively stronger signal observed in spots appearing in both these 
groups (see Table 5 for details of the fold increases). Thus, when we compared each non- 
treated stage with the corresponding CQ-treated stage (Table 1), the mean oxidation 
intensity was 3.3-fold higher in the presence of CQ for the schizonts, 1.2-fold higher for 
the trophozoites and 3.4-fold lower for the rings. Individual protein carlDonylation analysis 
(Table 5) revealed a  significant proportion of spots (around 25% ) only detected for a given 
stage or treatment.
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Table 1. Oxidized spots and oxidation signal intensities for control (C) and CQ-treated 
intraerythrocytic stages of P. falciparum Dd2. PDQuest v.7.3. was used to match spots among the different 
stages and treatments.
Total
Overall spot Intensity . 
(Arbitrary Units, AU)
Matched spots
Stage/Treatment No. of 
spots
Ring Trophozoite Schizont
C CQ C CQ C CQ
Ring
C 122 10480 122
CQ 80 3099 57 80
Trophozoite
0 132 11781 67 50 132
CQ 185 13578 94 63 81 185
Schizont
C 141 6249 94 61 74 115 141
CQ 260 20756 107 65 83 147 73 260
The proteomic changes produced by CQ were based on 6  h of transient exposure 
to IC50 to avoid massive parasite dam age. The observed effects of sublethal exposure 
could thus reflect both oxidative dam age produced as a consequence of CQ-inhibition of 
FP IX aggregation and additional protein oxidation damage caused by the specific 
parasite response to the oxidative stress.
Host cell oxidized proteins
Seven host cell proteins were identified as oxidized (Table 2). Of these, two 
proteins were members of the a-carbonic anhydrase family (spots 14-17), which were 
found to be highly oxidized in almost all the non-treated and CQ-treated stages, 
particularly in the trophozoites and CQ-treated schizonts. Further human proteins 
detected were: beta-actin (spot 38, more oxidized in treated schizonts), annexin A7 (spot 
39, significantly oxidized in both treated rings and schizonts), catalase (spot 50, only in 
non-treated trophozoites and CQ-treated schizonts), thioredoxin peroxidase B and 
peroxiredoxin 2 isoform b (spots 52 and 53, respectively, only in non-treated rings).
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Table 2. Redox-proteome changes Induced by chloroquine across the Intraerythrocytic stages of P. 
falciparum Dd2. Ring, R; Trophozoite, T; Schizont, 8; CQ, Chloroquine. Accession Nos. correspond to 
PlasmoDB or NCBI databases. An asterisk indicates that the sequence from NCBI does not appear in 
PlasmoDB. Two asterisks indicates that the PlasmoDB sequence varies scarcely with respect to the NCBI 
sequence. The protein with three asterisks was identified by manual sequencing based on mass spectra and 
database searches. Proteins not detected in a given stage are indicated n/d.
Spot signal Intensity (AU)
Spot Protein Description Accession No. R T 8 R+CQ T+CQ S+CQ
1 HSP PFI0875W 317 56 44 72 305 366
2 HSP PFI0875W 23 88 12 n/d 12 34
3 HSP60 PF10_0153 97 289 50 72 144 215
4 HSP60 PF10_0153 115 236 82 49 210 197
5 HSP60 PF10_0153 84 149 125 11 88 200
6 HSP hsp70 homologue PF11_0351 57 48 84 30 50 90
7 HSP70 PF08_0054 122 144 88 n/d 310 406
8 HSP 86 PF07_0029 21 88 22 3 147 40
9 HSP, putative PF14_0417 34 55 26 2 92 101
10 Co-chaperone GrpE, putative PF11_0258 38 56 97 n/d 165 219
11 Disulphide isomerase precursor, putative MAL8P1.17 63 56 35 8 163 176
12 Cell division cycle protein 48 homologue, putative PFF0940C 23 6 39 5 138 56
13 Peptidase, putative PF14_0517 45 34 52 7 46 366
14 Cartxjnic anhydrase 1 [Homo sapiens] gi|115449 n/d 361 27 28 181 376
15 Cartx)nic anhydrase 1 [Homo sapiens] gi|115449 301 555 55 28 219 322
16 Cartx)nic anhydrase II [Homo sapiens] gi|4557395 225 445 49 n/d 55 246
17 Cartwnic anhydrase II [Homo sapiens] gi|4557395 140 404 49 n/d 247 217
18 Hypothetical protein PFF0190C 364 353 77 664 364 416
19 Erythrocyte membrane protein 1 gi|21886680 ’ 57 26 9 n/d 94 109
20 Erythrocyte membrane protein 1 gi|19071542* 65 n/d 51 2 57 153
21 Phosphoglycerate kinase PFI1105W 35 n/d 8 5 82 69
22 Hypothetical protein PFA0210c" 80 4 n/d 70 33 116
23 Hypothetical protein PF14_0046 PF14_0046 21 82 64 n/d 64 93
24 Hypothetical protein PFL1930W 108 118 13 58 122 301
25 GTP-binding nuclear protein ran/tc4 PF11_0183 11 71 75 4 125 222
26 26S Proteasome aaa-ATPase subunit Rpt3, putative PFD0665C 23 n/d 92 12 21 206
27 Ml-family aminopeptkJase MAL13P1.56 72 55 26 18 39 39
28 Ml-family aminopeptidase MAL13P1.56 n/d 73 15 20 47 16
29 Ml-family aminopeptidase MAL13P1.56 n/d 34 5 6 48 11
30 Ml-family aminopeptidase MAL13P1.56 n/d n/d n/d n/d 8 103
31 Proteasome beta-subunit MAL8P1.142 n/d 361 27 n/d 181 376
32 Fructose-bisphosphate aldolase PF14_0425 ” 14 n/d 26 n/d 3 113
33 Snmp protein, putative PFE0925C 24 n/d 15 n/d 6 43
34 Snmp protein, putative PFE0925C 99 n/d 68 n/d 17 125
35 Formin 2, putative PFL0925W 81 n/d n/d 42 136 162
36 Hypothetical protein PFB0145C PFB0145C 67 3 n/d 83 n/d 76
37 Hypothetical protein MALI 3P1.237 26 n/d 3 n/d 74 62
38 Actin, beta [Homo sapiens] gi|14250401 n/d 2 n/d 10 4 21
39 Annexin A7 [Homo sapiens] gi|55584155 69 n/d n/d 99 82 173
40 Glyceraldehyde-3-phosphate dehydrogenase PF14_0598 34 n/d 12 n/d 4 12
41 Cyclophilin, putative PFL0120C n/d n/d 15 n/d 10 115
42 Hypothetical protein PFA0725w PFA0725W 95 n/d n/d n/d 42 57
43 Elongation factor Tu, putative MAL13P1.164 ' n/d n/d 124 108 167 175
44 Enolase PF10_0155 n/d 85 80 n/d 11 33
45 Enolase PF10_0155 n/d 59 148 n/d n/d n/d
46 Enolase PF10_0155 n/d 130 171 n/d n/d n/d
47 Enolase PF10_0155 n/d 21 n/d n/d n/d 73
48 Endoplasmin homologue precursor, putative PFL1070C 73 n/d n/d n/d n/d 15
49 40S ribosomal protein, putative PF10_0264 n/d 118 n/d n/d n/d 32
50 Catalase [Homo sapiens] gi|179950 n/d 10 n/d n/d n/d 42
51 Hypothetical protein PFE1595c 61 n/d n/d n/d n/d n/d
52 Thioredoxin peroxidase B [Homo sapiens] gi|9955016 56 n/d n/d n/d n/d n/d
53 Peroxiredoxin 2 isoform b [Homo sapiens] gi|33188452 72 n/d n/d n/d n/d n/d
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Table 3. Redox-proteome changes in the intraerythrocytic stages of the control P. falciparum Dd2 cultures. 
The schizont stage showed the highest number of spots and was thus used as reference to calculate fold 
changes in oxidation intensity (values from Table 2) given as the ratios ring/schizont (R/S) and 
trophozoite/schizont (T/S). Accession Nos. are from the PlasmoDB or NCBI databases.
Spot Protein Description AccessionNo. R/S T/S
1 Heat shock protein PFI0875W 7.2 1.3
2 Heat shock protein PFI0875W 2.0 7.6
3 HSP60 PF10_0153 1.9 5.7
4 HSP60 PF10_0153 1.4 2.9
5 HSP60 PF10_0153 0.7 1.2
6 HSP hsp70 homologue PF11_0351 0.7 0.6
7 HSP70 PF08_0054 1.4 1.6
8 Heat shock protein 86 PF07_0029 1.0 4.1
9 Heat shock protein, putative PF14_0417 1.3 2.1
10 Co-chaperone GrpE. putative PF11_0258 0.4 0.6
11 Disulfide isomerase precursor, putative MAL8P1.17 1.8 1.6
12 Cell division cycle protein 48 homologue, putative PFF0940C 0.6 0.1
13 Peptidase, putative PF14_0517 0.9 0.7
14 Carbonic Anhydrase 1 [Homo sapiens] gi|115449 Only in S 13.4
15 Carbonic Anhydrase 1 [Homo sapiens] gijl 15449 5.5 10.1
16 Carbonic Anhydrase II [Homo sapiens] gi|4557395 4.6 9.1
17 Carbonic Anhydrase II [Homo sapiens] gi|4557395 2.8 8.2
18 Hypothetical protein PFF0190C 4.7 4.6
19 Erythrocyte membrane protein 1 gi|21886680 6.6 3.0
20 Erythrocyte membrane protein 1 gi|19071542 1.3 Only in S
21 Phosphoglycerate kinase PFI1105W 4.4 Only in S
22 Hypothetical protein PFA0210C Only in R Only in T
23 Hypothetical protein PF14_0046 PF14_0046 0.3 1.3
24 Hypothetical protein PFL1930W 8.0 8.8
25 GTP-binding nuclear protein ran/tc4 PF11_0183 0.1 0.9
26 26s Proteasome aaa-ATPase subunit Rpt3. putative PFD0665C 0.2 Only in S
27 M1 -family aminopeptidase MAL13P1.56 2.7 2.1
28 Ml -family aminopeptidase MAL13P1.56 Only in S 5.0
29 Ml -family aminopeptidase MAL13P1.56 Only in S 6.7
30 Ml -family aminopeptidase MAL13P1.56 no no
31 Proteasome beta-subunit MAL8P1.142 Only in S 13.4
32 Fructose-bisphosphate aldolase PF14_0425 0.5 Only in S
33 Snmp protein, putative PFE0925C 1.6 Only in S
34 Snmp protein, putative PFE0925C 1.4 Only in S
35 Formin 2. putative PFL0925W Only in R no
36 Hypothetical protein PFB0145c PFB0145C Only in R Only in T
37 Hypothetical protein MALI 3P1.237 8.8 Only in S
38 Actin. beta [Homo sapiens] gi|14250401 no Only in T
39 Annexin A7 [Homo sapiens] gi|55584155 Only in R no
40 Glyceraldehyde-3-phosphate dehydrogenase PF14_0598 2.8 Only in S
41 Cyclophilin.putative PFL0120C Only in S Only in S
42 Hypothetical protein PFA0725w PFA0725W Only in R no
43 Elongation factor Tu, putative MALI 3P1.164 Only in S Only in S
44 Enolase PF10_0155 Only in S 1.1
45 Enolase PF10_0155 Only in S 0.4
46 Enolase PF10_0155 Only in S 0.8
47 Enolase PF10_0155 no Only in T
48 Endoplasmin homolog precursor, putative PFL1070C Only in R no
49 40S ribosomal protein, putative PF10_0264 no Only in T
50 Catalase [Homo sapiens] gi|179950 no Only in T
51 Hypothetical protein PFE1595C Only in R no
52 Thioredoxin Peroxidase B [Homo sapiens] gi|9955016 Only in R no
53 Peroxiredoxin 2 isoform b [Homo sapiens] gi|33188452 Only in R no
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Table 4. Redox-proteome changes in the intraerythrocytic stages of the CQ-treated P. falciparum Dd2 
cultures. The schizont stage showed the highest number of spots and was thus used as reference to calculate 
fold changes in oxidation intensity (values from Table 2) given as the ratios ring/schizont (RCQ/SCQ) and 
trophozoite/schizont (TCQ/SCQ). Accession Nos. are from the PlasmoDB or NCBI databases.
Spot Protein Description AccessionNo. RCQ/SCQ TCQ/SCQ
1 Heat shock protein PFI0875W 0.2 0.8
2 Heat shock protein PFI0875W Only In SCO 0.3
3 HSP60 PF10_0153 0.3 0.7
4 HSP60 PF10_0153 0.2 1.1
5 HSP60 PF10_0153 0.1 0.4
6 HSP hsp70 homologue PF11_0351 0.3 0.6
7 HSP70 PF08_0054 Only in SCO 0.8
8 Heat shock protein 86 PF07_0029 0.1 3.7
9 Heat shock protein, putative PF14_0417 0.0 0.9
10 Co-chaperone GrpE. putative PF11_0258 Only In SCO 0.8
11 Disulfide Isomerase precursor, putative MAL8P1.17 0.0 0.9
12 Cell division cycle protein 48 homologue, putative PFF0940C 0.1 2.4
13 Peptidase, putative PF14_0517 0.0 0.1
14 Carbonic Anhydrase 1 [Homo sapiens] gl|115449 0.1 0.5
15 Carbonic Anhydrase 1 [Homo sapiens] gl| 115449 0.1 0.7
16 Carbonic Anhydrase II [Homo sapiens] gl|4557395 Only in SCO 0.2
17 Carbonic Anhydrase 11 [Homo sapiens] gl|4557395 Only in SCO 1.1
18 Hypothetical protein PFF0190C 1.6 0.9
19 Erythrocyte membrane protein 1 gl|21886680 Only In SCO 0.9
20 Erythrocyte membrane protein 1 gl|19071542 0.0 0.4
21 Phosphoglycerate kinase PFI1105W 0.1 1.2
22 Hypothetical protein PFA0210C 0.6 0.3
23 Hypothetical protein PF14_0046 PF14_0046 Only In SCO 0.7
24 Hypothetical protein PFL1930W 0.2 0.4
25 GTP-binding nuclear protein ran/tc4 PF11_0183 0.0 0.6
26 26s Proteasome aaa-ATPase subunit Rpt3. putative PFD0665C 0.1 0.1
27 Ml -family aminopeptidase MAL13P1.56 0.4 1.0
28 Ml-family aminopeptidase MAL13P1.56 1.2 2.9
29 Ml-family aminopeptidase MAL13P1.56 0.5 4.3
30 Ml-family aminopeptidase MAL13P1.56 Only In SCO 0.1
31 Proteasome beta-subunit MAL8P1.142 Only In SCO 0.5
32 Fructose-bisphosphate aldolase PF14_0425 Only In SCO 0.0
33 Snmp protein, putative PFE0925C Only In SCO 0.1
34 Snmp protein, putative PFE0925C Only In SCO 0.1
35 Formin 2. putative PFL0925W 0.3 0.8
36 Hypothetical protein PFB0145c PFB0145C 1.1 Only in SCO
37 Hypothetical protein MALI 3P1.237 Only In SCO 1.2
38 Actin. beta [Homo sapiens] gl|14250401 0.5 0.2
39 Annexin A7 [Homo sapiens] gl|55584155 0.6 0.5
40 Glyceraldehyde-3-phosphate dehydrogenase PF14_0598 Only In SCO 0.4
41 Cyclophilin.putative PFL0120C Only In SCO 0.1
42 Hypothetical protein PFA0725w PFA0725W Only In SCO 0.7
43 Elongation factor Tu, putative MAL13P1.164 0.6 1
44 Enolase PF10_0155 Only In SCO 0.3
45 Enolase PF10_0155 no no
46 Enolase PF10_0155 no no
47 Enolase PF10_0155 Only In SCO Only in SCO
48 Endoplasmin homolog precursor, putative PFL1070C Only In SCO Only in SCO
49 40S ribosomal protein, putative PF10_0264 Only In SCO Only in SCO
50 Catalase [Homo sapiens] gl|179950 Only In SCO Only in SCO
51 Hypothetical protein PFE1595c no no
52 Thioredoxin Peroxidase B [Homo sapiens] gl|9955016 no no
53 Peroxiredoxin 2 Isoform b [Homo sapiens] gl|33188452 no no
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Table 5. Redox-proteome changes induced by CQ at each intraerythrocytic stage in P. falciparum Dd2. The 
fold change in oxidation intensity (values from Table 2) appears as the ratio of the value obtained for the CQ- 
treated stage to that for its corresponding control stage. Accession Nos. are from PlasmoDB or NCBI 
databases.
Spot Protein Description AccessionNo. RCQ/R TCQ/T SCQ/S
1 Heat shock protein PFI0875W 0.2 5.4 8.3
2 Heat shock protein PFI0875W Only In R 0.1 2.9
3 HSP60 PF10_0153 0.7 0.5 4.3
4 HSP60 PF10_0153 0.4 0.9 2.4
5 HSP60 PF10_0153 0.1 0.6 1.6
6 HSP hsp70 homologue PF11_0351 0.5 1.0 1.1
7 HSP70 PF08_0054 Only In R 2.2 4.6
8 Heat shock protein 86 PF07_0029 0.1 1.7 1.8
9 Heat shock protein, putative PF14_0417 0.1 1.7 3.8
10 Co-chaperone GrpE. putative PF11_0258 Only in R 2.9 2.3
11 Disulfide isomerase precursor, putative MAL8P1.17 0.1 2.9 5.0
12 Cell division cycle protein 48 homologue, putative PFF0940C 0.2 23.5 1.4
13 Peptidase, putative PF14_0517 0.2 1.4 7.1
14 Cartxxiic Anhydrase 1 [Homo sapiens] gi|115449 Only In RCQ 0.5 13.9
15 Carbonic Anhydrase 1 [Homo sapiens] gl|115449 0.1 0.4 5.8
16 CartK>nic Anhydrase II [Homo sapiens] gi|4557395 Only In R 0.1 5.0
17 Carbonic Anhydrase II [Homo sapiens] gi|4557395 Only In R 0.6 4.4
18 Hypothetical protein PFF0190C 1.8 1.0 5.4
19 Erythrocyte membrane protein 1 gi|21886680 Only In R 3.6 12.4
20 Erythrocyte membrane protein 1 gi| 19071542 0.0 Only In TCQ 3.0
21 Phosphoglycerate kinase PFI1105W 0.2 Only In TCQ 8.7
22 Hypothetical protein PFA0210C 0.9 8.7 Only In SCO
23 Hypothetical protein PF14_0046 PF14_0046 Only In R 0.8 1.4
24 Hypothetical protein PFL1930W 0.5 1.0 22.3
25 GTP-binding nuclear protein ran/tc4 PF11_0183 0.4 1.8 3.0
26 26s Proteasome aaa-ATPase subunit Rpt3. putative PFD0665C 0.5 Only In TCQ 2.2
27 Ml-family aminopeptidase MAL13P1.56 0.2 0.7 1.5
28 Ml -family aminopeptidase MAL13P1.56 Only In RCQ 0.6 1.1
29 Ml-family aminopeptidase MAL13P1.56 Only In RCQ 1.4 2.2
30 Ml-family aminopeptidase MAL13P1.56 no Only In TCQ Only in SCO
31 Proteasome beta-subunit MAL8P1.142 no 0.5 13.9
32 Fructose-bisphosphate aldolase PF14_0425 Only In R Only In TCQ 4.3
33 Snmp protein, putative PFE0925C Only In R Only In TCQ 2.9
34 Snmp protein, putative PFE0925C Only In R Only In TCQ 1.8
35 Formin 2. putative PFL0925W 0.5 Only In TCQ Only In SCO
36 Hypothetical protein PFB0145c PFB0145C 1.2 Only In T Only In SCO
37 Hypothetical protein MAL13P1.237 Only in R Only In TCQ 21.1
38 Actin. beta [Homo sapiens] gi| 14250401 Only In RCQ 2.4 Only In SCO
39 Annexin A7 [Homo sapiens] gi|55584155 1.4 Only In TCQ Only In SCO
40 Glyceraldehyde-3-phosphate dehydrogenase PF14_0598 Only In R Only In TCQ 1.0
41 Cyclophilin.putative PFL0120C no Only In TCQ 7.8
42 Hypothetical protein PFA0725w PFA0725W Only In R Only In TCQ Only In SCO
43 Elongation factor Tu, putative MALI 3P1.164 Only In RCQ Only In TCQ 1.4
44 Enolase PF10.0155 no 0.1 0.4
45 Enolase PF10_0155 no Only In T Only In S
46 Enolase PF10_0155 no Only in T Only in S
47 Enolase PF10_0155 no Only in T Only In SCO
48 Endoplasmin homolog precursor, putative PFL1070C Only In R no Only In SCO
49 40S ribosomal protein, putative PF10_0264 no Only In T Only In SCO
50 Catalase [Homo sapiens] gi| 179950 no Only In T Only In SCO
51 Hypothetical protein PFE1595C Only In R no no
52 Thioredoxin Peroxidase B [Homo sapiens] gl|9955016 Only In R no no
53 Peroxiredoxin 2 Isoform b [Homo sapiens] gi|33188452 Only In R no no
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Parasite  oxid ized  proteins
Oxidized proteins in non-treated and CQ-treated cultures were sorted into main 
functional classes (Fig. 3) according to the Munich Information Centre for Protein 
Sequences (M IPS) catalogue (Ruepp et al., 2004) and the proteomic categories defined 
previously for P. falciparum (Florens at a/., 2002). The carbonylated proteins identified 
(Fig. 3 and Table 6) were mostly assigned to the category protein fate (15), followed by a 
second large group of hypothetical proteins (8) and a third group of metabolic proteins (4).
Metabolism
8%
Unknown \  Protein synttiesis 
31% 1 4%
Structural 
2%
Cell surface 
4%
Protein fate 
31%
Tra^rtp tion  Hypolhellcal 
16%
Signal transduction
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(B) Metabolism8%
Unknown \  Protein synttiesis
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2%
Protein fate
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° 15%
Signal transduction
2%
Fig. 3. Functional profiles of the parasite carbonylated proteins identified. Proteins identified in control 
untreated and CQ-treated parasites are classified according to their functional definition in the MIPS catalogue 
(Ruepp at a!., 2004). To avoid redundancy, only one class was assigned per protein. (A): Functional 
categories for control parasites. (B); Functional categories for CQ-treated parasites.
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In the protein fate class, chaperones were the most frequently appearing oxidized 
proteins (Table 2) in almost all the non-treated and CQ-treated stages (remarkably in the 
CQ-treated schizonts, details in Table 5) and included species of the heat shock protein 
(HSP) 70 (spots 1, 2, 6 and 7), HSP60 (spots 3-5), HSP86 (spot 8, noticeably oxidized in 
treated trophozoites), a putative HSP (spot 9) and putative endoplasmin homologue 
precursor (spot 48, significantly oxidized in non-treated rings); the latter two are members 
of the H SP90 family. Further chaperones identified were a putative co-chaperone GrpE  
(spot 10), a putative disulphide isomerase precursor (spot 11), and a  putative cyclophilin 
(spot 41).
Other identified oxidized proteins of the protein fate class were; a putative cell 
division cycle protein 48 homologue, significantly oxidized in the CQ-treated trophozoites, 
with proteolysis, peptidolysis and chaperone-like functions (spot 12); a  putative peptidase, 
mainly oxidized in treated schizonts (spot 13); a putative 26S  proteasome aaa-ATPase  
subunit Rpt3, mostly oxidized in CQ-treated schizonts (spot 26); an M l-fam ily  
aminopeptidase (spots 27-30), and the 20S proteasome beta-subunit, which was highly 
oxidized in non-treated trophozoites and treated schizonts (spot 31).
In the metabolic protein class, four glycolytic enzymes were found to be oxidized 
(Table 2 and Table 6): phosphoglycerate kinase (spot 21, significantly oxidized in treated 
trophozoites), fructose-bisphosphate aldolase (spot 32, remarkably oxidized in treated 
schizonts), glyceraldehyde-3-phosphate dehydrogenase (spot 40, markedly oxidized in 
non-treated rings), and four species of enolase (spots 44-47, non-detectable in rings).
Within the cell surface class (Table 6), two proteins from the var gene family were 
identified, both designated erythrocyte membrane protein 1 (P fE M P I) (spots 19 and 20, 
more oxidized in CQ-treated schizonts).
Two oxidized proteins of the protein synthesis class (Table 6) were identified, the 
putative elongation factor Tu (spot 43, oxidized in all CQ-treated stages and in non-treated 
schizonts) and a  putative 40S  ribosomal protein (spot 49, oxidized in non-treated 
trophozoites and CQ-treated schizonts).
Other oxidized proteins of the classes signal transduction, transcription, and 
structural (Table 2 and 6) detected were: the GTP-binding nuclear protein ran/tc4 of the 
Ras family (spot 25, markedly oxidized in treated schizonts); a putative Snrnp protein 
(spots 33 and 34, significantly oxidized in treated schizonts), and a  putative formin 2 (spot 
35, more oxidized in treated schizonts) respectively (Table 2).
For each of the stages, some spots identified were designated as hypothetical 
parasite proteins (Table 2, spots 18, 22, 23, 24, 36, 37, 42, 51) and therefore ascribed to 
the hypothetical protein class (Table 6) with unknown functional roles and cellular
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localization. Among these, spot 18, the most striking oxidized protein in treated rings, was 
the most carbonylated protein in all the non-treated and CQ-treated stages.
It should be noted that approximately 25%  of the spots could not be identified by 
M ALDI-TO F/TO F MS analysis and database searches. These unidentified spots are not 
included in Tables 2 and 6.
138
I
s
o
CO
Q
0  
E1
I
I
I
8
Z
§
I
I
1
•o
I
I
I
I
Cl
E
(0
§
(O
I
2
Q.
SI
co
oc
<
I
i
o .
IllIII
y  Q- .
illIf
Ë l 2  .
®  ^  <JJ CVJ
Ni
c5 o ci
n i l
c
0
1
(0
II
Q.
CO
X
i
u .
CL
I
I
CL
III
1
0 0) 0.
’= l ï
III
Û. « E
ifiIP &#4
° i i i
c  5^
ill
S “ Q
IP
|i- =iill
Q- c
CO -o b  « O) o oc EIIÎÎ
Ig
s
u .
CL
I
I
Q.
2 2  § 
III
l i l t 'fill
'.O Q-ij o
t i l e
C ^ O  i .  .
îlf
0)
I
I
c
R
C L
0 .
CO
X
I
I
CL
tii
2cvi
_  8
C3)-D O CL 
C  7 ;  ^  .
I
If
2 i  
8..I
i P i
ilil
itir
g¥
I
I
I
CL
tfil 
?  8 =  ”
— r-
«II*fPf
n  Q.-y
Hi
m CO 
—  ■ 2
III
3
CO o  
CO o
§ 5 IIc
g
0_
i
I
I
Q.
iS IJ!lil
■g 2 CO
I I
p E a B
Hill
ô “ i i i
O  C  T 3  CD CO
lllli
CO
CL
CO
X
s
I
I
êi
I
II1
p
§ 1 1
- i l
II
I I
4
se. <.
iI
i
g
CTI
I
ülll«Il
! §  §  •
i
CD 3
i
i
"On
g
Sf
lliî
8 2 g ’ “i
2  ®4|!
fit
i P I
$ z g :
it
lliî
ii
i
I
I5
" D
E
H
III
jll
i=l
3  —  (D  Q .  
Q .  CD
|l
i t
H
1o 0)
!|
8 g 
3 a  
CD O
il
II
ç E
SI
ii
m3ET3I
3
3"
01
&
x>i
s
ll}
i i flit
8 8
2 8
00 se
8SSP
p
I!
Ii
î
f
i
o
-3
m
TD
S
I I
o i • •
il
II
II
II
}l
I i
ilCD CDii
-K 3 
0 )  Q .
S i -
If
i lœ A
iltt
I
6"
3
" D
I
I
8
■ 0
o
I
?>
o
o
à.3
C&
I
■ Q
j
Ü
u >
»g
2
a .
I
Ic
<
0
1
I
CL
i
1
CQ
il
3
«
|iItII
III"Si
I® 
!'si
1o
3  
C  
Co 
,
(0 Q.
i1
1
«0
CL
CO
I
I
CL
> » . bX  X  ^H IO O (0
ill
11!
2  c  cQ. OJ O
ill
" 8 sill
5 S Î
C  <D
2 
CL ..
C  h -
0  m
e 1o m o a1111
CL >,
O) <D ^  0) CC
1 1 ^ 1 3
5  E  S  ^■ti (0  CO
CO
II
Q .
CO Ü■rs
Î2 *  C
o E
il
li
I I  
! i f
CO £  œ  <
i  =  i o
n§
sf *
f l s l l
g  0 ) . C  CO .Q
Ü
■I CO
g
I &
Ü  ° -  
3
Z
I F
CD
CD X 3
E  2ft
o S
ii!
CO «  O )Ie -
3 ^ ®
-2 3 -5
c n-, O
IIÎ
CD O  t s
I I I
i l l
IIII F
■D  CO CD
5 TJ .I
:ll
i S “
g
»  »  ,E
I
-  T3 ^ll?
|i| 
=
C  C  
3  CO 3  
0 ) ^ 3  
3  C  3  
CO C  CO
CO
jg O g 
111til
CD "® ^
CO c  ;=
® ® s
III
1 1 1
CD
£ l §
III!|§
î P111
° g g.
III
c = „
g  S -
2  CO COHill
i
X )
3
E
CD
I
Q .
CO
I
I
Q .
D >
i  I
: M # . 
Iflti
l|i?i
s
I
I?
I
a .
CD
I
is
i
£
U _
a
I
I
Q.
TI 1 I
T3
I
3
I
(D
mE
Q)
§I
O
3
3
C
3E
I
if
*1
3"
8 
2. "2. 
i.a
5T ®
II
- 0 (
i P g
till
I I ?
o  ^
P i. 5w >  ja
® r<2
4 ^ 8
9 I t s
l|
IIO M 
c6 9
II
II M
I
T I
8
S
I
I
Ililiff
3 . <
i.
II!
i
iff
II!
" G
I!® « q
IIIw CO r>
II?
i ° sg
O  CO
ill
I
§
OD
0
Î
1
II
I
I
mm
O C Q  
-0 3
3 8
o  ®
è  S’
■ 3 ^= :  CD
D> (Q 0).ilI?
3TCQ
l i
3 oj W ?  Ü5
tii
II
I
I
9Lg
i
oTSPCrt® 0.(0 5  O
3 
3
CD 
3fiflt
illPi*
llîîfP
l^i!l{
s i t l l *
Il
0)
I
i
\
?
I
s?8
?
I
cn
Î
I
I
I
E3
C
ü
<Ô
I
l
I
Co
g
5
I
I
i
I
(0
i l
LL
I I
II
i l
il
=11
!ï
Î5 -.2 0) e
II!
I
D.
i
Q.
I
CCO
I
illï
13::
.  co o  
0) ?  E (g|l:-i
| Ï 5 g £
i|l|
3l: >*= ._ «
li
ili
I
Q.
I
X)
ü
S
0
3
1 (0
S
liH
il
' 1 1
S-B-oôIIIP
üw d cô •- l:
lllll
0)
E 5 I
I
Q.
m
I•C
C /D
$
8I
I0_
<0 O) il
il
“e
CJ) (0
ü
111
O ü  Æ ® ü-
I
c
0
1
c
o
LU
CL
CO
I
I
CL
.1 8
g ) £
o  0.
Il
■i i(0 co
i
CL
S
3
o
2
œ
Redox proteomios
4-Hydroxynonenal-modified proteins
As shown in Figure 4, protein carbonylation caused by HNE was limited to two 
major bands of 69 and 42 kDa detected at the different intraerythrocytic stages in the non­
treated and CQ-treated parasites. Interestingly, although CQ slightly increased oxidation 
of the 69 kDa band in mature rings and schizonts, it clearly inhibited lipoperoxide-induced 
oxidation of both bands in young rings and trophozoites. This effect was particularly 
noticeable in trophozoites, at which stage greatest HNE-protein modification was 
observed in the absence of CQ and practically no modifications were detected in both 
bands in the presence of an IC50 of CQ.
yR mR yT m l
- 69 kDa
- 42 kDa
Fig. 4. HNE-modlfied proteins at different intraerythrocytic stages of P. falciparum  Dd2. yR, young ring; 
mR, mature ring; yT, young trophozoite; m l, mature trophozoite and S, schizont of control (-) and IC50 CQ- 
treated (+) cultures. The exposure time of the membrane to the film was 30 min.
5. Discussion
Although the malaria parasite is susceptible to oxidative stress during its 
erythrocytic life stages given the red blood cell environment contains oxygen and iron, 
factors required for the formation of ROS, it is also well adapted to such oxidative stress 
through specialized systems (Becker et al., 2004) Thus, toxic FP IX (Fe^^), which is 
released upon haemoglobin degradation by the parasite, is mostly (up to 90% ) detoxified 
by biomineralisation (Egan et al., 2002) to form inert haemozoin. Notwithstanding, it has 
been reported that a considerable amount of FP IX (possibly as much as 50% ) escapes 
biomineralisation and must be detoxified by alternative pathways (Muller, 2004). In 
addition, low intracellular levels of ROS are maintained by a number of redox and 
antioxidant systems described for the erythrocytic stages of P. falciparum  such as those 
comprised of superoxide dismutases, mitochondrial redox and antioxidant systems, and 
enzymatic control of intracellular glutathione levels by redox cascades including 
glutathione reductase, glutaredoxins, glyoxalases, glutathione S-tranferases, thioredoxins, 
peroxiredoxins and glucose-6 -phosphate dehydrogenase (Muller, 2004). Effectively, the
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induction of several antioxidant enzymes upon transient silencing of glucose-6-phosphate 
dehydrogenase*6-phosphogluconolactonase (Crooke et a!., 2006) has revealed the key 
role of such enzyme cascades in maintaining oxidative homeostasis.
Despite functioning FP IX detoxification systems and a number of enzymatic and 
non-enzymatic antioxidant systems, the high number of oxidatively modified proteins in P. 
falciparum  relative to numbers reported for eukaryotic organisms (Poon at a/., 2004; Poon 
at a/., 2005; Reverter-Branchat at  a/., 2004; Singh at a/., 2007; Sultana at a i ,  2006) 
suggests a highly oxidative environment of the parasite, probably as a consequence of 
toxic haem escaping detoxification, increasing ROS generation and causing dam age to 
intracellular proteins (Ginsburg at a i,  1998; Loria at a i ,  1999). Our present observation of 
increased protein oxidation induced by CQ  in the mature stages of the parasite's 
intraerythrocytic cycle, which is when most haemoglobin is digested, suggests that CQ  
interferes with haem detoxification, in agreement with current hypotheses on the 
antimalarial mechanism of C Q  action (Egan at a i,  2000; Egan and Ncokazi, 2005; 
Ginsburg at a i,  1998; Loria at a i ,  1999).
Although protein carbonylation produced by HNE adducts only represents a  
fraction of the oxidative damage derivatized by DNPH, the lower number of oxidized spots 
and reduced spot intensities detected in CQ-treated parasite rings could reflect the 
inhibition by CQ  of protein-HNE adducts in early stages of parasite development. Thus, 
lipoperoxides could be a main driving component of protein oxidation in early development 
stages. Subsequent to this, when haemoglobin degradation by trophozoites reaches a 
significant rate, the main source of oxidation would switch to free haem. CQ-induced 
inhibition of haem biomineralisation would then enhance protein oxidation, as indicated by 
our results. Indeed, increased haem production in mature stages has been also described 
as a source for HNE formation in parasitized erythrocyte membranes (Arese and 
Schwarzer, 1997); (Skorokhod at a i ,  2007). This would also explain the slight increase in 
HNE adducts also detected in our CQ-treated schizonts.
Protein carbonyl detection as a  measure of oxidative dam age indicated that some 
groups of proteins such as molecular chaperones, proteases and glycolytic enzymes were 
more susceptible to oxidation than others. Interestingly, some of these oxidation targets or 
their isozymes, such as HSP60, HSP70, HSP86, 26S proteasome subunit, 
glyceraldehyde-3-phosphate dehydrogenase, enolase, fructose-1,6-bisphosphate
aldolase, carbonic anhydrase isoenzymes, beta-actin, and catalase have been identified 
as oxidatively-modified proteins in eukaryotic cells subjected to oxidative stress, from 
yeast to human cells (Butterfield, 2004; Cabiscol at a i,  2000; England at a i,  2004; Ishii at 
a i,  2005; Poon at a i,  2004; Reverter-Branchat at a i ,  2004; Sultana at a i ,  2006). The  
significant sequence divergence between P. falciparum  proteins and their functional
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homologues in other organisms, suggests a  common oxidative signalling mechanism  
controlling protein turnover across this wide evolutionary scale (Dalle-Donne et a i ,  2006).
Although great care was taken to only extract parasite proteins using our 
differential lysis and treatment method, not all the proteins detected were of plasmodial 
origin, around 1/6 were derived from the human erythrocyte host. This effect has also 
been detected in other malaria proteomic studies (Florens at a i ,  2002; Nirmalan at a i,
2004) and suggests that some of the host proteins detected correspond to erythrocyte 
proteins internalised by the parasite, or proteins arising from host-parasite interaction or 
from cross-contamination during erythrocyte lysis. Thus, in practically all the parasite 
stages, erythrocyte cytosolic carbonic anhydrase I and II were among the most oxidized 
proteins in both non-treated and CQ-treated parasites. Particularly high oxidation signals 
were observed in non-treated trophozoites followed by treated schizonts. Carbonic 
anhydrase has been identified as a major intracellular peroxidation target in erythrocytes 
(Uchida at a!., 1997). High concentrations of carbonic anhydrase have been found in the 
erythrocyte cytosol (Ozensoy at a i,  2004). Also, carbonic anhydrase III, the main 
oxyradical scavenger cytosolic isoenzyme expressed at high levels in skeletal muscle 
(Raisanen at a i ,  1999), is strongly carbonylated independently of endogenous oxidative 
stress (Barreiro at a i,  2005). Hence, the oxidized carbonic anhydrases detected in all the 
parasite stages examined could be attributed to oxidative stress in the parasitized 
erythrocytes irrespective of the presence CQ. Thus, if oxidative dam age to an essential 
red blood cell enzyme also occurs during in vivo infection, this could modify the 
phagocytosis rate of parasitized cells and consequently the course of malaria-associated 
anaemia, as described in oxidative red cell defects (Cappadoro at ai., 1998).
A further three important redox-related enzymes from the human host were also 
found to be oxidized in our experiments. Thus, peroxiredoxin 2 isoform b and thioredoxin 
peroxidase B were detected in non-treated rings, and catalase in non-treated trophozoites 
and CQ-treated schizonts. Although Piasmodium  lacks the antioxidant enzymes catalase 
and glutathione peroxidase, high H2O 2 concentrations released during haemoglobin 
digestion in the parasite vacuole are directed towards its own cytoplasmic peroxidases 
and thioredoxins (Nickel at ai., 2006) with the additional participation of the host cell 
antioxidant system, including catalase (Atamna at a i,  1994). Host catalase imported into 
the food vacuole (Fairfield at a i,  1988) has been reported to remain active at pH 5 and 
achieve H2O 2 detoxification until it is also digested by vacuolar proteases (Tilley, 2001). 
Thus, the four-fold increase in oxidized catalase in CQ-treated schizonts suggests an 
ancillary effect of the drug against host-imported antioxidant proteins, which could 
enhance oxidative damage in the parasite.
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The vast majority of the carbonylated proteins identified were of plasmodial origin 
(83% ). Strikingly, nearly one-third of these plasmodial proteins belonged to chaperone 
families or exhibited chaperone properties. Our results revealed that chaperones from 
different families became carbonylated in almost all non-treated and CQ-treated parasites, 
but carbonylation was especially intense in CQ-treated schizonts. Several carbonylated 
HSPs of 60, 70, 82 and 8 6  kD have been identified under different oxidative stress 
conditions in eukaryotic cells (Butterfield, 2004; Poon et al., 2004; Reverter-Branchat et 
al., 2004; Sultana et al., 2006). Molecular chaperones in eukaryotes both contribute to 
protein folding, assembly and translocation and regulate the activities of protein kinases 
and transcription factors, inducing their expression under several types of cellular stress 
(Parsell, 1994). HSP members of families 60, 70 and 90 are expressed throughout the 
intraerythrocytic cycle of the parasite (Banumathy et a!., 2003). Additionally, HSP90 has 
been identified as the target of the antimalarial activity of geldanamycin (Kumar et a!., 
2003). The high propensity for oxidation revealed by this class of proteins in P. falciparum  
might suggest their rapid turnover in quickly replicating parasite cells. In addition, the 
increased carbonylation of HSPs observed in the mature stages of CQ-treated parasites 
at IC50 could indicate interference with the cellular chaperone protective role giving rise to 
the build-up of harmful misfolded proteins (Dalle-Donne at a i ,  2006), thus further affecting 
cell survival at the mature stages, in agreement with an observed inhibitory effect of CQ  
on schizonts in culture (Yayon at a i,  1983).
In the cell, chaperone and degradation systems are functionally linked (Berke and 
Paulson, 2003). Two proteins involved in protein catabolism, the 2 0 8  proteasome beta- 
subunit and a putative 2 68  proteasome aaa-ATPase subunit Rpt3, were also identified in 
our experiments as carbonylated proteins. In both these proteins, most oxidation was 
detected in CQ-treated schizonts (up to a  14-fold increase with respect to non-treated 
schizonts) although the former was also notably oxidized in non-treated trophozoites. 
Oxidative modification of proteasome subunits under different oxidative stress conditions 
has been reported in neuroblastoma cells (Ishii at a i,  2005), T  cells (Ponnappan at a i,  
2007), and myocardiocytes (Bulteau at a i,  2001). On the other hand, oxidatively modified 
proteins are degraded in the proteasome (Bulteau et al., 2001), whose activity gradually 
diminishes as a consequence of oxidative damage (Dalle-Donne at a i,  2006). Thus, the 
increased oxidation by CQ observed in the parasite proteasome could modify the overall 
protein turnover machinery, also compromised by the intense oxidation of chaperones 
mentioned above. Recently, a  critical mutation associated with resistance to CQ in P. 
chabaudi has been found in a deubiquinating enzyme involved in the ATP-dependent 
protein degradation pathway (Hunt at a i,  2007). Adaptation to CQ of these proteins with 
common cellular functions, whether by mutation or chemical modification, suggests that
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the parasite protein fate machinery has a physiological role in fighting against the 
oxidative stress caused by sublethal concentrations of the drug. This hypothesis is also 
supported by the identification of a deubiquinating protease as the carbonylated target of 
the oxidative stress induced in mutant superoxide dismutase deficient mice (Poon et al.,
2005). Thus, targeting the P. falciparum  proteasome complex, as reported for lactacystin 
(Certad et al., 1999), may be an alternative or a complementary therapeutic strategy in 
combination with antimalarials that trigger oxidative stress in the parasite.
Besides processing proteases, the proteolytic M l-fam ily aminopeptidase 
responsible for haemoglobin digestion and erythrocyte invasion (Allary at a i,  2002), also 
appeared carbonylated in almost all non-treated and treated stages, with the most intense 
carbonylation signal observed in treated schizonts. Up to four species of the enzyme were 
detected: three, showing slight size differences, which were probably generated through 
autoproteolysis and a fourth species, which was largely trimmed. The latter species was 
seen oxidized only in CQ-treated schizonts suggesting differences in conformational state 
or posttranslational modifications induced by CQ-related oxidative stress. Although post- 
translational modifications in a variety of P. falciparum  proteins have been observed by 
quantitative proteomic analysis (Nirmalan at a i,  2004), clues about their nature have not 
yet emerged. On the other hand, the antimalarial activity of inhibitors of the M l-fam ily  
aminopeptidase (Flipo at a i ,  2003) suggest an essential role for this protease in the 
parasite’s life cycle. Given that blocking FP IX aggregation is a main effect of CQ (Egan  
and Ncokazi, 2005), parallel increased ROS formation and oxidative inactivation of this 
essential protease could promote dam age in the parasite as a secondary effect (Becker at 
a i,  2004; Orjih at a i ,  1994).
Four glycolytic enzymes, phosphoglycerate kinase, fructose-bisphosphate 
aldolase, glyceraldehyde-3-phosphate dehydrogenase and enolase were identified as 
oxidized parasite proteins. It should be stressed that all have already been identified as 
oxidatively-modified proteins associated with oxidative stress in other cells (Butterfield, 
2004; Cabiscol at a i ,  2000; England at a i ,  2004; Poon at a i,  2004; Reverter-Branchat at 
a i,  2004; Sultana at a i ,  2006). Since high concentrations of a given protein favour its 
oxidation and turnover (Dalle-Donne at a i ,  2006), the identification of these oxidized 
glycolytic enzymes in the parasite suggests the need for relatively high concentrations to 
sustain the major energy dependence on glycolysis of the parasite (Lang-Unnasch and 
Murphy, 1998). Further, the increase in glucose flux in parasitized erythrocytes related to 
the parasitaemia and peak levels in trophozoites (Mehta at a i,  2005) are in agreement 
with the elevated oxidative turnover found in parasite glycolytic enzymes and clarifies their 
parasite origin (Roth at a i ,  1988). Phosphoglycerate kinase and fructose-bisphosphate 
aldolase were significantly oxidized in mature stages of CQ-treated parasites while
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glyceraldehyde-3-phosphate dehydrogenase showed little change between treated and 
non-treated parasites. Enolase deserves a  more detailed discussion given the four 
species identified of close molecular weights with slightly different isoelectric points. Thus, 
while all four enolase forms were highly oxidized in mature stages, none of the forms 
appeared oxidized in rings. Strikingly, three of these enolase species- the most acidic- 
were highly oxidized in non-treated parasites but not in CQ-treated cultures. In contrast, 
the most basic enolase species was highly oxidized in CQ-treated schizonts and only very 
slightly in not-treated trophozoites. This different susceptibility of enolase species points to 
different roles under CQ pressure and could reflect different conformational states caused 
by oxidative stress. This was also observed here for the M1- family aminopeptidase (see  
above) and has been described in another P. falciparum  proteomic analysis (Nirmalan et 
a i,  2004).
Phosphoglycerate kinase and fructose-bisphosphate aldolase were found to be 
highly oxidized in mature stages of CQ-treated parasites. Given the importance of 
glycolysis as a source of cellular ATP, this has key implications for cell function, and is 
thus consistent with reports indicating that mature parasites are considerably more 
sensitive to CQ than ring-stage parasites following glycolysis inhibition by CQ (Yayon et 
a/., 1983).
Further to the previous rationale on the secondary effect of CQ on 
aminopeptidase, CQ-induced binding of FP IX to parasite glycolytic enzymes could also 
inhibit glycolysis as a secondary effect, as previously suggested (Campanale at a/., 2003; 
Famin and Ginsburg, 2003).
Only two cell surface proteins appeared oxidized. These two proteins are the 
products of two separate genes of the highly polymorphic var family that code for R EM P1  
harbouring Duffy-binding-like domains. Both proteins were found highly carbonylated in 
CQ-treated schizonts. These two P fE M P Is  are encoded by genes of the highly 
polymorphic var family which, coincidentally, are commonly occurring and expressed in 
placental field isolates of P. falciparum  (Fried and Duffy, 2002; Rowe at ai., 2002). 
P fE M P Is  have been linked to the adhesion properties of parasitized erythrocytes (Howard 
and Gilladoga, 1989; Singh at ai., 2006) and implicated in many features of severe 
malaria and its pathogenesis, particularly malaria in pregnancy (Kirchgatter and Del 
Portillo, 2005). Carbonylation of these proteins could -a lb e it very tentatively- indicate a  
change in the cytoadhesion properties of CQ-treated parasites related to the non­
prevention of P. falciparum infection in pregnant women on regular CQ prophylaxis, who 
nevertheless exhibit lower densities and rates of placental infection (McDermott at ai., 
1988).
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In this first redox proteomic profiling of CQ-resistance in P. falciparum  across its 
intraerythrocytic stages, the proteins identified as oxidized are key instruments of the 
parasite’s main functions, such as protein folding, protein fate, energy metabolism, signal 
transduction and pathogenesis. Our findings provide new insight into the molecular 
mechanisms triggering the parasite’s response to CQ, along with information on normal 
protein-oxidation modifications that could play a role in its development and 
pathophysiology. Our results also indicate that redox proteomios is an appropriate tool for 
identifying CQ-response systems, which if targeted might render new ways of fighting 
against CQ-resistant strains. Among these, HSPs, the parasite’s specific proteolytic 
machinery and glycolytic enzyme systems are the best candidates, given the long 
stretches of identity loss between their protein sequences and those of their homologues 
in the host (Fig. 5).
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Fig. 5. Protein alignments of HSP70 (PF08_0054), HSP86 (PF07_0029), M1-family aminopeptidase 
(MAL13P1.56) and proteasome beta-subunit (MAL8P1.142) from P. falciparum with their corresponding host 
homologues showing the long stretches of identity loss between the parasite and host protein sequences (in 
boxes).
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5. CONCLUSIONS
The results presented in this thesis represent new perspectives for biology of the 
parasite and antimalarial chemotherapy. The following conclusions can be raised from the 
results obtained:
1- The high expression levels of PfNnal gene and transcriptional up-regulation by PCI in 
the mature-stage parasites suggest the involvement of this putative protein in essential 
activities for the parasite survival.
2- The unique bifunctional Plasmodium  G 6PD -6PG L protein varies in size depending on 
the parasite developmental stage. In fact, a controlled pattern of PfG6PD-6PG L  
processing during parasite maturation can be hypothesized. Detecting two different band 
sizes using the anti-G6PD and anti-6PGL antibodies implies that the bifunctional protein 
could mature to render two different polypeptides with separate enzyme activities.
3- Proteomic profiling of oxidation is dependent on the time course of the intraerythrocytic 
stages of P. falciparum  either in non-treated or in chloroquine-treated parasites.
4- Oxidative damage in P. falciparum  is identified in the following key components of the 
parasite cellular functions: protein folding, protein turnover and proteolytic processing, 
energy metabolism, signal transduction and pathogenesis.
5- Detection of specific 4-hydroxy-2-nonenal adducts indicates that protein 
lipoperoxidation is inhibited by chloroquine, particularly at early stages of development.
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7. ANNEX I
Protocols for Plamodium falciparum culture
1. Preparation of Culture Medium
Nomenclature of culture medium:
- COMPLETE MEDIUM (blue medium) ^  RPMI 1640 + HEPES + ALBUMAX I + 
HYPOXANTHINE + GENTAMICINE + BICARBONATE. Prepare just before using it. 
INCOMPLETE MEDIUM -> Like complete medium without BICARBONATE. Prepare weekly 
(7-10 days) (LASTS UP TO 7 DAYS, 4°C; 10 DAYS, -20°C).
WASHING MEDIUM (yellow medium)-^ Like compiete medium without ALBUMAX I. Prepare 
every 15-21  days. (LASTS UP TO 14-20 DAYS, 4°C).
Reagents:
. 50mg Gentamicine (bottle) + 1 ml distilled water Final concentration = 50 mg/ml 
. 0.1M Hypoxhantine: 1.361 g in 100ml 1M NaOH [MW Hypoxhantine: 136.1].
. 1M NaOH: 4g in 100ml destilled water [MW NaOH: 40].
. 5% Sodium bicarbonate: 5 g sodium bicarbonate in 100 ml distilled water [MW = 84.01] (Lasts up 
to 5 days at 4®C).
STOCK SOLUTIONS: All stock solutions should be stored at 4*C.
Reagent Company Reference
RPM11640 Sigma R6504-1L (10 shachets)
HEPES 1M Sigma H0887 (100 ml)
SODIUM BICARBONATE Sigma S 5761 (500g)
HYPOXANTHINE Sigma H9636 (1g)
ALBUMAX1 Gibco 11020-021 (25g)
GENTAMICINE Sigma G-1264 (50 mg)
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INCOMPLETE CULTURE MEDIUM (1 L):
1. Add 800 ml of milllQ or bidistilled water in a beaker.
2. Add one sachet of RPM11640 to the water and constantly shake the mix on a shaker.
3. Add 25 ml 1M HEPES (pH =7.4)
4. Transfer 150 ml (approximately) of this medium to another beaker and add the following:
1 ml hypoxanthine from the 0.1 M stock solution, shake and 
5g Albumax. Mix well.
5. Add that mix into the general RPMI medium.
6. Add 250 pi Gentamicine.
7. Adjust pH = 7.25 (The culture medium pH has to be 7.4 but when we filter the medium, the pH 
increase).
8. Add milliQ or bidistilled water until the total volume is 1 L.
9. Filter the culture medium with sterile 500 ml micropore bottles (pore 0  = 0.22 pm).
10. Label the bottle, mentioning name and date. Store at 4°C.
The freeze incomplete culture medium is valid for 10 days at -20®C (MR4). At 4°C it is valid for 
approximately 7 days.
INCOMPLETE MEDIUM 
(1L)
Doses Final concentration Initial concentration
RPMI 1640 10.4 9 10.4 g/l
HEPES buffer solution 25 ml 25 mM 1 M
ALBUMAX 5g 0.5%
HYPOXANTHINE 0.1 M 1 ml 100 pM 0.1 M
GENTAMICINE 250 pi 12.5 pg/ml 50 mg/ml
COMPLETE CULTURE MEDIUM (100 ml):
According to MR4 protocol, the complete culture medium works well for 3D7, Dd2, W2, and 
HB3 strains. In our laboratory only strains of 3D7, Dd2 and a clinical isolate from Guinea have been 
cultured with this medium.
All manipulations of cultures should be carried out in a laminar flow hood, using standard 
aseptic techniques. Gloves must always be worn.
The medium should be warmed up at 37®C before use.
Prepare this medium just before using it. We need a molarity of 23.8 mM for Sodium 
bicarbonate in complete culture medium. Add 4 ml of Sodium bicarbonate 5% (0.59 M) to 100 ml of 
incomplete medium. The colour of culture is very important; avoid using culture medium with purple 
colour.
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An initial culture with 1% haematocrit and 10% parasitaemia can grow well without any 
need to change the medium for 24h.
2. Extraction human whole blood
Normal Human RBC (Type or A* or B )^ are obtained from donors malaria no immune.
Reagents:
. CPD anticoagulant (100 ml)
Reagents Amount Company Reference
Citrate acid (monohydride) or 
Citrate acid (anhydride)
0.327 g or 
0.288 g
Panreac 131808
Sodium citrate (dihydrate) or 
Sodium citrate (anhydride)
2.630 g 
2.255 g
Panreac 141653
Sodium phosphate monobasic 0.222 g Panreac 131965
Dextrose anhydride (D-glucose) 4.630 g Panreac 131341
MilliQ water 100 ml
Final concentration citrate acid: 0.015M.
1. Add 80 ml (preferably sterile) milliQ water to a beaker. We should add the reagents keeping the 
order indicated in the table above. Dissolve while shaking for 5-10 min.
2. Add (sterile) milliQ water till 100ml.
3. Filter by syringe and aliquote them in sterile tubes. Filtering should be done in a laminar flow 
hood.
4. Store at 4°C.
Extraction Material
Rack with vacuum tubes (7 per extraction)
Pippet (blue) and pippet-sampler
Plastic band, pair of scissors, gauze and plaster
Method
1. Extract whole blood
2. Add 1.4 ml CDP anti coagulant solution RAPIDLY in 10 ml whole blood. Mix it by inverting 
the tubes 2-3 times, do not mix with pippet.
3. Cover tubes with Parafilm (totally) and store at 4°C.
This blood is valid up to 20 days.
Annex I
3. Preparation of Red Blood Cells
Blood only should be washed when it is needed and only the necessary amount, because without 
washing it can be kept longer.
Method (White cell removal with Lymphoprep)
1. Centrifuge the whole blood at 2300 rpm, 10 min (blood should be stored at 4°C at least 
one day after blood extraction).
2. Discard the upper serum layer (approximately half the tube).
3. Mix 5 ml of RBCs with 5 ml of washing medium and add the mixture carefully onto 5 ml 
of Lymphoprep.
4. Centrifuge at 2300 rpm, 20 min. Discard the supernatant.
5. Wash RBCs with 10 ml of washing medium.
6. Centrifuge at 2300 rpm, 5 min. Discard the supernatant.
7. Store RBCs by 50% diluting the packed cells with incomplete culture medium.
4. Thawing of glycerol-frozen parasites with NaCI
Reagents:
Solution A Sterile 12% NaCI
Solution B Sterile 1.6% NaCI
Pre-warm for 15 minutes at 37 C  water bath before using.
Method
1. Take a vial containing malaria parasites from -80“C/liquid nitrogen and thaw it during 2-3 
min in a 37®C water bath or keeping it in hand to warm it.
2. Spray the vial tube with 70% ethanol.
3. Transfer the vial contents to a 50-ml centrifuge tube using a 1ml serological pipette
Measure the total volume (V).
4. Add 0.1 X V of solution A slowly, dropwise, while swirling the tube.
5. Let the tube stand for 5 min at room temperature.
6. Add 10X V of solution B slowly, dropwise at first, while swirling the tube.
7. Centrifuge at 1800 rpm (240 [g]), (*  37®C), 5 min, brake 4.
When we work with infected RBC, never use centrifugation speed > 1500 rpm.
8. Discard the supernatant. Resuspend the pellet in 10 ml washing medium and transfer to 
a sterile tube.
9. Centrifuge, and remove the supernatant.
10. Estimate the pellet volume and add equal amount of fresh RBC, mix well. Resuspend 
the mixture in complete medium to keep haematocrit 1-2%.
IV
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11. Flush flasks for 60 sec or less with gas mixture (1% O2, 3% CO2, 96% N2) at 150 Bar 
pressure (15°C).
12. Incubate the flask at 37®C for 48 hours.
13. Assess viability (count ring-stage parasites).
Example:
V = 600 fjl (300 fjl Infected RBC + 300pi freezing solution)
1. Solution A = 0.1 * 600 = 60 pi solution A
2. Solution B 10* 600 = 6000 pi solution B
3. Fresfi R B C 300 pi (*)
4. Complete medium
1% haematocrit -> 60 mi compiete medium (little flask).
2% haematocrit 60 mi compiete medium + RBC. Total RBC should be 1200 pi (300 pi 
infected RBC (*) + 900 pi fresh RBC).
lOTECA
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5. Parasite synchronization
We use sorbitol synchronization method in our laboratory.
5% Sorbitol: To keep the parasites synchronized, the sorbitol treatment must be performed 
once a week. However, it can be done after each cycie (48 h) if a very synchronized culture 
is needed. Objective: eliminate or iysis of mature stages (trophozoites and schizonts) thus 
selecting ring-stage parasites.
Never freeze your parasite just after sorbitol synchronization. Grow them one more 
cycle before storing in the liquid Ng bank.
Sorbitol-synchronization
The most important thing for synchronization is to be sure that you have enough ring-stage 
parasites (more than 5%). The rings must not be later than 10 to 12 h postinvasion to treatment 
with sorbitol. Do not synchronize more than 3 flasks.
To deposit the parasites in the bank, synchronize one flask and divide it into 3 flasks to grow one 
more cycle.
Add 80 ml milliQ water to a beaker. Dissolve the sorbitol 
Reagents: while shaking for 5-10 min. Add water till 100 ml. Filter with
Sorbitol: Sterile 5% sorbitol syringe (0.22 p) and store at 4°C
Method
1. Take out 5% sorbitol from 4°C one hour before use and warm up at room temperature ( or 
5 min at 37°C).
2. Remove some medium from the flasks with a pump and mix the rest (approximately 15 ml 
medium or more) with RBC. Transfer the contents to 15ml centrifuge tubes.
3. Spin down the parasite culture for 5 min in swing-out centrifuge at 2000rpm; brake 4. When 
working with infected RBC, never use centrifugation speed over 1500-2000 rpm.
4. Discard the supernatant, estimate the pellet volume and add 9-1 OX 5% sorbitol.
5. Vortex 15 sec.
6. Incubate at 37*’C, 8 min (better, in agitation).
7. Vortex 15 sec.
8. Centrifuge 5 min, 2000rpm and remove supernatant (we should see haemolysis).
9. Add 10X washing medium -> centrifuge for 5 min at 2000 rpm.
10. Discard supernatant and repeat step 9.
11. Make a smear to assess the presence of ring forms.
12. Resuspend the pellet adding complete medium to reach 1-2% haematocrit. Transfer to 
a sterile flask, gas the flasks, seal them and incubate at 37°C incubator, as usual.
VI
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6. Store-freezing infected RBC In liquid nitrogen
- The minimum parasitaemia required to freeze the parasites cultures is 5% and the cycle stage 
must be young rings (< 12h).
- Take the flasks from the incubator and aspirate the medium with a pump. Resuspend the RBCs in
3-4 ml of washing medium and transfer to a 15 ml flask.
- Centrifuge 1500-2000 rpm for 5 min 35°C.
- Discard the supernatant.
- Estimate the volume of RBC pellet and add equal amount of freezing solution dropwise while 
swirling the tube and mix them with the help of the pippet.
- Aliquote the mixture in 1 ml Ng-vials (the minimum amount in each vial must be: 300 pi).
- Store at liquid nitrogen as soon as possible.
7. Parasite harvest
Reagents:
. Freezing solution
Reagent Fv = 100 ml Fv = 250 ml
NaCI 0.65 g 1.63 g
Sorbitol 3.02 g 7.55 g
Bidistilled sterile water 72.0 ml 180.0 ml
Glycerine 28.0 ml 70.0 ml
1. Add all the reagents in the same order than indicated in the table above.
2. Filter with syringe (0=O.22pm) and put on sterile tube. Filter should be carried out in a laminar 
flow hood.
3. Store at 4®C.
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Method
1 - Take the culture and aspirate the medium with a pump.
2- Transfer the monolayer of parasites to 50 ml tubes with a 10 ml pippet.
3- Centrifuge at 2700-2800 rpm, 7 min, 37°C.
4- Discard supernatant.
5- Reduce the number of tubes to one with the help of washing medium.
6- Centrifuge 2700-2800 rpm, 7 min.
7- Transfer to a 15 ml Falcon. Centrifuge 2700-2800 rpm, 7 min at 37®C.
8- Discard supernatant and keep the parasites pellet at -80°C for further analysis (for 
RNA expression analysis the use of RNAIater solution is recommended).
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